date generated: 2024-04-16

Background

Mitch performs unidimensional and multidimensional gene set enrichment analysis. The concept behind this dates to work by Cox and Mann (https://doi.org/10.1186/1471-2105-13-S16-S12). This implementation is suited to R based workflows of multi-omics datasets. This software was developed by Antony Kaspi and Mark Ziemann. Learn more about Mitch at the website: https://github.com/markziemann/Mitch

Input profiles

Here is the first few lines of the input profile.

The profiling data being passed to mitch
RNA expression H3K9 Acetylati
HSPA1A 103.91955 1.9187698
NR4A3 68.07237 10.7310014
HSPA1B 47.19114 18.8135158
DNAJB1 35.12799 2.4326980
MIR133A1HG -27.36199 8.9061962
KLF2 26.52373 0.4202366

Here are some metrics about the input data profile:

Profiling data metrics
Profile metrics
num_genes_in_profile 13119
duplicated_genes_present 0
num_profile_genes_in_sets 6521
num_profile_genes_not_in_sets 6598
profile_pearson_correl 0.1324
profile_spearman_correl 0.13759

Here is a plot of the input profiles. Note the dynamic ranges.

Here is the contour plot of the profile including all detected genes.

Input genesets

Here are some metrics about the gene sets used:

GMT file of genesets:
Gene set metrics
Gene sets metrics
num_genesets 2263
num_genesets_excluded 1062
num_genesets_included 1201

Gene sets by quadrant


Number of significant gene sets (FDR<0.05)= 522

Interactive enrichment scatterplot

All sets with FDR<0.05. Try hovering over the points.

Top N sets irrespective of FDR. Try hovering over the points.

A heatmap of S values for top results


A plot of effect size versus significance


Significance is the -log2(p.adjustMANOVA) and effect size is the s.dist which is the hypotenuse of the s scores.

Results table

Top N= 5 gene sets
set setSize pMANOVA p.adjustMANOVA s.dist s.RNA.expression s.H3K9.Acetylati p.RNA.expression p.H3K9.Acetylati
Signal Transduction 1466 1.77e-37 2.13e-34 0.220 0.182 0.1240 4.30e-30 9.09e-15
Metabolism of RNA 545 1.74e-26 1.04e-23 0.256 -0.142 0.2130 1.71e-08 3.20e-17
Translation 228 1.28e-25 5.13e-23 0.390 -0.362 0.1450 5.01e-21 1.77e-04
Regulation of expression of SLITs and ROBOs 125 2.44e-22 7.34e-20 0.490 -0.458 0.1730 8.97e-19 8.49e-04
Viral mRNA Translation 62 1.39e-20 3.34e-18 0.687 -0.684 0.0611 1.16e-20 4.06e-01


Results (complete table)


Click HERE to show results for all gene sets

Complete results
set setSize pMANOVA p.adjustMANOVA s.dist s.RNA.expression s.H3K9.Acetylati p.RNA.expression p.H3K9.Acetylati
Signal Transduction 1466 1.77e-37 2.13e-34 0.22000 0.182000 0.124000 4.30e-30 9.09e-15
Metabolism of RNA 545 1.74e-26 1.04e-23 0.25600 -0.142000 0.213000 1.71e-08 3.20e-17
Translation 228 1.28e-25 5.13e-23 0.39000 -0.362000 0.145000 5.01e-21 1.77e-04
Regulation of expression of SLITs and ROBOs 125 2.44e-22 7.34e-20 0.49000 -0.458000 0.173000 8.97e-19 8.49e-04
Viral mRNA Translation 62 1.39e-20 3.34e-18 0.68700 -0.684000 0.061100 1.16e-20 4.06e-01
Peptide chain elongation 63 2.43e-20 4.87e-18 0.67500 -0.672000 0.072500 2.86e-20 3.20e-01
Eukaryotic Translation Elongation 66 4.13e-20 7.08e-18 0.65600 -0.652000 0.071600 4.91e-20 3.15e-01
Selenocysteine synthesis 67 5.23e-20 7.85e-18 0.65000 -0.646000 0.066700 5.40e-20 3.46e-01
SRP-dependent cotranslational protein targeting to membrane 81 8.57e-20 1.14e-17 0.58200 -0.573000 0.103000 4.61e-19 1.08e-01
Immune System 1306 3.94e-19 4.73e-17 0.16500 0.123000 0.110000 2.64e-13 6.28e-11
Formation of a pool of free 40S subunits 74 1.64e-18 1.79e-16 0.59300 -0.589000 0.068600 1.85e-18 3.08e-01
Cap-dependent Translation Initiation 91 2.31e-18 2.14e-16 0.52900 -0.521000 0.091500 8.58e-18 1.32e-01
Eukaryotic Translation Initiation 91 2.31e-18 2.14e-16 0.52900 -0.521000 0.091500 8.58e-18 1.32e-01
Eukaryotic Translation Termination 66 3.24e-18 2.78e-16 0.62200 -0.616000 0.080500 4.64e-18 2.58e-01
Selenoamino acid metabolism 86 1.03e-17 8.22e-16 0.53700 -0.532000 0.071500 1.48e-17 2.52e-01
Gene expression (Transcription) 1120 2.70e-17 2.03e-15 0.16500 0.067900 0.150000 1.67e-04 8.60e-17
GTP hydrolysis and joining of the 60S ribosomal subunit 84 6.80e-17 4.80e-15 0.52800 -0.522000 0.081900 1.34e-16 1.95e-01
L13a-mediated translational silencing of Ceruloplasmin expression 83 7.78e-17 5.19e-15 0.52800 -0.518000 0.103000 3.51e-16 1.05e-01
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) 69 1.90e-16 1.20e-14 0.57600 -0.571000 0.076900 2.32e-16 2.70e-01
Diseases of signal transduction 288 6.22e-16 3.74e-14 0.30400 0.161000 0.258000 3.04e-06 5.59e-14
Metabolism of proteins 1426 1.17e-15 6.70e-14 0.13200 -0.005590 0.132000 7.30e-01 3.39e-16
Signaling by ROBO receptors 163 1.31e-15 7.17e-14 0.35200 -0.303000 0.179000 2.55e-11 8.49e-05
Cytokine Signaling in Immune system 551 4.16e-15 2.17e-13 0.21700 0.180000 0.121000 7.75e-13 1.59e-06
RNA Polymerase II Transcription 1005 5.37e-15 2.63e-13 0.16000 0.065700 0.146000 5.21e-04 1.06e-14
Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins. 75 5.61e-15 2.63e-13 0.50400 -0.411000 0.292000 7.51e-10 1.29e-05
Post-translational protein modification 1023 5.70e-15 2.63e-13 0.16000 0.072200 0.143000 1.23e-04 3.22e-14
Metabolism 1414 9.36e-15 4.16e-13 0.12100 -0.086200 0.085200 1.12e-07 1.59e-07
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) 88 1.33e-14 5.52e-13 0.46800 -0.439000 0.161000 1.07e-12 9.03e-03
Nonsense-Mediated Decay (NMD) 88 1.33e-14 5.52e-13 0.46800 -0.439000 0.161000 1.07e-12 9.03e-03
Respiratory electron transport 71 1.98e-14 7.94e-13 0.50800 -0.420000 0.286000 9.30e-10 3.11e-05
The citric acid (TCA) cycle and respiratory electron transport 119 2.24e-14 8.69e-13 0.39100 -0.270000 0.283000 3.77e-07 1.02e-07
Antigen processing: Ubiquitination & Proteasome degradation 259 6.89e-14 2.59e-12 0.28900 0.076100 0.279000 3.57e-02 1.22e-14
Class I MHC mediated antigen processing & presentation 304 7.91e-14 2.88e-12 0.27000 0.095400 0.253000 4.41e-03 4.39e-14
Cellular responses to external stimuli 337 8.99e-14 3.17e-12 0.25200 0.059400 0.245000 6.24e-02 1.27e-14
Cellular responses to stress 332 9.83e-14 3.37e-12 0.25300 0.052000 0.247000 1.05e-01 1.17e-14
Membrane Trafficking 477 1.22e-13 4.07e-12 0.21900 0.111000 0.189000 3.48e-05 2.36e-12
ESR-mediated signaling 134 2.58e-13 8.37e-12 0.40700 0.288000 0.287000 8.78e-09 1.02e-08
Signaling by Nuclear Receptors 191 3.73e-13 1.18e-11 0.33900 0.217000 0.261000 2.63e-07 5.83e-10
Adaptive Immune System 512 5.04e-13 1.55e-11 0.20600 0.096300 0.182000 2.16e-04 2.59e-12
rRNA processing 149 8.24e-13 2.47e-11 0.33800 -0.323000 0.099500 1.03e-11 3.64e-02
Vesicle-mediated transport 500 2.04e-12 5.99e-11 0.20500 0.117000 0.168000 8.43e-06 1.72e-10
mRNA Splicing 159 2.55e-12 7.29e-11 0.31900 -0.111000 0.299000 1.60e-02 8.08e-11
Influenza Viral RNA Transcription and Replication 102 3.48e-12 9.54e-11 0.40400 -0.398000 0.066100 3.80e-12 2.49e-01
Generic Transcription Pathway 903 3.49e-12 9.54e-11 0.15200 0.071400 0.134000 3.34e-04 1.50e-11
Mitochondrial translation initiation 63 3.85e-12 1.03e-10 0.49800 -0.453000 0.206000 5.01e-10 4.64e-03
Metabolism of amino acids and derivatives 255 4.38e-12 1.14e-10 0.25700 -0.255000 0.032800 2.86e-12 3.70e-01
Chromatin modifying enzymes 186 7.66e-12 1.92e-10 0.32100 0.157000 0.281000 2.38e-04 4.57e-11
Chromatin organization 186 7.66e-12 1.92e-10 0.32100 0.157000 0.281000 2.38e-04 4.57e-11
rRNA processing in the nucleus and cytosol 142 7.82e-12 1.92e-10 0.33300 -0.322000 0.086900 3.76e-11 7.46e-02
Processing of Capped Intron-Containing Pre-mRNA 205 9.33e-12 2.24e-10 0.27400 -0.096700 0.257000 1.73e-02 2.54e-10
Mitochondrial translation termination 63 1.25e-11 2.93e-10 0.48700 -0.443000 0.202000 1.24e-09 5.56e-03
Major pathway of rRNA processing in the nucleolus and cytosol 136 1.67e-11 3.87e-10 0.33700 -0.329000 0.073600 3.64e-11 1.39e-01
Extracellular matrix organization 189 2.41e-11 5.47e-10 0.27500 0.168000 -0.218000 6.92e-05 2.69e-07
Infectious disease 296 3.01e-11 6.67e-10 0.21900 -0.148000 0.162000 1.28e-05 1.87e-06
mRNA Splicing - Major Pathway 154 3.05e-11 6.67e-10 0.31000 -0.096000 0.295000 4.03e-02 2.93e-10
Mitochondrial translation elongation 62 3.31e-11 7.11e-10 0.47900 -0.424000 0.222000 7.60e-09 2.51e-03
FOXO-mediated transcription 52 3.66e-11 7.71e-10 0.59000 0.335000 0.485000 3.00e-05 1.41e-09
Circadian Clock 62 4.87e-11 1.01e-09 0.53700 0.301000 0.444000 4.22e-05 1.44e-09
PIP3 activates AKT signaling 212 5.68e-11 1.16e-09 0.28600 0.111000 0.264000 5.67e-03 3.91e-11
Estrogen-dependent gene expression 81 6.35e-11 1.27e-09 0.47000 0.306000 0.356000 1.93e-06 3.14e-08
Mitochondrial translation 68 6.81e-11 1.34e-09 0.45000 -0.397000 0.213000 1.56e-08 2.42e-03
Disease 758 8.29e-11 1.61e-09 0.14800 0.015200 0.147000 4.82e-01 9.77e-12
Deubiquitination 211 9.50e-11 1.81e-09 0.28300 0.107000 0.263000 7.72e-03 5.53e-11
Neddylation 192 9.84e-11 1.85e-09 0.28300 0.006130 0.283000 8.84e-01 1.56e-11
Complex I biogenesis 37 1.17e-10 2.16e-09 0.60700 -0.561000 0.232000 3.49e-09 1.45e-02
Signaling by Receptor Tyrosine Kinases 332 2.87e-10 5.23e-09 0.22600 0.177000 0.141000 3.55e-08 1.07e-05
Influenza Life Cycle 110 3.27e-10 5.87e-09 0.34900 -0.334000 0.099600 1.46e-09 7.16e-02
Signaling by TGF-beta family members 90 3.68e-10 6.49e-09 0.42900 0.310000 0.297000 3.96e-07 1.14e-06
Signaling by WNT 203 4.95e-10 8.61e-09 0.27200 0.055500 0.266000 1.74e-01 6.59e-11
Intracellular signaling by second messengers 246 5.53e-10 9.48e-09 0.25300 0.103000 0.232000 5.53e-03 4.51e-10
Interleukin-4 and Interleukin-13 signaling 64 1.04e-09 1.76e-08 0.47300 0.464000 0.093100 1.37e-10 1.98e-01
Apoptosis 140 1.05e-09 1.76e-08 0.31900 0.047100 0.315000 3.37e-01 1.28e-10
Developmental Biology 578 1.14e-09 1.87e-08 0.16500 0.073100 0.148000 2.91e-03 1.54e-09
Programmed Cell Death 142 1.30e-09 2.11e-08 0.31600 0.055400 0.311000 2.56e-01 1.64e-10
Ub-specific processing proteases 144 1.52e-09 2.43e-08 0.31700 0.088900 0.304000 6.62e-02 3.04e-10
Downstream signaling events of B Cell Receptor (BCR) 68 2.67e-09 4.22e-08 0.41300 -0.204000 0.359000 3.70e-03 3.09e-07
MAPK family signaling cascades 211 3.32e-09 5.18e-08 0.26300 0.125000 0.232000 1.74e-03 7.23e-09
Signaling by Interleukins 292 5.05e-09 7.77e-08 0.22400 0.181000 0.132000 1.09e-07 1.13e-04
APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint 57 9.34e-09 1.40e-07 0.43300 -0.321000 0.290000 2.76e-05 1.55e-04
Cdc20:Phospho-APC/C mediated degradation of Cyclin A 57 9.34e-09 1.40e-07 0.43300 -0.321000 0.290000 2.76e-05 1.55e-04
HSP90 chaperone cycle for steroid hormone receptors (SHR) 33 1.17e-08 1.73e-07 0.64800 0.478000 0.437000 1.98e-06 1.38e-05
Influenza Infection 120 1.23e-08 1.80e-07 0.30600 -0.294000 0.083200 2.77e-08 1.16e-01
Autodegradation of Cdh1 by Cdh1:APC/C 55 1.36e-08 1.97e-07 0.43600 -0.335000 0.279000 1.73e-05 3.46e-04
DNA Replication 97 1.79e-08 2.56e-07 0.33000 -0.294000 0.150000 5.89e-07 1.06e-02
Synthesis of DNA 94 2.20e-08 3.11e-07 0.33400 -0.304000 0.138000 3.47e-07 2.06e-02
APC/C:Cdc20 mediated degradation of Securin 55 2.25e-08 3.14e-07 0.43000 -0.321000 0.286000 3.84e-05 2.48e-04
Signaling by TGF-beta Receptor Complex 66 2.33e-08 3.21e-07 0.45000 0.295000 0.340000 3.50e-05 1.82e-06
APC/C:Cdc20 mediated degradation of mitotic proteins 58 2.40e-08 3.27e-07 0.41800 -0.309000 0.281000 4.62e-05 2.19e-04
GLI3 is processed to GLI3R by the proteasome 51 2.44e-08 3.30e-07 0.44500 -0.312000 0.317000 1.17e-04 8.85e-05
Host Interactions of HIV factors 109 2.53e-08 3.37e-07 0.30600 -0.180000 0.247000 1.19e-03 8.51e-06
Transcriptional regulation by RUNX1 149 2.88e-08 3.80e-07 0.29300 0.119000 0.268000 1.25e-02 1.80e-08
PTEN Regulation 126 2.93e-08 3.82e-07 0.30500 0.026600 0.304000 6.07e-01 4.04e-09
CLEC7A (Dectin-1) signaling 83 2.98e-08 3.84e-07 0.35600 -0.115000 0.337000 7.15e-02 1.15e-07
Switching of origins to a post-replicative state 70 3.01e-08 3.84e-07 0.37900 -0.312000 0.216000 6.32e-06 1.84e-03
FCERI mediated NF-kB activation 67 3.18e-08 4.02e-07 0.39000 -0.181000 0.345000 1.05e-02 1.03e-06
Activation of NF-kappaB in B cells 55 3.29e-08 4.12e-07 0.42500 -0.274000 0.325000 4.42e-04 3.02e-05
TCF dependent signaling in response to WNT 137 3.36e-08 4.16e-07 0.29300 0.033900 0.291000 4.95e-01 4.48e-09
Orc1 removal from chromatin 54 3.70e-08 4.54e-07 0.43100 -0.371000 0.218000 2.38e-06 5.53e-03
Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins 59 4.22e-08 5.12e-07 0.40800 -0.311000 0.264000 3.71e-05 4.53e-04
FBXL7 down-regulates AURKA during mitotic entry and in early mitosis 46 4.26e-08 5.12e-07 0.46200 -0.371000 0.276000 1.33e-05 1.23e-03
Degradation of DVL 48 4.63e-08 5.51e-07 0.45000 -0.314000 0.323000 1.70e-04 1.09e-04
Regulation of APC/C activators between G1/S and early anaphase 64 5.33e-08 6.28e-07 0.38900 -0.283000 0.266000 8.95e-05 2.35e-04
DNA Replication Pre-Initiation 63 6.30e-08 7.35e-07 0.39300 -0.342000 0.194000 2.69e-06 7.89e-03
Signaling by Rho GTPases 284 7.09e-08 8.19e-07 0.21100 0.176000 0.116000 3.83e-07 8.26e-04
RHO GTPase Effectors 180 7.43e-08 8.49e-07 0.26400 0.164000 0.207000 1.47e-04 1.82e-06
Vif-mediated degradation of APOBEC3G 43 7.57e-08 8.57e-07 0.46900 -0.362000 0.298000 3.97e-05 7.19e-04
APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 57 7.66e-08 8.60e-07 0.40800 -0.316000 0.258000 3.75e-05 7.67e-04
Cellular response to hypoxia 60 8.68e-08 9.66e-07 0.40000 -0.188000 0.353000 1.19e-02 2.35e-06
Degradation of GLI1 by the proteasome 50 9.35e-08 1.03e-06 0.43200 -0.292000 0.318000 3.52e-04 9.98e-05
Regulation of mRNA stability by proteins that bind AU-rich elements 77 9.73e-08 1.06e-06 0.36300 -0.058400 0.359000 3.76e-01 5.40e-08
Degradation of GLI2 by the proteasome 51 1.14e-07 1.24e-06 0.42500 -0.302000 0.299000 1.92e-04 2.20e-04
APC/C-mediated degradation of cell cycle proteins 65 1.20e-07 1.27e-06 0.37600 -0.265000 0.267000 2.17e-04 2.04e-04
Regulation of mitotic cell cycle 65 1.20e-07 1.27e-06 0.37600 -0.265000 0.267000 2.17e-04 2.04e-04
MyD88-independent TLR4 cascade 84 1.28e-07 1.34e-06 0.37900 0.241000 0.292000 1.36e-04 3.68e-06
TRIF(TICAM1)-mediated TLR4 signaling 84 1.28e-07 1.34e-06 0.37900 0.241000 0.292000 1.36e-04 3.68e-06
Transcriptional Regulation by TP53 292 1.43e-07 1.48e-06 0.19900 0.072200 0.186000 3.45e-02 5.27e-08
Negative regulation of NOTCH4 signaling 48 1.47e-07 1.51e-06 0.43500 -0.340000 0.272000 4.63e-05 1.13e-03
CDK-mediated phosphorylation and removal of Cdc6 57 1.66e-07 1.69e-06 0.39800 -0.299000 0.262000 9.51e-05 6.24e-04
Toll Like Receptor 3 (TLR3) Cascade 82 1.83e-07 1.85e-06 0.37800 0.222000 0.307000 5.31e-04 1.63e-06
Signaling by the B Cell Receptor (BCR) 89 2.06e-07 2.06e-06 0.31700 -0.184000 0.258000 2.66e-03 2.60e-05
Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha 55 2.12e-07 2.09e-06 0.40200 -0.252000 0.313000 1.23e-03 5.96e-05
TP53 Regulates Metabolic Genes 70 2.13e-07 2.09e-06 0.38000 0.004260 0.380000 9.51e-01 3.83e-08
Hedgehog ligand biogenesis 49 2.14e-07 2.09e-06 0.42500 -0.321000 0.279000 1.01e-04 7.35e-04
Assembly of the pre-replicative complex 53 2.47e-07 2.39e-06 0.40900 -0.346000 0.218000 1.29e-05 6.09e-03
Regulation of RUNX2 expression and activity 59 2.67e-07 2.57e-06 0.39100 -0.156000 0.359000 3.89e-02 1.88e-06
Fc epsilon receptor (FCERI) signaling 109 2.72e-07 2.57e-06 0.29900 -0.024900 0.298000 6.53e-01 8.04e-08
Hh mutants abrogate ligand secretion 46 2.74e-07 2.57e-06 0.43500 -0.311000 0.304000 2.60e-04 3.65e-04
Hh mutants that don’t undergo autocatalytic processing are degraded by ERAD 46 2.74e-07 2.57e-06 0.43500 -0.311000 0.304000 2.60e-04 3.65e-04
Defective CFTR causes cystic fibrosis 49 2.86e-07 2.66e-06 0.42100 -0.280000 0.315000 7.02e-04 1.39e-04
CDT1 association with the CDC6:ORC:origin complex 46 2.97e-07 2.74e-06 0.43500 -0.337000 0.274000 7.71e-05 1.30e-03
Separation of Sister Chromatids 123 3.09e-07 2.81e-06 0.27600 -0.058300 0.270000 2.65e-01 2.52e-07
Vpu mediated degradation of CD4 44 3.10e-07 2.81e-06 0.44400 -0.342000 0.282000 8.63e-05 1.21e-03
SCF-beta-TrCP mediated degradation of Emi1 46 3.11e-07 2.81e-06 0.43400 -0.327000 0.285000 1.25e-04 8.45e-04
Mitotic Anaphase 133 3.45e-07 3.09e-06 0.26700 -0.036900 0.264000 4.63e-01 1.50e-07
Toll Like Receptor 9 (TLR9) Cascade 80 3.53e-07 3.14e-06 0.37600 0.249000 0.282000 1.22e-04 1.32e-05
HIV Infection 189 3.80e-07 3.36e-06 0.21700 -0.087100 0.199000 3.96e-02 2.59e-06
Ubiquitin Mediated Degradation of Phosphorylated Cdc25A 43 3.90e-07 3.37e-06 0.44500 -0.347000 0.279000 8.21e-05 1.57e-03
p53-Independent DNA Damage Response 43 3.90e-07 3.37e-06 0.44500 -0.347000 0.279000 8.21e-05 1.57e-03
p53-Independent G1/S DNA damage checkpoint 43 3.90e-07 3.37e-06 0.44500 -0.347000 0.279000 8.21e-05 1.57e-03
Mitotic Metaphase and Anaphase 134 4.26e-07 3.66e-06 0.26400 -0.033100 0.262000 5.10e-01 1.66e-07
Regulation of activated PAK-2p34 by proteasome mediated degradation 42 4.33e-07 3.69e-06 0.44900 -0.341000 0.291000 1.31e-04 1.09e-03
Dectin-1 mediated noncanonical NF-kB signaling 51 4.43e-07 3.73e-06 0.40800 -0.245000 0.326000 2.53e-03 5.64e-05
AUF1 (hnRNP D0) binds and destabilizes mRNA 47 4.45e-07 3.73e-06 0.42500 -0.247000 0.346000 3.38e-03 4.19e-05
SCF(Skp2)-mediated degradation of p27/p21 47 4.80e-07 4.00e-06 0.42200 -0.304000 0.293000 3.12e-04 5.08e-04
Protein localization 125 5.42e-07 4.49e-06 0.26000 -0.138000 0.221000 7.92e-03 2.06e-05
NIK–>noncanonical NF-kB signaling 50 5.88e-07 4.84e-06 0.40800 -0.246000 0.325000 2.67e-03 6.94e-05
FLT3 Signaling 187 5.92e-07 4.84e-06 0.23600 0.081900 0.222000 5.41e-02 1.85e-07
Transcriptional regulation by RUNX2 96 8.45e-07 6.86e-06 0.31200 0.020100 0.312000 7.34e-01 1.33e-07
Ubiquitin-dependent degradation of Cyclin D 44 8.65e-07 6.97e-06 0.42800 -0.317000 0.287000 2.75e-04 9.88e-04
Regulation of Apoptosis 45 1.00e-06 8.01e-06 0.42100 -0.291000 0.304000 7.26e-04 4.30e-04
Regulation of PTEN stability and activity 58 1.02e-06 8.13e-06 0.37500 -0.169000 0.335000 2.63e-02 1.05e-05
Signaling by PDGF 44 1.15e-06 9.10e-06 0.44700 0.446000 -0.032500 3.14e-07 7.09e-01
Degradation of beta-catenin by the destruction complex 73 1.19e-06 9.33e-06 0.33500 -0.123000 0.312000 7.02e-02 4.18e-06
Cell Cycle 430 1.20e-06 9.33e-06 0.14800 0.010200 0.147000 7.20e-01 1.89e-07
Translocation of SLC2A4 (GLUT4) to the plasma membrane 46 1.32e-06 1.02e-05 0.45900 0.150000 0.434000 7.76e-02 3.54e-07
PPARA activates gene expression 97 1.38e-06 1.06e-05 0.32400 0.184000 0.267000 1.79e-03 5.60e-06
ABC-family proteins mediated transport 79 1.42e-06 1.09e-05 0.31400 -0.230000 0.214000 4.18e-04 1.03e-03
Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) 99 1.45e-06 1.09e-05 0.32100 0.185000 0.262000 1.50e-03 6.87e-06
Formation of the ternary complex, and subsequently, the 43S complex 39 1.45e-06 1.09e-05 0.46100 -0.448000 0.109000 1.30e-06 2.39e-01
Hemostasis 369 1.47e-06 1.11e-05 0.15900 0.158000 0.021300 2.19e-07 4.84e-01
MyD88 dependent cascade initiated on endosome 77 1.67e-06 1.24e-05 0.36300 0.244000 0.269000 2.18e-04 4.71e-05
Toll Like Receptor 7/8 (TLR7/8) Cascade 77 1.67e-06 1.24e-05 0.36300 0.244000 0.269000 2.18e-04 4.71e-05
RUNX1 regulates transcription of genes involved in differentiation of HSCs 63 1.76e-06 1.30e-05 0.35200 -0.169000 0.309000 2.05e-02 2.31e-05
Toll Like Receptor 4 (TLR4) Cascade 103 1.99e-06 1.45e-05 0.31100 0.247000 0.189000 1.50e-05 9.32e-04
Autodegradation of the E3 ubiquitin ligase COP1 44 2.07e-06 1.51e-05 0.41600 -0.342000 0.236000 8.77e-05 6.69e-03
Collagen chain trimerization 28 2.21e-06 1.60e-05 0.56200 -0.075600 -0.557000 4.89e-01 3.34e-07
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation 76 2.36e-06 1.70e-05 0.36000 0.239000 0.269000 3.11e-04 5.04e-05
MAPK6/MAPK4 signaling 73 2.58e-06 1.85e-05 0.33600 -0.033500 0.334000 6.22e-01 8.11e-07
Toll-like Receptor Cascades 117 3.13e-06 2.22e-05 0.28800 0.217000 0.188000 5.01e-05 4.43e-04
Degradation of AXIN 46 3.14e-06 2.22e-05 0.39900 -0.281000 0.282000 9.77e-04 9.24e-04
PI3K/AKT Signaling in Cancer 65 3.18e-06 2.24e-05 0.38400 0.301000 0.239000 2.72e-05 8.82e-04
S Phase 129 3.25e-06 2.27e-05 0.23900 -0.155000 0.182000 2.44e-03 3.80e-04
ABC transporter disorders 60 3.59e-06 2.48e-05 0.34700 -0.243000 0.248000 1.15e-03 8.91e-04
FOXO-mediated transcription of cell cycle genes 15 3.60e-06 2.48e-05 0.79500 0.508000 0.611000 6.51e-04 4.13e-05
Transcriptional regulation of white adipocyte differentiation 69 3.64e-06 2.50e-05 0.37100 0.223000 0.296000 1.35e-03 2.17e-05
Cell Cycle Checkpoints 186 4.14e-06 2.82e-05 0.20800 -0.014300 0.208000 7.38e-01 1.09e-06
Regulation of ornithine decarboxylase (ODC) 40 4.57e-06 3.10e-05 0.42200 -0.334000 0.258000 2.63e-04 4.78e-03
Signaling by NOTCH1 65 4.83e-06 3.26e-05 0.37900 0.268000 0.267000 1.86e-04 1.96e-04
MyD88 cascade initiated on plasma membrane 74 4.92e-06 3.26e-05 0.35500 0.232000 0.268000 5.76e-04 6.68e-05
Toll Like Receptor 10 (TLR10) Cascade 74 4.92e-06 3.26e-05 0.35500 0.232000 0.268000 5.76e-04 6.68e-05
Toll Like Receptor 5 (TLR5) Cascade 74 4.92e-06 3.26e-05 0.35500 0.232000 0.268000 5.76e-04 6.68e-05
Stabilization of p53 47 5.02e-06 3.31e-05 0.38700 -0.294000 0.252000 4.94e-04 2.80e-03
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer 43 6.01e-06 3.87e-05 0.45900 0.263000 0.376000 2.91e-03 1.98e-05
MyD88:MAL(TIRAP) cascade initiated on plasma membrane 79 6.02e-06 3.87e-05 0.34100 0.239000 0.243000 2.50e-04 1.91e-04
Toll Like Receptor 2 (TLR2) Cascade 79 6.02e-06 3.87e-05 0.34100 0.239000 0.243000 2.50e-04 1.91e-04
Toll Like Receptor TLR1:TLR2 Cascade 79 6.02e-06 3.87e-05 0.34100 0.239000 0.243000 2.50e-04 1.91e-04
Toll Like Receptor TLR6:TLR2 Cascade 79 6.02e-06 3.87e-05 0.34100 0.239000 0.243000 2.50e-04 1.91e-04
Assembly of collagen fibrils and other multimeric structures 41 6.74e-06 4.30e-05 0.44300 -0.048100 -0.440000 5.95e-01 1.07e-06
Glutathione conjugation 25 7.27e-06 4.62e-05 0.53900 -0.522000 0.136000 6.37e-06 2.40e-01
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S 46 7.79e-06 4.92e-05 0.39100 -0.359000 0.153000 2.51e-05 7.22e-02
Cellular Senescence 114 8.54e-06 5.27e-05 0.27900 0.163000 0.226000 2.65e-03 3.19e-05
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants 52 8.61e-06 5.27e-05 0.41100 0.228000 0.341000 4.47e-03 2.07e-05
Constitutive Signaling by NOTCH1 PEST Domain Mutants 52 8.61e-06 5.27e-05 0.41100 0.228000 0.341000 4.47e-03 2.07e-05
Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer 52 8.61e-06 5.27e-05 0.41100 0.228000 0.341000 4.47e-03 2.07e-05
Signaling by NOTCH1 PEST Domain Mutants in Cancer 52 8.61e-06 5.27e-05 0.41100 0.228000 0.341000 4.47e-03 2.07e-05
Signaling by NOTCH1 in Cancer 52 8.61e-06 5.27e-05 0.41100 0.228000 0.341000 4.47e-03 2.07e-05
Translation initiation complex formation 45 9.18e-06 5.60e-05 0.39300 -0.364000 0.148000 2.45e-05 8.59e-02
Transcriptional activation of mitochondrial biogenesis 49 1.03e-05 6.22e-05 0.42000 0.232000 0.350000 4.91e-03 2.33e-05
C-type lectin receptors (CLRs) 102 1.05e-05 6.36e-05 0.26400 -0.060900 0.257000 2.88e-01 7.55e-06
SUMOylation 149 1.13e-05 6.81e-05 0.24200 0.167000 0.175000 4.35e-04 2.36e-04
Class A/1 (Rhodopsin-like receptors) 64 1.21e-05 7.26e-05 0.32000 0.189000 -0.259000 9.00e-03 3.46e-04
MAPK1/MAPK3 signaling 179 1.23e-05 7.32e-05 0.21500 0.075300 0.201000 8.33e-02 3.76e-06
Intrinsic Pathway for Apoptosis 44 1.26e-05 7.44e-05 0.43400 0.189000 0.391000 3.02e-02 7.31e-06
Downregulation of SMAD2/3:SMAD4 transcriptional activity 23 1.32e-05 7.79e-05 0.60300 0.311000 0.517000 9.89e-03 1.76e-05
Integrin cell surface interactions 43 1.33e-05 7.80e-05 0.38800 0.253000 -0.295000 4.15e-03 8.34e-04
ER to Golgi Anterograde Transport 114 1.34e-05 7.83e-05 0.26900 0.114000 0.244000 3.65e-02 6.89e-06
Signaling by NTRK1 (TRKA) 69 1.40e-05 8.09e-05 0.35100 0.225000 0.269000 1.22e-03 1.14e-04
Transport to the Golgi and subsequent modification 136 1.40e-05 8.09e-05 0.24700 0.115000 0.219000 2.12e-02 1.06e-05
Metabolism of polyamines 47 1.42e-05 8.15e-05 0.37100 -0.297000 0.223000 4.35e-04 8.31e-03
RAF/MAP kinase cascade 174 1.49e-05 8.53e-05 0.21400 0.059800 0.205000 1.74e-01 3.19e-06
Golgi Associated Vesicle Biogenesis 46 1.56e-05 8.89e-05 0.42600 0.253000 0.343000 2.96e-03 5.81e-05
Downstream signal transduction 27 1.58e-05 8.98e-05 0.54300 0.509000 0.187000 4.64e-06 9.29e-02
Ribosomal scanning and start codon recognition 45 1.69e-05 9.52e-05 0.38500 -0.367000 0.118000 2.10e-05 1.72e-01
MAP kinase activation 60 1.73e-05 9.70e-05 0.37000 0.193000 0.315000 9.70e-03 2.42e-05
Mitotic G1-G1/S phases 114 1.93e-05 1.08e-04 0.23800 -0.109000 0.211000 4.38e-02 1.03e-04
Signaling by NOTCH4 71 2.10e-05 1.17e-04 0.30100 -0.115000 0.279000 9.43e-02 4.96e-05
Cross-presentation of soluble exogenous antigens (endosomes) 39 2.12e-05 1.17e-04 0.40000 -0.327000 0.231000 4.17e-04 1.25e-02
Regulation of RUNX3 expression and activity 46 2.13e-05 1.17e-04 0.36700 -0.260000 0.259000 2.29e-03 2.37e-03
p53-Dependent G1 DNA Damage Response 52 2.20e-05 1.20e-04 0.34500 -0.239000 0.249000 2.88e-03 1.94e-03
p53-Dependent G1/S DNA damage checkpoint 52 2.20e-05 1.20e-04 0.34500 -0.239000 0.249000 2.88e-03 1.94e-03
Mitochondrial biogenesis 67 2.28e-05 1.24e-04 0.34200 0.140000 0.312000 4.80e-02 1.03e-05
G1/S Transition 100 2.35e-05 1.27e-04 0.24900 -0.153000 0.197000 8.43e-03 6.93e-04
Collagen formation 61 2.52e-05 1.36e-04 0.34100 -0.022900 -0.340000 7.57e-01 4.42e-06
Mitochondrial protein import 44 2.64e-05 1.41e-04 0.37300 -0.214000 0.306000 1.41e-02 4.57e-04
Cyclin E associated events during G1/S transition 68 2.80e-05 1.50e-04 0.30100 -0.146000 0.263000 3.71e-02 1.77e-04
Transcriptional regulation by RUNX3 82 2.93e-05 1.56e-04 0.29400 0.036700 0.292000 5.66e-01 4.91e-06
G1/S DNA Damage Checkpoints 54 3.17e-05 1.68e-04 0.33300 -0.224000 0.246000 4.35e-03 1.81e-03
Asymmetric localization of PCP proteins 53 3.36e-05 1.77e-04 0.33500 -0.226000 0.247000 4.49e-03 1.85e-03
Activation of HOX genes during differentiation 50 3.39e-05 1.77e-04 0.39500 0.248000 0.307000 2.41e-03 1.72e-04
Activation of anterior HOX genes in hindbrain development during early embryogenesis 50 3.39e-05 1.77e-04 0.39500 0.248000 0.307000 2.41e-03 1.72e-04
NOTCH1 Intracellular Domain Regulates Transcription 44 3.44e-05 1.79e-04 0.41500 0.182000 0.372000 3.68e-02 1.93e-05
PCP/CE pathway 74 3.55e-05 1.84e-04 0.28400 -0.163000 0.233000 1.56e-02 5.48e-04
Signaling by BMP 24 3.70e-05 1.91e-04 0.56800 0.423000 0.379000 3.39e-04 1.30e-03
The role of GTSE1 in G2/M progression after G2 checkpoint 49 4.17e-05 2.14e-04 0.34500 -0.240000 0.247000 3.72e-03 2.74e-03
Apoptotic execution phase 37 4.41e-05 2.25e-04 0.45300 0.274000 0.360000 3.93e-03 1.50e-04
Cyclin A:Cdk2-associated events at S phase entry 70 4.53e-05 2.30e-04 0.28900 -0.153000 0.245000 2.69e-02 3.93e-04
Cell Cycle, Mitotic 355 4.61e-05 2.34e-04 0.13700 -0.005760 0.137000 8.53e-01 1.10e-05
TGF-beta receptor signaling activates SMADs 30 5.21e-05 2.63e-04 0.49800 0.294000 0.402000 5.41e-03 1.38e-04
Extra-nuclear estrogen signaling 56 5.51e-05 2.77e-04 0.36300 0.299000 0.207000 1.12e-04 7.47e-03
Estrogen-dependent nuclear events downstream of ESR-membrane signaling 20 5.67e-05 2.84e-04 0.60800 0.391000 0.466000 2.44e-03 3.11e-04
Muscle contraction 137 5.78e-05 2.88e-04 0.22100 0.026900 0.219000 5.87e-01 9.98e-06
Regulation of TP53 Degradation 28 6.26e-05 3.09e-04 0.49900 0.175000 0.467000 1.10e-01 1.87e-05
Regulation of TP53 Expression and Degradation 28 6.26e-05 3.09e-04 0.49900 0.175000 0.467000 1.10e-01 1.87e-05
Signaling by SCF-KIT 34 6.49e-05 3.20e-04 0.44800 0.431000 0.122000 1.39e-05 2.20e-01
RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function 36 6.55e-05 3.21e-04 0.45100 0.337000 0.299000 4.65e-04 1.91e-03
Disorders of transmembrane transporters 119 6.74e-05 3.29e-04 0.21700 -0.132000 0.172000 1.27e-02 1.25e-03
Regulation of RAS by GAPs 58 7.51e-05 3.65e-04 0.30900 -0.172000 0.256000 2.34e-02 7.39e-04
Innate Immune System 647 7.59e-05 3.67e-04 0.10800 0.069000 0.083000 3.02e-03 3.61e-04
TNFR2 non-canonical NF-kB pathway 62 7.91e-05 3.81e-04 0.29700 -0.177000 0.239000 1.62e-02 1.14e-03
M Phase 251 8.01e-05 3.85e-04 0.15700 -0.008360 0.157000 8.20e-01 2.00e-05
SUMO E3 ligases SUMOylate target proteins 143 8.04e-05 3.85e-04 0.22500 0.157000 0.161000 1.19e-03 9.40e-04
HATs acetylate histones 74 8.32e-05 3.96e-04 0.30500 0.128000 0.277000 5.74e-02 3.79e-05
FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes 22 9.06e-05 4.30e-04 0.56500 0.331000 0.458000 7.29e-03 2.03e-04
Signaling by Hippo 19 9.49e-05 4.47e-04 0.60700 0.482000 0.368000 2.73e-04 5.52e-03
Collagen biosynthesis and modifying enzymes 44 9.49e-05 4.47e-04 0.37700 -0.042400 -0.375000 6.27e-01 1.69e-05
RHO GTPases Activate Formins 84 1.03e-04 4.84e-04 0.28800 0.169000 0.233000 7.57e-03 2.28e-04
Constitutive Signaling by AKT1 E17K in Cancer 23 1.05e-04 4.90e-04 0.54900 0.418000 0.357000 5.26e-04 3.05e-03
RHO GTPases activate PKNs 34 1.06e-04 4.95e-04 0.45200 0.324000 0.315000 1.08e-03 1.46e-03
Diseases associated with O-glycosylation of proteins 41 1.07e-04 4.96e-04 0.39000 -0.056600 -0.386000 5.31e-01 1.90e-05
Interleukin-17 signaling 63 1.09e-04 5.06e-04 0.33000 0.178000 0.278000 1.49e-02 1.39e-04
MAPK targets/ Nuclear events mediated by MAP kinases 29 1.12e-04 5.15e-04 0.48800 0.321000 0.368000 2.81e-03 6.14e-04
Asparagine N-linked glycosylation 235 1.17e-04 5.37e-04 0.16500 0.035600 0.161000 3.49e-01 2.23e-05
Signaling by NOTCH 155 1.20e-04 5.47e-04 0.20800 0.087500 0.188000 6.06e-02 5.47e-05
Signaling by EGFR 41 1.23e-04 5.60e-04 0.40800 0.267000 0.309000 3.16e-03 6.15e-04
Downregulation of TGF-beta receptor signaling 25 1.25e-04 5.68e-04 0.52100 0.327000 0.407000 4.73e-03 4.34e-04
Signaling by NTRKs 83 1.26e-04 5.68e-04 0.28700 0.189000 0.217000 3.02e-03 6.58e-04
Downstream TCR signaling 76 1.27e-04 5.72e-04 0.26800 -0.079800 0.256000 2.30e-01 1.15e-04
Attenuation phase 20 1.40e-04 6.25e-04 0.58000 0.427000 0.393000 9.45e-04 2.36e-03
Intra-Golgi and retrograde Golgi-to-ER traffic 144 1.51e-04 6.76e-04 0.20900 0.058200 0.201000 2.29e-01 3.39e-05
GPCR ligand binding 107 1.80e-04 8.00e-04 0.22700 0.027400 -0.225000 6.25e-01 5.89e-05
Transcriptional Regulation by MECP2 44 1.87e-04 8.29e-04 0.38300 0.218000 0.315000 1.23e-02 3.02e-04
Formation of the beta-catenin:TCF transactivating complex 30 2.22e-04 9.78e-04 0.46100 0.295000 0.354000 5.20e-03 7.83e-04
Beta-catenin independent WNT signaling 114 2.23e-04 9.81e-04 0.21400 -0.050000 0.208000 3.58e-01 1.27e-04
UCH proteinases 75 2.28e-04 1.00e-03 0.25400 -0.164000 0.195000 1.42e-02 3.60e-03
ER-Phagosome pathway 68 2.32e-04 1.01e-03 0.26700 -0.158000 0.216000 2.46e-02 2.10e-03
HSF1-dependent transactivation 29 2.52e-04 1.09e-03 0.46500 0.285000 0.367000 7.96e-03 6.20e-04
Myogenesis 25 2.54e-04 1.10e-03 0.49100 0.195000 0.451000 9.15e-02 9.66e-05
DARPP-32 events 21 2.58e-04 1.11e-03 0.52900 0.163000 0.504000 1.96e-01 6.46e-05
trans-Golgi Network Vesicle Budding 60 2.65e-04 1.14e-03 0.32100 0.180000 0.267000 1.62e-02 3.59e-04
Nuclear Receptor transcription pathway 41 2.66e-04 1.14e-03 0.38800 0.205000 0.329000 2.35e-02 2.67e-04
Platelet activation, signaling and aggregation 169 2.67e-04 1.14e-03 0.18900 0.174000 0.074900 1.00e-04 9.39e-02
Dectin-2 family 10 2.71e-04 1.15e-03 0.74100 -0.054000 -0.739000 7.67e-01 5.24e-05
COPI-mediated anterograde transport 71 2.84e-04 1.21e-03 0.28300 0.060000 0.277000 3.83e-01 5.61e-05
COPI-independent Golgi-to-ER retrograde traffic 28 3.06e-04 1.30e-03 0.46800 0.298000 0.361000 6.34e-03 9.62e-04
Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways 42 3.26e-04 1.38e-03 0.38100 0.284000 0.254000 1.44e-03 4.46e-03
VEGFA-VEGFR2 Pathway 78 3.55e-04 1.49e-03 0.27900 0.205000 0.189000 1.78e-03 3.98e-03
Mitotic G2-G2/M phases 149 3.63e-04 1.52e-03 0.17800 -0.083500 0.157000 7.92e-02 9.79e-04
Apoptotic cleavage of cellular proteins 28 3.68e-04 1.53e-03 0.46300 0.306000 0.347000 5.06e-03 1.48e-03
Resolution of Sister Chromatid Cohesion 69 3.71e-04 1.54e-03 0.29300 0.158000 0.247000 2.33e-02 3.92e-04
G2/M Transition 148 3.80e-04 1.57e-03 0.17700 -0.088000 0.154000 6.52e-02 1.25e-03
RORA activates gene expression 17 3.82e-04 1.58e-03 0.59300 0.424000 0.414000 2.48e-03 3.10e-03
Cellular response to heat stress 87 3.85e-04 1.58e-03 0.25700 0.099100 0.237000 1.11e-01 1.36e-04
O-glycosylation of TSR domain-containing proteins 26 4.24e-04 1.74e-03 0.44500 -0.021900 -0.445000 8.47e-01 8.66e-05
HDMs demethylate histones 21 4.27e-04 1.74e-03 0.53000 0.380000 0.369000 2.58e-03 3.43e-03
G2/M Checkpoints 103 4.28e-04 1.74e-03 0.21000 -0.113000 0.177000 4.79e-02 1.93e-03
Intra-Golgi traffic 35 4.36e-04 1.77e-03 0.39800 0.131000 0.376000 1.79e-01 1.19e-04
Interleukin-1 signaling 83 4.38e-04 1.77e-03 0.24100 -0.053400 0.235000 4.01e-01 2.24e-04
Peptide ligand-binding receptors 39 4.40e-04 1.77e-03 0.33900 0.194000 -0.278000 3.63e-02 2.63e-03
Signaling by VEGF 85 5.17e-04 2.08e-03 0.25900 0.214000 0.146000 6.42e-04 2.04e-02
Formation of Incision Complex in GG-NER 40 5.33e-04 2.13e-03 0.33300 -0.155000 0.295000 9.01e-02 1.26e-03
Signaling by MET 56 5.56e-04 2.22e-03 0.31900 0.209000 0.241000 6.79e-03 1.85e-03
Global Genome Nucleotide Excision Repair (GG-NER) 76 5.74e-04 2.28e-03 0.23800 -0.177000 0.160000 7.70e-03 1.63e-02
Regulation of localization of FOXO transcription factors 11 6.11e-04 2.42e-03 0.71400 0.486000 0.523000 5.23e-03 2.66e-03
Activation of BH3-only proteins 24 6.61e-04 2.61e-03 0.48100 0.326000 0.354000 5.77e-03 2.67e-03
Regulation of PTEN gene transcription 56 7.04e-04 2.77e-03 0.31200 0.169000 0.262000 2.85e-02 7.01e-04
Disassembly of the destruction complex and recruitment of AXIN to the membrane 25 7.69e-04 3.02e-03 0.45800 0.194000 0.415000 9.36e-02 3.26e-04
Negative regulation of MAPK pathway 39 7.73e-04 3.02e-03 0.35600 0.063600 0.350000 4.92e-01 1.56e-04
Oxidative Stress Induced Senescence 64 7.81e-04 3.05e-03 0.28800 0.139000 0.253000 5.48e-02 4.79e-04
TICAM1, RIP1-mediated IKK complex recruitment 18 8.14e-04 3.16e-03 0.52400 0.115000 0.512000 3.97e-01 1.72e-04
Elastic fibre formation 33 8.87e-04 3.44e-03 0.35000 0.242000 -0.254000 1.63e-02 1.17e-02
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) 31 9.12e-04 3.52e-03 0.41400 0.284000 0.301000 6.15e-03 3.72e-03
Defective B3GALTL causes Peters-plus syndrome (PpS) 25 9.68e-04 3.73e-03 0.42600 0.005530 -0.426000 9.62e-01 2.30e-04
Regulation of TP53 Activity 130 9.99e-04 3.83e-03 0.20200 0.142000 0.143000 5.19e-03 4.94e-03
Cell-Cell communication 74 1.01e-03 3.85e-03 0.25600 0.248000 0.063100 2.24e-04 3.48e-01
IGF1R signaling cascade 30 1.11e-03 4.23e-03 0.41500 0.284000 0.303000 7.14e-03 4.11e-03
Signaling by FGFR2 52 1.12e-03 4.26e-03 0.31200 0.153000 0.272000 5.61e-02 7.12e-04
Mitotic Spindle Checkpoint 74 1.14e-03 4.34e-03 0.25600 0.081400 0.243000 2.27e-01 3.07e-04
TCR signaling 90 1.16e-03 4.39e-03 0.21700 -0.041300 0.213000 4.99e-01 4.90e-04
Signaling by FGFR1 in disease 31 1.18e-03 4.43e-03 0.40600 0.305000 0.269000 3.33e-03 9.60e-03
Interleukin-3, Interleukin-5 and GM-CSF signaling 29 1.18e-03 4.45e-03 0.40900 0.383000 0.146000 3.64e-04 1.74e-01
Misspliced GSK3beta mutants stabilize beta-catenin 15 1.28e-03 4.69e-03 0.57700 0.319000 0.481000 3.25e-02 1.26e-03
S33 mutants of beta-catenin aren’t phosphorylated 15 1.28e-03 4.69e-03 0.57700 0.319000 0.481000 3.25e-02 1.26e-03
S37 mutants of beta-catenin aren’t phosphorylated 15 1.28e-03 4.69e-03 0.57700 0.319000 0.481000 3.25e-02 1.26e-03
S45 mutants of beta-catenin aren’t phosphorylated 15 1.28e-03 4.69e-03 0.57700 0.319000 0.481000 3.25e-02 1.26e-03
T41 mutants of beta-catenin aren’t phosphorylated 15 1.28e-03 4.69e-03 0.57700 0.319000 0.481000 3.25e-02 1.26e-03
phosphorylation site mutants of CTNNB1 are not targeted to the proteasome by the destruction complex 15 1.28e-03 4.69e-03 0.57700 0.319000 0.481000 3.25e-02 1.26e-03
Phase II - Conjugation of compounds 50 1.28e-03 4.69e-03 0.27700 -0.188000 0.204000 2.19e-02 1.25e-02
Interleukin-6 signaling 11 1.32e-03 4.84e-03 0.66300 0.605000 0.270000 5.07e-04 1.21e-01
IRS-related events triggered by IGF1R 29 1.35e-03 4.93e-03 0.41600 0.274000 0.313000 1.07e-02 3.57e-03
Rho GTPase cycle 113 1.40e-03 5.10e-03 0.19300 0.191000 -0.022600 4.48e-04 6.79e-01
Death Receptor Signalling 114 1.41e-03 5.10e-03 0.20600 0.186000 0.090100 6.28e-04 9.71e-02
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell 39 1.42e-03 5.15e-03 0.32400 0.058200 -0.319000 5.30e-01 5.71e-04
Beta-catenin phosphorylation cascade 16 1.45e-03 5.23e-03 0.55300 0.300000 0.464000 3.76e-02 1.30e-03
Signaling by FGFR1 38 1.48e-03 5.30e-03 0.36100 0.259000 0.252000 5.83e-03 7.20e-03
RMTs methylate histone arginines 29 1.48e-03 5.30e-03 0.38800 0.029000 0.387000 7.87e-01 3.15e-04
Insulin receptor signalling cascade 31 1.52e-03 5.42e-03 0.39800 0.253000 0.308000 1.48e-02 3.05e-03
Gluconeogenesis 22 1.55e-03 5.51e-03 0.41900 -0.385000 0.165000 1.80e-03 1.80e-01
Nuclear Events (kinase and transcription factor activation) 23 1.57e-03 5.58e-03 0.45800 0.237000 0.391000 4.89e-02 1.16e-03
MECP2 regulates neuronal receptors and channels 11 1.64e-03 5.81e-03 0.65300 0.593000 0.273000 6.64e-04 1.16e-01
Meiosis 42 1.66e-03 5.85e-03 0.33200 0.118000 0.310000 1.86e-01 5.09e-04
Oncogenic MAPK signaling 58 1.66e-03 5.86e-03 0.29000 0.201000 0.209000 8.10e-03 6.02e-03
RAF activation 30 1.76e-03 6.17e-03 0.38400 0.088000 0.374000 4.04e-01 3.93e-04
Semaphorin interactions 55 1.83e-03 6.41e-03 0.27100 0.269000 -0.027800 5.61e-04 7.22e-01
IRS-mediated signalling 26 1.87e-03 6.51e-03 0.42800 0.274000 0.329000 1.58e-02 3.69e-03
Activation of BAD and translocation to mitochondria 13 1.87e-03 6.53e-03 0.59900 0.296000 0.520000 6.44e-02 1.16e-03
RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known 34 1.95e-03 6.77e-03 0.36900 0.184000 0.321000 6.38e-02 1.22e-03
Transcriptional regulation of granulopoiesis 26 1.97e-03 6.82e-03 0.42400 0.353000 0.235000 1.84e-03 3.82e-02
Signaling by FGFR 61 2.00e-03 6.90e-03 0.27700 0.159000 0.227000 3.24e-02 2.15e-03
SUMOylation of intracellular receptors 26 2.00e-03 6.90e-03 0.42600 0.292000 0.310000 9.97e-03 6.21e-03
Glycogen metabolism 24 2.06e-03 7.07e-03 0.41400 0.020700 0.413000 8.61e-01 4.59e-04
Regulation of cholesterol biosynthesis by SREBP (SREBF) 51 2.07e-03 7.07e-03 0.30400 0.223000 0.206000 5.93e-03 1.09e-02
Cyclin D associated events in G1 38 2.24e-03 7.62e-03 0.34100 0.126000 0.317000 1.79e-01 7.30e-04
G1 Phase 38 2.24e-03 7.62e-03 0.34100 0.126000 0.317000 1.79e-01 7.30e-04
G alpha (12/13) signalling events 56 2.30e-03 7.79e-03 0.26200 0.260000 -0.033100 7.57e-04 6.69e-01
Mitochondrial calcium ion transport 21 2.31e-03 7.80e-03 0.40900 -0.322000 0.252000 1.06e-02 4.61e-02
Glycogen synthesis 13 2.36e-03 7.98e-03 0.55000 -0.009700 0.550000 9.52e-01 5.91e-04
Regulation of MECP2 expression and activity 28 2.42e-03 8.13e-03 0.39900 0.189000 0.351000 8.30e-02 1.29e-03
Signaling by NOTCH3 40 2.46e-03 8.24e-03 0.33800 0.232000 0.246000 1.11e-02 7.21e-03
Synthesis of active ubiquitin: roles of E1 and E2 enzymes 29 2.48e-03 8.29e-03 0.36200 -0.048100 0.359000 6.54e-01 8.36e-04
BMAL1:CLOCK,NPAS2 activates circadian gene expression 23 2.53e-03 8.44e-03 0.44400 0.339000 0.287000 4.95e-03 1.72e-02
COPII-mediated vesicle transport 57 2.54e-03 8.45e-03 0.28200 0.211000 0.188000 5.92e-03 1.43e-02
Meiotic synapsis 26 2.60e-03 8.63e-03 0.40800 0.162000 0.375000 1.52e-01 9.46e-04
mTOR signalling 37 2.65e-03 8.78e-03 0.32700 0.019700 0.326000 8.36e-01 5.95e-04
FOXO-mediated transcription of cell death genes 13 2.72e-03 8.98e-03 0.58500 0.340000 0.476000 3.39e-02 2.97e-03
HSF1 activation 24 2.73e-03 8.98e-03 0.43000 0.245000 0.353000 3.77e-02 2.73e-03
Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal 60 2.78e-03 9.11e-03 0.27100 0.140000 0.232000 6.03e-02 1.93e-03
Amplification of signal from the kinetochores 60 2.78e-03 9.11e-03 0.27100 0.140000 0.232000 6.03e-02 1.93e-03
mRNA Splicing - Minor Pathway 39 2.79e-03 9.12e-03 0.29700 -0.149000 0.257000 1.08e-01 5.44e-03
RET signaling 27 2.96e-03 9.65e-03 0.39600 0.366000 0.151000 1.01e-03 1.75e-01
Deactivation of the beta-catenin transactivating complex 36 3.01e-03 9.78e-03 0.34900 0.209000 0.279000 3.00e-02 3.73e-03
Signaling by NODAL 11 3.03e-03 9.80e-03 0.63100 0.495000 0.392000 4.51e-03 2.43e-02
Autophagy 94 3.07e-03 9.90e-03 0.20600 0.036000 0.203000 5.47e-01 6.75e-04
MET activates RAP1 and RAC1 10 3.07e-03 9.90e-03 0.66100 0.401000 0.525000 2.80e-02 4.05e-03
Striated Muscle Contraction 30 3.11e-03 1.00e-02 0.34300 -0.092300 0.330000 3.82e-01 1.74e-03
Protein ubiquitination 59 3.13e-03 1.00e-02 0.26700 0.103000 0.246000 1.73e-01 1.08e-03
AMER1 mutants destabilize the destruction complex 14 3.18e-03 1.00e-02 0.55500 0.303000 0.465000 4.96e-02 2.62e-03
APC truncation mutants have impaired AXIN binding 14 3.18e-03 1.00e-02 0.55500 0.303000 0.465000 4.96e-02 2.62e-03
AXIN missense mutants destabilize the destruction complex 14 3.18e-03 1.00e-02 0.55500 0.303000 0.465000 4.96e-02 2.62e-03
AXIN mutants destabilize the destruction complex, activating WNT signaling 14 3.18e-03 1.00e-02 0.55500 0.303000 0.465000 4.96e-02 2.62e-03
Truncations of AMER1 destabilize the destruction complex 14 3.18e-03 1.00e-02 0.55500 0.303000 0.465000 4.96e-02 2.62e-03
truncated APC mutants destabilize the destruction complex 14 3.18e-03 1.00e-02 0.55500 0.303000 0.465000 4.96e-02 2.62e-03
Nucleotide Excision Repair 97 3.33e-03 1.04e-02 0.18500 -0.133000 0.128000 2.36e-02 2.99e-02
tRNA processing 86 3.33e-03 1.04e-02 0.19800 -0.178000 0.087900 4.41e-03 1.59e-01
Nephrin family interactions 17 3.34e-03 1.04e-02 0.48500 0.469000 0.123000 8.06e-04 3.81e-01
Signaling by FGFR3 29 3.38e-03 1.05e-02 0.38500 0.242000 0.300000 2.39e-02 5.23e-03
Regulation of PTEN mRNA translation 12 3.38e-03 1.05e-02 0.60000 0.405000 0.442000 1.51e-02 8.05e-03
Phosphorylation of CD3 and TCR zeta chains 12 3.50e-03 1.08e-02 0.52600 0.254000 -0.460000 1.28e-01 5.78e-03
Signaling by BRAF and RAF fusions 54 3.50e-03 1.08e-02 0.28100 0.168000 0.226000 3.31e-02 4.11e-03
Hedgehog ‘on’ state 71 3.70e-03 1.14e-02 0.21400 -0.152000 0.150000 2.72e-02 2.88e-02
Constitutive Signaling by EGFRvIII 15 3.87e-03 1.19e-02 0.52800 0.428000 0.310000 4.15e-03 3.77e-02
Signaling by EGFRvIII in Cancer 15 3.87e-03 1.19e-02 0.52800 0.428000 0.310000 4.15e-03 3.77e-02
NRAGE signals death through JNK 44 3.99e-03 1.22e-02 0.28800 0.288000 0.007490 9.57e-04 9.32e-01
Glycogen storage diseases 13 4.01e-03 1.23e-02 0.50100 -0.219000 0.451000 1.72e-01 4.92e-03
Antigen processing-Cross presentation 77 4.05e-03 1.23e-02 0.20400 -0.111000 0.171000 9.13e-02 9.38e-03
RNA Polymerase II Transcription Termination 54 4.13e-03 1.25e-02 0.24300 -0.151000 0.190000 5.44e-02 1.61e-02
Retrograde transport at the Trans-Golgi-Network 44 4.14e-03 1.26e-02 0.29200 0.040900 0.289000 6.39e-01 9.25e-04
Diseases of glycosylation 97 4.23e-03 1.28e-02 0.19500 -0.015700 -0.194000 7.90e-01 9.64e-04
Post-translational modification: synthesis of GPI-anchored proteins 42 4.36e-03 1.31e-02 0.31300 -0.199000 -0.242000 2.54e-02 6.77e-03
IKK complex recruitment mediated by RIP1 20 4.39e-03 1.32e-02 0.44400 0.176000 0.408000 1.73e-01 1.58e-03
Activation of gene expression by SREBF (SREBP) 39 4.42e-03 1.33e-02 0.32500 0.218000 0.241000 1.88e-02 9.10e-03
Activation of GABAB receptors 23 4.70e-03 1.40e-02 0.36700 0.215000 -0.298000 7.40e-02 1.35e-02
GABA B receptor activation 23 4.70e-03 1.40e-02 0.36700 0.215000 -0.298000 7.40e-02 1.35e-02
Metabolism of lipids 509 4.80e-03 1.43e-02 0.08780 0.025000 0.084200 3.39e-01 1.25e-03
Cell-extracellular matrix interactions 15 4.89e-03 1.45e-02 0.51900 0.382000 0.351000 1.04e-02 1.87e-02
Smooth Muscle Contraction 35 4.94e-03 1.47e-02 0.32000 0.036100 0.318000 7.12e-01 1.12e-03
AKT phosphorylates targets in the nucleus 10 5.03e-03 1.49e-02 0.63300 0.478000 0.416000 8.92e-03 2.28e-02
Interleukin-1 family signaling 103 5.13e-03 1.51e-02 0.18400 -0.000140 0.184000 9.98e-01 1.30e-03
Tie2 Signaling 14 5.14e-03 1.51e-02 0.52600 0.470000 0.238000 2.34e-03 1.24e-01
Signaling by FGFR4 31 5.16e-03 1.52e-02 0.35900 0.243000 0.265000 1.95e-02 1.07e-02
Axon guidance 382 5.25e-03 1.54e-02 0.09640 0.001110 0.096400 9.70e-01 1.31e-03
DNA Repair 236 5.29e-03 1.55e-02 0.11500 -0.058000 0.099200 1.26e-01 8.89e-03
Signaling by EGFR in Cancer 21 5.38e-03 1.57e-02 0.43500 0.308000 0.307000 1.46e-02 1.50e-02
Pyruvate metabolism and Citric Acid (TCA) cycle 48 5.43e-03 1.58e-02 0.26500 -0.014600 0.265000 8.61e-01 1.52e-03
Negative regulation of the PI3K/AKT network 73 5.50e-03 1.59e-02 0.23300 0.175000 0.154000 9.78e-03 2.33e-02
Signaling by NOTCH2 27 5.50e-03 1.59e-02 0.38200 0.302000 0.233000 6.54e-03 3.64e-02
Senescence-Associated Secretory Phenotype (SASP) 44 5.75e-03 1.66e-02 0.28700 0.068000 0.278000 4.35e-01 1.40e-03
PI3K Cascade 22 5.77e-03 1.66e-02 0.41900 0.224000 0.354000 6.87e-02 4.10e-03
Downstream signaling of activated FGFR2 17 5.98e-03 1.72e-02 0.47600 0.389000 0.274000 5.48e-03 5.04e-02
L1CAM interactions 69 6.22e-03 1.78e-02 0.23400 0.206000 0.110000 3.05e-03 1.16e-01
Platelet Aggregation (Plug Formation) 23 6.29e-03 1.80e-02 0.38100 0.381000 0.004610 1.58e-03 9.69e-01
Hedgehog ‘off’ state 88 6.33e-03 1.80e-02 0.18200 -0.131000 0.127000 3.40e-02 3.95e-02
APC-Cdc20 mediated degradation of Nek2A 20 6.37e-03 1.81e-02 0.38200 -0.235000 0.302000 6.92e-02 1.96e-02
Epigenetic regulation of gene expression 80 6.46e-03 1.83e-02 0.21900 0.138000 0.170000 3.32e-02 8.63e-03
Amino acid transport across the plasma membrane 21 6.63e-03 1.88e-02 0.37700 -0.153000 0.344000 2.24e-01 6.35e-03
Transport of small molecules 447 6.64e-03 1.88e-02 0.08190 -0.050400 0.064500 6.97e-02 2.03e-02
Glucose metabolism 72 6.75e-03 1.90e-02 0.20300 -0.087400 0.183000 2.00e-01 7.22e-03
Cell surface interactions at the vascular wall 76 7.17e-03 2.02e-02 0.20300 0.202000 -0.024300 2.36e-03 7.15e-01
Citric acid cycle (TCA cycle) 21 7.19e-03 2.02e-02 0.39600 0.028400 0.395000 8.22e-01 1.72e-03
Uptake and actions of bacterial toxins 22 7.33e-03 2.05e-02 0.40700 0.357000 0.196000 3.79e-03 1.12e-01
Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA 14 7.35e-03 2.05e-02 0.50200 0.172000 0.472000 2.67e-01 2.24e-03
CD28 dependent PI3K/Akt signaling 14 7.41e-03 2.06e-02 0.51000 0.255000 0.442000 9.86e-02 4.20e-03
tRNA modification in the nucleus and cytosol 30 7.65e-03 2.13e-02 0.31400 -0.298000 0.098400 4.76e-03 3.51e-01
NOD1/2 Signaling Pathway 29 7.69e-03 2.13e-02 0.35700 0.258000 0.247000 1.63e-02 2.13e-02
Downstream signaling of activated FGFR1 21 7.77e-03 2.15e-02 0.41600 0.352000 0.222000 5.27e-03 7.83e-02
EGFR downregulation 25 7.83e-03 2.16e-02 0.38100 0.205000 0.321000 7.54e-02 5.48e-03
Deadenylation-dependent mRNA decay 50 7.88e-03 2.17e-02 0.26900 0.143000 0.228000 7.97e-02 5.29e-03
TNFR1-induced NFkappaB signaling pathway 24 7.95e-03 2.18e-02 0.38200 0.144000 0.354000 2.24e-01 2.68e-03
Regulation of RUNX1 Expression and Activity 17 8.04e-03 2.21e-02 0.44900 0.429000 0.133000 2.21e-03 3.43e-01
Integrin alphaIIb beta3 signaling 20 8.11e-03 2.21e-02 0.40700 0.400000 0.072600 1.94e-03 5.74e-01
Integrin signaling 20 8.11e-03 2.21e-02 0.40700 0.400000 0.072600 1.94e-03 5.74e-01
CLEC7A (Dectin-1) induces NFAT activation 11 8.18e-03 2.23e-02 0.53800 0.023900 0.538000 8.91e-01 2.02e-03
Synthesis of PIPs at the early endosome membrane 16 8.33e-03 2.26e-02 0.47700 0.333000 0.341000 2.12e-02 1.82e-02
Degradation of the extracellular matrix 58 8.35e-03 2.26e-02 0.21900 0.174000 -0.132000 2.17e-02 8.24e-02
GPCR downstream signalling 296 8.36e-03 2.26e-02 0.09920 0.091300 -0.038800 7.16e-03 2.52e-01
Pre-NOTCH Processing in Golgi 16 8.47e-03 2.29e-02 0.41400 0.299000 -0.287000 3.85e-02 4.70e-02
G alpha (q) signalling events 79 8.88e-03 2.39e-02 0.20500 0.199000 0.050600 2.27e-03 4.37e-01
Interleukin-12 family signaling 35 8.91e-03 2.39e-02 0.31000 0.093100 0.296000 3.41e-01 2.49e-03
Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors 25 8.95e-03 2.40e-02 0.37800 0.240000 0.292000 3.77e-02 1.16e-02
ERK/MAPK targets 20 9.09e-03 2.43e-02 0.41900 0.220000 0.356000 8.84e-02 5.80e-03
Downstream signaling of activated FGFR3 15 9.23e-03 2.46e-02 0.48400 0.404000 0.265000 6.69e-03 7.52e-02
Energy dependent regulation of mTOR by LKB1-AMPK 26 9.25e-03 2.46e-02 0.34400 0.002430 0.344000 9.83e-01 2.41e-03
Metabolism of nucleotides 77 9.26e-03 2.46e-02 0.19100 -0.177000 0.072600 7.44e-03 2.71e-01
Signaling by GPCR 321 9.27e-03 2.46e-02 0.09350 0.081300 -0.046200 1.27e-02 1.57e-01
Pre-NOTCH Expression and Processing 48 9.38e-03 2.48e-02 0.25700 0.255000 0.029100 2.25e-03 7.27e-01
Generation of second messenger molecules 18 9.39e-03 2.48e-02 0.38800 0.318000 -0.222000 1.96e-02 1.03e-01
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription 31 9.64e-03 2.54e-02 0.33500 0.178000 0.283000 8.57e-02 6.37e-03
Adenylate cyclase inhibitory pathway 12 9.69e-03 2.55e-02 0.47400 0.402000 -0.252000 1.58e-02 1.31e-01
Loss of function of MECP2 in Rett syndrome 11 9.83e-03 2.57e-02 0.53300 0.065400 0.529000 7.07e-01 2.36e-03
Pervasive developmental disorders 11 9.83e-03 2.57e-02 0.53300 0.065400 0.529000 7.07e-01 2.36e-03
DNA Damage Recognition in GG-NER 35 9.95e-03 2.60e-02 0.27600 -0.207000 0.182000 3.42e-02 6.23e-02
Detoxification of Reactive Oxygen Species 23 1.00e-02 2.61e-02 0.34000 -0.251000 0.229000 3.76e-02 5.72e-02
MET promotes cell motility 24 1.03e-02 2.69e-02 0.38000 0.296000 0.238000 1.22e-02 4.36e-02
Ion homeostasis 42 1.06e-02 2.76e-02 0.27400 0.055400 0.268000 5.35e-01 2.63e-03
Regulation of signaling by CBL 14 1.11e-02 2.86e-02 0.47900 0.455000 0.149000 3.21e-03 3.34e-01
EPH-Ephrin signaling 68 1.11e-02 2.86e-02 0.22400 0.177000 0.138000 1.18e-02 4.94e-02
activated TAK1 mediates p38 MAPK activation 18 1.13e-02 2.91e-02 0.43300 0.247000 0.356000 7.00e-02 9.03e-03
Factors involved in megakaryocyte development and platelet production 84 1.16e-02 2.97e-02 0.18900 0.188000 0.016400 2.86e-03 7.95e-01
VEGFR2 mediated vascular permeability 21 1.16e-02 2.97e-02 0.39600 0.184000 0.351000 1.44e-01 5.43e-03
Non-integrin membrane-ECM interactions 33 1.22e-02 3.11e-02 0.28700 0.278000 -0.070900 5.77e-03 4.81e-01
Binding and Uptake of Ligands by Scavenger Receptors 26 1.22e-02 3.11e-02 0.31500 0.166000 -0.267000 1.43e-01 1.84e-02
RUNX2 regulates bone development 26 1.22e-02 3.12e-02 0.35800 0.224000 0.279000 4.83e-02 1.37e-02
Signaling by FGFR3 in disease 12 1.23e-02 3.12e-02 0.52700 0.394000 0.350000 1.81e-02 3.59e-02
Signaling by FGFR3 point mutants in cancer 12 1.23e-02 3.12e-02 0.52700 0.394000 0.350000 1.81e-02 3.59e-02
Downstream signaling of activated FGFR4 17 1.24e-02 3.12e-02 0.43700 0.386000 0.206000 5.93e-03 1.41e-01
Peroxisomal protein import 50 1.24e-02 3.12e-02 0.22600 -0.139000 0.177000 8.86e-02 3.01e-02
Fcgamma receptor (FCGR) dependent phagocytosis 69 1.24e-02 3.13e-02 0.21700 0.194000 0.096500 5.34e-03 1.66e-01
RNA polymerase II transcribes snRNA genes 64 1.27e-02 3.19e-02 0.22600 0.122000 0.190000 9.06e-02 8.46e-03
Signaling by ERBB2 41 1.27e-02 3.19e-02 0.28300 0.162000 0.232000 7.27e-02 1.01e-02
CD28 co-stimulation 22 1.27e-02 3.19e-02 0.38600 0.219000 0.318000 7.57e-02 9.81e-03
Signaling by Erythropoietin 21 1.28e-02 3.20e-02 0.38400 0.366000 0.119000 3.72e-03 3.47e-01
Competing endogenous RNAs (ceRNAs) regulate PTEN translation 11 1.28e-02 3.20e-02 0.54800 0.364000 0.410000 3.67e-02 1.86e-02
PD-1 signaling 13 1.29e-02 3.21e-02 0.44100 0.240000 -0.370000 1.34e-01 2.08e-02
Processing of SMDT1 14 1.29e-02 3.22e-02 0.42600 -0.364000 0.221000 1.85e-02 1.52e-01
Signalling to ERKs 30 1.37e-02 3.41e-02 0.33000 0.235000 0.231000 2.60e-02 2.85e-02
Import of palmitoyl-CoA into the mitochondrial matrix 11 1.39e-02 3.43e-02 0.53900 0.458000 0.284000 8.57e-03 1.03e-01
p75 NTR receptor-mediated signalling 73 1.41e-02 3.49e-02 0.20400 0.195000 0.060100 4.02e-03 3.75e-01
Assembly of active LPL and LIPC lipase complexes 10 1.44e-02 3.55e-02 0.49600 0.407000 -0.283000 2.58e-02 1.21e-01
Activated NOTCH1 Transmits Signal to the Nucleus 26 1.45e-02 3.57e-02 0.33400 0.330000 0.052600 3.62e-03 6.43e-01
Defective B3GALT6 causes EDSP2 and SEMDJL1 11 1.46e-02 3.58e-02 0.47200 0.386000 -0.271000 2.66e-02 1.19e-01
Keratan sulfate biosynthesis 18 1.46e-02 3.58e-02 0.38600 0.384000 -0.041600 4.78e-03 7.60e-01
Nucleotide salvage 18 1.46e-02 3.58e-02 0.37000 -0.312000 0.199000 2.20e-02 1.45e-01
Deadenylation of mRNA 24 1.48e-02 3.62e-02 0.36500 0.240000 0.274000 4.15e-02 2.00e-02
Transcriptional regulation of pluripotent stem cells 11 1.49e-02 3.62e-02 0.53400 0.273000 0.459000 1.17e-01 8.44e-03
Transport of Mature mRNA derived from an Intron-Containing Transcript 62 1.50e-02 3.66e-02 0.19900 -0.110000 0.165000 1.33e-01 2.47e-02
Pre-NOTCH Transcription and Translation 34 1.51e-02 3.67e-02 0.30200 0.269000 0.137000 6.69e-03 1.68e-01
TAK1 activates NFkB by phosphorylation and activation of IKKs complex 21 1.52e-02 3.68e-02 0.38900 0.292000 0.257000 2.07e-02 4.12e-02
Rap1 signalling 13 1.55e-02 3.74e-02 0.49300 0.316000 0.378000 4.83e-02 1.84e-02
Cell death signalling via NRAGE, NRIF and NADE 58 1.55e-02 3.74e-02 0.22800 0.213000 0.082400 5.12e-03 2.78e-01
mRNA 3’-end processing 46 1.57e-02 3.78e-02 0.22900 -0.140000 0.181000 9.98e-02 3.43e-02
Syndecan interactions 15 1.60e-02 3.83e-02 0.40800 0.385000 -0.134000 9.81e-03 3.68e-01
NCAM1 interactions 21 1.61e-02 3.86e-02 0.35500 0.028600 -0.354000 8.21e-01 5.02e-03
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling 67 1.62e-02 3.89e-02 0.21600 0.166000 0.139000 1.91e-02 4.95e-02
B-WICH complex positively regulates rRNA expression 30 1.66e-02 3.96e-02 0.32200 0.234000 0.222000 2.69e-02 3.54e-02
NR1H2 and NR1H3-mediated signaling 37 1.67e-02 3.98e-02 0.28600 0.133000 0.253000 1.62e-01 7.72e-03
DNA strand elongation 28 1.67e-02 3.98e-02 0.32300 -0.307000 -0.098400 4.91e-03 3.68e-01
Purine salvage 13 1.72e-02 4.09e-02 0.42600 -0.348000 0.245000 2.98e-02 1.27e-01
RUNX3 regulates NOTCH signaling 12 1.74e-02 4.13e-02 0.50400 0.408000 0.295000 1.43e-02 7.65e-02
Diseases of carbohydrate metabolism 27 1.79e-02 4.24e-02 0.29600 -0.262000 0.138000 1.84e-02 2.16e-01
Constitutive Signaling by Aberrant PI3K in Cancer 41 1.82e-02 4.30e-02 0.27100 0.221000 0.158000 1.45e-02 8.05e-02
Ovarian tumor domain proteases 34 1.83e-02 4.30e-02 0.29500 0.137000 0.261000 1.69e-01 8.35e-03
mTORC1-mediated signalling 21 1.84e-02 4.32e-02 0.34900 -0.032500 0.347000 7.97e-01 5.90e-03
Prolonged ERK activation events 12 1.86e-02 4.36e-02 0.49200 0.200000 0.450000 2.30e-01 7.02e-03
NOTCH3 Intracellular Domain Regulates Transcription 18 1.90e-02 4.44e-02 0.40500 0.347000 0.209000 1.08e-02 1.25e-01
Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer’s disease models 17 1.90e-02 4.44e-02 0.41600 0.205000 0.362000 1.44e-01 9.78e-03
Neurodegenerative Diseases 17 1.90e-02 4.44e-02 0.41600 0.205000 0.362000 1.44e-01 9.78e-03
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants 19 1.92e-02 4.47e-02 0.39700 0.251000 0.308000 5.87e-02 2.03e-02
Signaling by Ligand-Responsive EGFR Variants in Cancer 19 1.92e-02 4.47e-02 0.39700 0.251000 0.308000 5.87e-02 2.03e-02
Other semaphorin interactions 15 1.99e-02 4.61e-02 0.38800 0.277000 -0.271000 6.32e-02 6.90e-02
Protein methylation 14 2.01e-02 4.66e-02 0.40600 -0.172000 0.369000 2.67e-01 1.70e-02
Glycolysis 58 2.02e-02 4.67e-02 0.20400 -0.044900 0.199000 5.54e-01 8.72e-03
Transcription-Coupled Nucleotide Excision Repair (TC-NER) 67 2.10e-02 4.84e-02 0.18500 -0.164000 0.085000 2.05e-02 2.29e-01
Interleukin-10 signaling 15 2.14e-02 4.92e-02 0.41200 0.412000 0.016800 5.78e-03 9.10e-01
Transcriptional Regulation by E2F6 31 2.18e-02 5.01e-02 0.30300 0.260000 0.155000 1.21e-02 1.34e-01
ECM proteoglycans 34 2.31e-02 5.31e-02 0.25600 0.231000 -0.111000 1.98e-02 2.64e-01
Platelet degranulation 85 2.36e-02 5.41e-02 0.17300 0.172000 0.017200 6.24e-03 7.85e-01
E3 ubiquitin ligases ubiquitinate target proteins 40 2.39e-02 5.45e-02 0.26300 0.125000 0.231000 1.71e-01 1.13e-02
NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux 31 2.39e-02 5.45e-02 0.29500 0.104000 0.276000 3.16e-01 7.91e-03
Regulation of glycolysis by fructose 2,6-bisphosphate metabolism 11 2.40e-02 5.45e-02 0.49400 0.172000 0.463000 3.22e-01 7.86e-03
Regulation of HSF1-mediated heat shock response 71 2.45e-02 5.56e-02 0.19500 0.075800 0.180000 2.70e-01 8.84e-03
RNA Polymerase III Transcription Termination 18 2.46e-02 5.57e-02 0.36700 0.000865 0.367000 9.95e-01 6.98e-03
Scavenging by Class A Receptors 13 2.49e-02 5.64e-02 0.41900 0.091800 -0.409000 5.67e-01 1.07e-02
Signaling by FGFR in disease 45 2.50e-02 5.65e-02 0.24900 0.197000 0.152000 2.23e-02 7.73e-02
Rab regulation of trafficking 103 2.51e-02 5.66e-02 0.16500 0.102000 0.129000 7.29e-02 2.35e-02
Extension of Telomeres 27 2.52e-02 5.66e-02 0.30200 -0.301000 -0.021700 6.78e-03 8.45e-01
NOTCH4 Intracellular Domain Regulates Transcription 17 2.54e-02 5.70e-02 0.40000 0.349000 0.197000 1.28e-02 1.60e-01
N-glycan trimming in the ER and Calnexin/Calreticulin cycle 32 2.55e-02 5.70e-02 0.27300 -0.006390 0.273000 9.50e-01 7.49e-03
Signaling by Non-Receptor Tyrosine Kinases 45 2.55e-02 5.70e-02 0.24800 0.150000 0.198000 8.20e-02 2.17e-02
Signaling by PTK6 45 2.55e-02 5.70e-02 0.24800 0.150000 0.198000 8.20e-02 2.17e-02
Synthesis of glycosylphosphatidylinositol (GPI) 15 2.56e-02 5.70e-02 0.42000 -0.390000 -0.156000 8.86e-03 2.95e-01
Organelle biogenesis and maintenance 223 2.58e-02 5.74e-02 0.10900 0.032200 0.104000 4.09e-01 7.72e-03
Chromosome Maintenance 51 2.59e-02 5.74e-02 0.21200 -0.210000 0.033000 9.57e-03 6.84e-01
Gastrin-CREB signalling pathway via PKC and MAPK 13 2.62e-02 5.80e-02 0.46000 0.361000 0.285000 2.41e-02 7.54e-02
Dual Incision in GG-NER 36 2.67e-02 5.90e-02 0.24700 -0.235000 0.077000 1.48e-02 4.24e-01
Apoptotic factor-mediated response 16 2.67e-02 5.90e-02 0.38100 -0.026700 0.380000 8.53e-01 8.44e-03
PERK regulates gene expression 25 2.68e-02 5.90e-02 0.31500 0.052800 0.311000 6.48e-01 7.16e-03
Translesion synthesis by POLI 17 2.69e-02 5.92e-02 0.35300 -0.307000 0.174000 2.83e-02 2.15e-01
Membrane binding and targetting of GAG proteins 12 2.72e-02 5.97e-02 0.42400 -0.155000 0.395000 3.53e-01 1.80e-02
Synthesis And Processing Of GAG, GAGPOL Polyproteins 12 2.72e-02 5.97e-02 0.42400 -0.155000 0.395000 3.53e-01 1.80e-02
PECAM1 interactions 10 2.73e-02 5.98e-02 0.45700 0.381000 -0.253000 3.71e-02 1.66e-01
SHC1 events in EGFR signaling 10 2.78e-02 6.06e-02 0.51400 0.458000 0.232000 1.21e-02 2.05e-01
Assembly Of The HIV Virion 14 2.83e-02 6.16e-02 0.39300 -0.120000 0.374000 4.38e-01 1.53e-02
Interleukin-7 signaling 12 2.87e-02 6.24e-02 0.47300 0.373000 0.291000 2.54e-02 8.08e-02
SUMOylation of transcription cofactors 40 2.87e-02 6.24e-02 0.26000 0.172000 0.194000 5.96e-02 3.35e-02
Other interleukin signaling 16 2.88e-02 6.24e-02 0.35800 0.216000 -0.285000 1.34e-01 4.83e-02
Inflammasomes 14 2.91e-02 6.29e-02 0.43400 0.372000 0.224000 1.61e-02 1.46e-01
Regulation of KIT signaling 14 2.92e-02 6.30e-02 0.39600 0.387000 -0.082800 1.22e-02 5.92e-01
Clathrin-mediated endocytosis 110 2.93e-02 6.33e-02 0.15700 0.111000 0.110000 4.43e-02 4.60e-02
APC/C:Cdc20 mediated degradation of Cyclin B 19 2.99e-02 6.43e-02 0.32700 -0.194000 0.263000 1.43e-01 4.72e-02
Endosomal Sorting Complex Required For Transport (ESCRT) 26 3.01e-02 6.43e-02 0.28500 -0.098600 0.267000 3.85e-01 1.84e-02
Positive epigenetic regulation of rRNA expression 45 3.01e-02 6.43e-02 0.24300 0.183000 0.160000 3.34e-02 6.39e-02
Inactivation of APC/C via direct inhibition of the APC/C complex 16 3.01e-02 6.43e-02 0.35700 -0.190000 0.302000 1.88e-01 3.63e-02
Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components 16 3.01e-02 6.43e-02 0.35700 -0.190000 0.302000 1.88e-01 3.63e-02
Signaling by Hedgehog 114 3.04e-02 6.48e-02 0.13400 -0.077500 0.109000 1.54e-01 4.47e-02
Mitotic Prometaphase 133 3.05e-02 6.49e-02 0.13900 0.053100 0.128000 2.91e-01 1.09e-02
mRNA decay by 5’ to 3’ exoribonuclease 13 3.06e-02 6.51e-02 0.44400 0.198000 0.398000 2.18e-01 1.31e-02
Synaptic adhesion-like molecules 12 3.07e-02 6.51e-02 0.46600 -0.256000 -0.390000 1.25e-01 1.94e-02
PRC2 methylates histones and DNA 16 3.08e-02 6.53e-02 0.40100 0.192000 0.352000 1.83e-01 1.47e-02
Budding and maturation of HIV virion 23 3.09e-02 6.53e-02 0.30200 -0.101000 0.285000 4.04e-01 1.81e-02
Resolution of Abasic Sites (AP sites) 35 3.10e-02 6.54e-02 0.26100 -0.257000 -0.043600 8.42e-03 6.56e-01
Signaling by Insulin receptor 47 3.11e-02 6.55e-02 0.23500 0.121000 0.201000 1.51e-01 1.70e-02
Interleukin-15 signaling 11 3.12e-02 6.57e-02 0.48900 0.363000 0.328000 3.72e-02 6.00e-02
FGFR1 mutant receptor activation 24 3.15e-02 6.62e-02 0.33100 0.245000 0.222000 3.81e-02 5.94e-02
Neurexins and neuroligins 29 3.16e-02 6.63e-02 0.26300 0.150000 -0.216000 1.62e-01 4.42e-02
O-linked glycosylation 62 3.17e-02 6.63e-02 0.18600 0.035800 -0.183000 6.27e-01 1.28e-02
Molecules associated with elastic fibres 23 3.20e-02 6.69e-02 0.29900 0.278000 -0.110000 2.09e-02 3.60e-01
Oncogene Induced Senescence 30 3.24e-02 6.75e-02 0.29300 0.164000 0.243000 1.19e-01 2.14e-02
Late Phase of HIV Life Cycle 113 3.26e-02 6.78e-02 0.14200 0.004170 0.142000 9.39e-01 9.28e-03
Defective B3GAT3 causes JDSSDHD 12 3.27e-02 6.79e-02 0.40600 0.317000 -0.253000 5.75e-02 1.29e-01
Response to elevated platelet cytosolic Ca2+ 88 3.29e-02 6.83e-02 0.16500 0.161000 0.037000 9.28e-03 5.49e-01
Signaling by ERBB4 40 3.32e-02 6.88e-02 0.25100 0.114000 0.223000 2.14e-01 1.45e-02
Activation of the pre-replicative complex 21 3.34e-02 6.89e-02 0.32600 -0.326000 -0.001810 9.74e-03 9.89e-01
PI-3K cascade:FGFR2 10 3.37e-02 6.95e-02 0.50700 0.370000 0.346000 4.25e-02 5.79e-02
GABA receptor activation 25 3.37e-02 6.95e-02 0.28100 0.157000 -0.233000 1.75e-01 4.41e-02
Keratan sulfate/keratin metabolism 22 3.38e-02 6.95e-02 0.31000 0.305000 -0.055100 1.32e-02 6.55e-01
Plasma lipoprotein remodeling 15 3.39e-02 6.95e-02 0.36300 0.186000 -0.312000 2.12e-01 3.67e-02
Cytochrome c-mediated apoptotic response 13 3.41e-02 6.99e-02 0.41700 0.033600 0.416000 8.34e-01 9.45e-03
Cell junction organization 47 3.44e-02 7.04e-02 0.22900 0.209000 0.093700 1.33e-02 2.67e-01
Ephrin signaling 15 3.48e-02 7.11e-02 0.41100 0.326000 0.251000 2.90e-02 9.24e-02
The NLRP3 inflammasome 10 3.55e-02 7.24e-02 0.49900 0.424000 0.263000 2.02e-02 1.49e-01
Interleukin-12 signaling 30 3.57e-02 7.26e-02 0.27000 0.003930 0.270000 9.70e-01 1.04e-02
Formation of apoptosome 11 3.61e-02 7.31e-02 0.44400 -0.005380 0.444000 9.75e-01 1.08e-02
Regulation of the apoptosome activity 11 3.61e-02 7.31e-02 0.44400 -0.005380 0.444000 9.75e-01 1.08e-02
HIV Life Cycle 125 3.61e-02 7.31e-02 0.13100 -0.010700 0.131000 8.37e-01 1.19e-02
Formation of TC-NER Pre-Incision Complex 44 3.61e-02 7.31e-02 0.21000 -0.179000 0.111000 4.06e-02 2.05e-01
Macroautophagy 76 3.69e-02 7.45e-02 0.17000 0.006130 0.170000 9.27e-01 1.06e-02
Adrenaline,noradrenaline inhibits insulin secretion 18 3.71e-02 7.48e-02 0.34300 0.022800 -0.342000 8.67e-01 1.19e-02
Protein-protein interactions at synapses 47 3.74e-02 7.52e-02 0.20300 0.097500 -0.178000 2.48e-01 3.51e-02
Regulation of actin dynamics for phagocytic cup formation 49 3.79e-02 7.61e-02 0.22400 0.186000 0.125000 2.43e-02 1.31e-01
Fanconi Anemia Pathway 27 3.83e-02 7.68e-02 0.26400 -0.184000 0.189000 9.80e-02 8.93e-02
PKMTs methylate histone lysines 37 3.89e-02 7.79e-02 0.25800 0.192000 0.172000 4.29e-02 7.03e-02
TICAM1,TRAF6-dependent induction of TAK1 complex 11 3.92e-02 7.83e-02 0.44200 0.019800 0.441000 9.10e-01 1.13e-02
Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells 11 3.94e-02 7.86e-02 0.47200 0.366000 0.297000 3.54e-02 8.83e-02
Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA 14 4.01e-02 7.98e-02 0.40200 0.105000 0.388000 4.95e-01 1.19e-02
RAF-independent MAPK1/3 activation 21 4.08e-02 8.11e-02 0.33900 0.276000 0.196000 2.83e-02 1.21e-01
Synthesis of PIPs at the plasma membrane 46 4.10e-02 8.14e-02 0.23000 0.156000 0.169000 6.81e-02 4.73e-02
Recycling pathway of L1 22 4.14e-02 8.20e-02 0.31900 0.308000 0.085000 1.24e-02 4.90e-01
Signaling by FGFR4 in disease 11 4.16e-02 8.22e-02 0.46700 0.372000 0.282000 3.26e-02 1.05e-01
Dual incision in TC-NER 55 4.17e-02 8.23e-02 0.18500 -0.165000 0.083500 3.46e-02 2.84e-01
Signaling by WNT in cancer 27 4.32e-02 8.52e-02 0.29600 0.170000 0.243000 1.27e-01 2.92e-02
Telomere Maintenance 35 4.36e-02 8.59e-02 0.23300 -0.223000 0.069400 2.26e-02 4.77e-01
Notch-HLH transcription pathway 28 4.40e-02 8.65e-02 0.28900 0.247000 0.150000 2.39e-02 1.71e-01
RNA Polymerase III Abortive And Retractive Initiation 34 4.44e-02 8.70e-02 0.24300 -0.018800 0.242000 8.49e-01 1.47e-02
RNA Polymerase III Transcription 34 4.44e-02 8.70e-02 0.24300 -0.018800 0.242000 8.49e-01 1.47e-02
Signaling by Activin 12 4.45e-02 8.71e-02 0.44400 0.315000 0.312000 5.88e-02 6.11e-02
Mitochondrial iron-sulfur cluster biogenesis 10 4.47e-02 8.72e-02 0.42700 -0.374000 0.206000 4.07e-02 2.59e-01
RIP-mediated NFkB activation via ZBP1 13 4.50e-02 8.77e-02 0.42600 0.298000 0.304000 6.31e-02 5.77e-02
Mitotic Prophase 77 4.51e-02 8.77e-02 0.17500 0.128000 0.120000 5.27e-02 6.95e-02
PI-3K cascade:FGFR1 11 4.58e-02 8.90e-02 0.46100 0.337000 0.315000 5.29e-02 7.08e-02
Translesion synthesis by REV1 16 4.63e-02 8.99e-02 0.33400 -0.278000 0.185000 5.39e-02 2.01e-01
Regulation of IFNG signaling 12 4.66e-02 9.03e-02 0.43900 0.271000 0.346000 1.05e-01 3.80e-02
Cargo recognition for clathrin-mediated endocytosis 76 4.71e-02 9.12e-02 0.17500 0.107000 0.138000 1.08e-01 3.73e-02
Paradoxical activation of RAF signaling by kinase inactive BRAF 36 4.78e-02 9.18e-02 0.25200 0.138000 0.211000 1.52e-01 2.89e-02
Signaling by RAS mutants 36 4.78e-02 9.18e-02 0.25200 0.138000 0.211000 1.52e-01 2.89e-02
Signaling by moderate kinase activity BRAF mutants 36 4.78e-02 9.18e-02 0.25200 0.138000 0.211000 1.52e-01 2.89e-02
Signaling downstream of RAS mutants 36 4.78e-02 9.18e-02 0.25200 0.138000 0.211000 1.52e-01 2.89e-02
Metabolism of steroids 103 4.92e-02 9.44e-02 0.14800 0.075500 0.127000 1.86e-01 2.57e-02
TNF signaling 39 5.01e-02 9.59e-02 0.23400 0.073500 0.222000 4.27e-01 1.63e-02
IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation 13 5.02e-02 9.59e-02 0.40700 0.143000 0.381000 3.72e-01 1.74e-02
Transport of Mature Transcript to Cytoplasm 71 5.03e-02 9.61e-02 0.15600 -0.111000 0.109000 1.05e-01 1.12e-01
Class B/2 (Secretin family receptors) 40 5.04e-02 9.61e-02 0.23600 -0.201000 -0.124000 2.77e-02 1.75e-01
CD209 (DC-SIGN) signaling 16 5.15e-02 9.80e-02 0.37500 0.284000 0.244000 4.91e-02 9.05e-02
Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation 24 5.23e-02 9.94e-02 0.29300 0.069600 0.285000 5.55e-01 1.57e-02
Signaling by cytosolic FGFR1 fusion mutants 18 5.36e-02 1.02e-01 0.35000 0.211000 0.280000 1.22e-01 3.98e-02
Defective B4GALT7 causes EDS, progeroid type 12 5.37e-02 1.02e-01 0.37500 0.277000 -0.252000 9.65e-02 1.31e-01
Reproduction 49 5.39e-02 1.02e-01 0.20400 0.043300 0.199000 6.01e-01 1.60e-02
G alpha (i) signalling events 161 5.41e-02 1.02e-01 0.10300 0.058800 -0.084700 1.99e-01 6.44e-02
Costimulation by the CD28 family 45 5.46e-02 1.03e-01 0.22100 0.178000 0.131000 3.93e-02 1.28e-01
Negative regulation of FGFR2 signaling 21 5.47e-02 1.03e-01 0.32000 0.147000 0.284000 2.44e-01 2.44e-02
NCAM signaling for neurite out-growth 40 5.53e-02 1.04e-01 0.20400 0.140000 -0.149000 1.27e-01 1.03e-01
ATF4 activates genes in response to endoplasmic reticulum stress 21 5.54e-02 1.04e-01 0.31100 0.079500 0.301000 5.29e-01 1.70e-02
Activation of the AP-1 family of transcription factors 10 5.61e-02 1.05e-01 0.46500 0.385000 0.261000 3.52e-02 1.53e-01
Base Excision Repair 43 5.65e-02 1.06e-01 0.20500 -0.202000 0.034700 2.21e-02 6.94e-01
Erythropoietin activates RAS 12 5.66e-02 1.06e-01 0.41200 0.394000 0.120000 1.81e-02 4.70e-01
DNA Double Strand Break Response 41 5.68e-02 1.06e-01 0.23000 0.148000 0.177000 1.01e-01 5.05e-02
DAP12 interactions 22 5.86e-02 1.09e-01 0.28500 0.282000 -0.040200 2.19e-02 7.44e-01
Interconversion of nucleotide di- and triphosphates 20 5.91e-02 1.10e-01 0.28600 -0.185000 0.218000 1.53e-01 9.19e-02
NOTCH2 Activation and Transmission of Signal to the Nucleus 20 6.00e-02 1.11e-01 0.32300 0.282000 0.159000 2.93e-02 2.20e-01
G2/M DNA damage checkpoint 50 6.12e-02 1.13e-01 0.20600 0.126000 0.162000 1.23e-01 4.71e-02
Mucopolysaccharidoses 11 6.18e-02 1.14e-01 0.43700 -0.353000 -0.257000 4.27e-02 1.40e-01
Biological oxidations 107 6.20e-02 1.14e-01 0.12300 -0.075500 0.097100 1.78e-01 8.32e-02
Negative regulation of FGFR1 signaling 22 6.25e-02 1.15e-01 0.30500 0.141000 0.271000 2.54e-01 2.80e-02
Regulation of beta-cell development 17 6.31e-02 1.16e-01 0.35100 0.260000 0.236000 6.33e-02 9.22e-02
Constitutive Signaling by NOTCH1 HD Domain Mutants 14 6.32e-02 1.16e-01 0.38200 0.334000 0.186000 3.04e-02 2.29e-01
Signaling by NOTCH1 HD Domain Mutants in Cancer 14 6.32e-02 1.16e-01 0.38200 0.334000 0.186000 3.04e-02 2.29e-01
Interleukin-6 family signaling 19 6.43e-02 1.18e-01 0.32700 0.287000 0.157000 3.04e-02 2.36e-01
FCERI mediated MAPK activation 25 6.65e-02 1.21e-01 0.27100 0.269000 0.032700 1.99e-02 7.77e-01
JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 17 6.65e-02 1.21e-01 0.34000 0.315000 0.127000 2.46e-02 3.63e-01
Chaperone Mediated Autophagy 18 6.65e-02 1.21e-01 0.32500 0.082900 0.315000 5.43e-01 2.09e-02
Phase 0 - rapid depolarisation 25 6.71e-02 1.22e-01 0.25000 -0.170000 0.183000 1.42e-01 1.14e-01
Translesion synthesis by POLK 17 6.76e-02 1.23e-01 0.30200 -0.227000 0.199000 1.05e-01 1.55e-01
RAB GEFs exchange GTP for GDP on RABs 77 6.82e-02 1.24e-01 0.16300 0.125000 0.104000 5.77e-02 1.14e-01
Regulation of TNFR1 signaling 31 6.83e-02 1.24e-01 0.23900 0.008400 0.239000 9.35e-01 2.12e-02
PI3K events in ERBB2 signaling 12 6.93e-02 1.25e-01 0.37800 -0.024200 0.378000 8.85e-01 2.35e-02
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks 40 6.99e-02 1.26e-01 0.22500 0.147000 0.170000 1.07e-01 6.31e-02
AKT phosphorylates targets in the cytosol 13 7.15e-02 1.29e-01 0.39100 0.313000 0.234000 5.05e-02 1.43e-01
A tetrasaccharide linker sequence is required for GAG synthesis 15 7.19e-02 1.30e-01 0.31800 0.194000 -0.252000 1.92e-01 9.09e-02
RUNX2 regulates osteoblast differentiation 20 7.29e-02 1.31e-01 0.31500 0.194000 0.248000 1.34e-01 5.49e-02
HDACs deacetylate histones 32 7.32e-02 1.32e-01 0.24000 0.064700 0.231000 5.27e-01 2.36e-02
CRMPs in Sema3A signaling 13 7.35e-02 1.32e-01 0.34100 0.270000 -0.208000 9.25e-02 1.94e-01
MAP3K8 (TPL2)-dependent MAPK1/3 activation 16 7.47e-02 1.34e-01 0.31000 -0.134000 0.279000 3.54e-01 5.31e-02
CTLA4 inhibitory signaling 17 7.52e-02 1.35e-01 0.33900 0.263000 0.215000 6.06e-02 1.25e-01
GAB1 signalosome 13 7.53e-02 1.35e-01 0.38900 0.284000 0.265000 7.63e-02 9.79e-02
Frs2-mediated activation 10 7.57e-02 1.35e-01 0.41800 0.048200 0.415000 7.92e-01 2.31e-02
Telomere C-strand (Lagging Strand) Synthesis 22 7.64e-02 1.36e-01 0.28300 -0.279000 -0.047200 2.34e-02 7.01e-01
PI Metabolism 71 7.64e-02 1.36e-01 0.16600 0.130000 0.102000 5.77e-02 1.36e-01
Vasopressin regulates renal water homeostasis via Aquaporins 30 7.71e-02 1.37e-01 0.22200 0.156000 -0.158000 1.39e-01 1.35e-01
ERKs are inactivated 12 7.72e-02 1.37e-01 0.37800 0.028100 0.377000 8.66e-01 2.39e-02
Interleukin-2 family signaling 26 7.89e-02 1.40e-01 0.26400 0.250000 0.085600 2.73e-02 4.50e-01
Formation of Fibrin Clot (Clotting Cascade) 17 7.90e-02 1.40e-01 0.30100 0.092000 -0.286000 5.11e-01 4.09e-02
Metalloprotease DUBs 17 8.08e-02 1.43e-01 0.30200 -0.070800 0.294000 6.14e-01 3.62e-02
Cytosolic sensors of pathogen-associated DNA 48 8.09e-02 1.43e-01 0.19700 0.087800 0.176000 2.93e-01 3.52e-02
Laminin interactions 20 8.13e-02 1.43e-01 0.27600 0.263000 -0.083800 4.18e-02 5.17e-01
Diseases associated with glycosaminoglycan metabolism 27 8.30e-02 1.45e-01 0.23800 0.231000 -0.058100 3.78e-02 6.02e-01
IRAK2 mediated activation of TAK1 complex 10 8.30e-02 1.45e-01 0.40600 0.014700 0.405000 9.36e-01 2.65e-02
PI-3K cascade:FGFR4 10 8.30e-02 1.45e-01 0.43100 0.364000 0.231000 4.60e-02 2.06e-01
Ca2+ pathway 46 8.31e-02 1.45e-01 0.20300 0.144000 0.143000 9.13e-02 9.37e-02
Negative regulation of FGFR3 signaling 19 8.54e-02 1.49e-01 0.30800 0.134000 0.278000 3.13e-01 3.61e-02
Diseases associated with the TLR signaling cascade 18 8.58e-02 1.50e-01 0.32200 0.230000 0.226000 9.18e-02 9.76e-02
Diseases of Immune System 18 8.58e-02 1.50e-01 0.32200 0.230000 0.226000 9.18e-02 9.76e-02
Mitochondrial Fatty Acid Beta-Oxidation 27 8.77e-02 1.53e-01 0.22900 -0.189000 0.130000 9.01e-02 2.44e-01
SHC1 events in ERBB2 signaling 18 8.78e-02 1.53e-01 0.31800 0.171000 0.268000 2.10e-01 4.88e-02
NOTCH3 Activation and Transmission of Signal to the Nucleus 23 8.87e-02 1.54e-01 0.28200 0.162000 0.230000 1.78e-01 5.61e-02
FRS-mediated FGFR2 signaling 12 8.92e-02 1.54e-01 0.38400 0.347000 0.165000 3.75e-02 3.21e-01
VEGFR2 mediated cell proliferation 17 8.93e-02 1.54e-01 0.32600 0.274000 0.177000 5.06e-02 2.06e-01
Metabolism of carbohydrates 205 8.93e-02 1.54e-01 0.08960 0.007980 0.089200 8.44e-01 2.81e-02
DNA Damage/Telomere Stress Induced Senescence 24 9.00e-02 1.55e-01 0.27200 0.127000 0.241000 2.81e-01 4.12e-02
Negative regulation of NMDA receptor-mediated neuronal transmission 12 9.03e-02 1.56e-01 0.34000 -0.205000 0.272000 2.19e-01 1.03e-01
G alpha (z) signalling events 30 9.11e-02 1.57e-01 0.22000 0.208000 -0.071400 4.90e-02 4.99e-01
Interferon Signaling 149 9.20e-02 1.58e-01 0.10900 0.096000 0.052700 4.36e-02 2.68e-01
Downregulation of ERBB2 signaling 22 9.20e-02 1.58e-01 0.25900 -0.058900 0.252000 6.33e-01 4.08e-02
RHO GTPases Activate WASPs and WAVEs 31 9.23e-02 1.58e-01 0.24000 0.135000 0.199000 1.92e-01 5.57e-02
Signaling by NTRK2 (TRKB) 19 9.28e-02 1.59e-01 0.30600 0.255000 0.170000 5.42e-02 2.01e-01
Aquaporin-mediated transport 31 9.28e-02 1.59e-01 0.21100 0.128000 -0.167000 2.18e-01 1.07e-01
HS-GAG degradation 13 9.38e-02 1.60e-01 0.35800 -0.095100 -0.345000 5.53e-01 3.12e-02
Triglyceride catabolism 16 9.41e-02 1.60e-01 0.29900 -0.097600 0.282000 4.99e-01 5.07e-02
BBSome-mediated cargo-targeting to cilium 18 9.60e-02 1.63e-01 0.30100 -0.294000 -0.063800 3.09e-02 6.40e-01
Cardiac conduction 78 9.69e-02 1.65e-01 0.14600 0.045300 0.139000 4.89e-01 3.38e-02
Cargo concentration in the ER 24 9.77e-02 1.66e-01 0.27000 0.224000 0.150000 5.75e-02 2.03e-01
Signaling by high-kinase activity BRAF mutants 27 9.79e-02 1.66e-01 0.25500 0.199000 0.160000 7.34e-02 1.51e-01
Retinoid metabolism and transport 23 1.02e-01 1.72e-01 0.24300 0.099400 -0.222000 4.10e-01 6.57e-02
Gene Silencing by RNA 65 1.04e-01 1.75e-01 0.16000 0.070400 0.144000 3.27e-01 4.48e-02
Effects of PIP2 hydrolysis 20 1.04e-01 1.76e-01 0.26300 -0.066600 0.255000 6.06e-01 4.86e-02
Golgi-to-ER retrograde transport 87 1.05e-01 1.77e-01 0.13900 0.066500 0.122000 2.84e-01 4.98e-02
ER Quality Control Compartment (ERQC) 19 1.06e-01 1.78e-01 0.28900 0.078100 0.278000 5.56e-01 3.58e-02
TRAF6-mediated induction of TAK1 complex within TLR4 complex 14 1.07e-01 1.80e-01 0.34300 0.153000 0.307000 3.21e-01 4.70e-02
FRS-mediated FGFR1 signaling 13 1.07e-01 1.80e-01 0.35500 0.321000 0.152000 4.54e-02 3.41e-01
Integration of energy metabolism 75 1.07e-01 1.80e-01 0.14900 0.127000 0.078700 5.75e-02 2.39e-01
RNA Polymerase II Pre-transcription Events 62 1.10e-01 1.84e-01 0.16200 0.068600 0.147000 3.51e-01 4.62e-02
Insulin processing 15 1.11e-01 1.86e-01 0.29900 0.289000 -0.078300 5.28e-02 6.00e-01
Signaling by FGFR2 in disease 26 1.16e-01 1.93e-01 0.25000 0.201000 0.148000 7.55e-02 1.91e-01
Termination of O-glycan biosynthesis 13 1.17e-01 1.95e-01 0.32500 0.024300 -0.324000 8.79e-01 4.29e-02
Antiviral mechanism by IFN-stimulated genes 75 1.17e-01 1.95e-01 0.14600 0.125000 0.076300 6.17e-02 2.54e-01
MAP2K and MAPK activation 30 1.19e-01 1.98e-01 0.23100 0.186000 0.138000 7.82e-02 1.92e-01
Amyloid fiber formation 33 1.19e-01 1.98e-01 0.22100 0.162000 0.150000 1.07e-01 1.35e-01
Unblocking of NMDA receptors, glutamate binding and activation 12 1.20e-01 1.98e-01 0.31900 -0.243000 0.207000 1.45e-01 2.14e-01
GPVI-mediated activation cascade 19 1.20e-01 1.99e-01 0.27200 0.271000 0.010100 4.07e-02 9.40e-01
Chondroitin sulfate biosynthesis 14 1.21e-01 1.99e-01 0.30400 0.294000 -0.078600 5.69e-02 6.11e-01
FRS-mediated FGFR4 signaling 12 1.21e-01 2.00e-01 0.34900 0.342000 0.069100 4.04e-02 6.79e-01
Endogenous sterols 17 1.23e-01 2.02e-01 0.26800 0.224000 -0.147000 1.10e-01 2.95e-01
Microautophagy 26 1.25e-01 2.06e-01 0.22400 -0.034300 0.222000 7.62e-01 5.06e-02
Gap-filling DNA repair synthesis and ligation in TC-NER 54 1.26e-01 2.07e-01 0.15600 -0.156000 0.016200 4.81e-02 8.37e-01
Cyclin A/B1/B2 associated events during G2/M transition 17 1.27e-01 2.08e-01 0.28200 0.001940 0.282000 9.89e-01 4.38e-02
Regulation of PLK1 Activity at G2/M Transition 74 1.27e-01 2.08e-01 0.14300 0.055300 0.131000 4.11e-01 5.08e-02
FRS-mediated FGFR3 signaling 10 1.28e-01 2.09e-01 0.38400 0.361000 0.131000 4.78e-02 4.74e-01
Activation of G protein gated Potassium channels 11 1.29e-01 2.09e-01 0.34800 0.010900 -0.348000 9.50e-01 4.59e-02
G protein gated Potassium channels 11 1.29e-01 2.09e-01 0.34800 0.010900 -0.348000 9.50e-01 4.59e-02
Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits 11 1.29e-01 2.09e-01 0.34800 0.010900 -0.348000 9.50e-01 4.59e-02
Negative regulation of FGFR4 signaling 21 1.29e-01 2.09e-01 0.27000 0.144000 0.229000 2.53e-01 6.98e-02
tRNA processing in the nucleus 50 1.29e-01 2.09e-01 0.15400 -0.113000 0.104000 1.66e-01 2.03e-01
TP53 Regulates Transcription of Death Receptors and Ligands 10 1.31e-01 2.12e-01 0.34400 0.286000 -0.190000 1.17e-01 2.97e-01
ZBP1(DAI) mediated induction of type I IFNs 16 1.31e-01 2.13e-01 0.30700 0.268000 0.150000 6.37e-02 3.00e-01
Stimuli-sensing channels 52 1.32e-01 2.13e-01 0.15100 -0.085800 0.124000 2.85e-01 1.23e-01
Unfolded Protein Response (UPR) 74 1.35e-01 2.19e-01 0.14100 0.060400 0.128000 3.69e-01 5.82e-02
ISG15 antiviral mechanism 69 1.36e-01 2.20e-01 0.14800 0.114000 0.095200 1.03e-01 1.72e-01
Signal amplification 19 1.37e-01 2.21e-01 0.25900 0.257000 -0.024300 5.21e-02 8.55e-01
Synthesis of PIPs at the Golgi membrane 15 1.37e-01 2.21e-01 0.31200 0.280000 0.137000 6.02e-02 3.59e-01
Signaling by Retinoic Acid 33 1.38e-01 2.21e-01 0.20800 0.068700 0.196000 4.95e-01 5.15e-02
Nonhomologous End-Joining (NHEJ) 33 1.38e-01 2.21e-01 0.21400 0.157000 0.145000 1.18e-01 1.50e-01
Activation of SMO 13 1.38e-01 2.21e-01 0.30400 0.090500 -0.291000 5.72e-01 6.98e-02
SHC-mediated cascade:FGFR2 10 1.38e-01 2.22e-01 0.37800 0.351000 0.143000 5.50e-02 4.35e-01
Nitric oxide stimulates guanylate cyclase 17 1.39e-01 2.22e-01 0.26100 0.127000 -0.228000 3.65e-01 1.04e-01
G alpha (s) signalling events 66 1.40e-01 2.24e-01 0.14700 -0.056400 -0.136000 4.29e-01 5.63e-02
Glycosaminoglycan metabolism 80 1.41e-01 2.24e-01 0.12100 0.111000 -0.048100 8.61e-02 4.58e-01
PKA-mediated phosphorylation of CREB 17 1.41e-01 2.25e-01 0.26000 0.230000 -0.121000 1.01e-01 3.87e-01
Metabolism of fat-soluble vitamins 26 1.42e-01 2.26e-01 0.21000 0.098600 -0.185000 3.85e-01 1.02e-01
Glycogen breakdown (glycogenolysis) 13 1.43e-01 2.26e-01 0.32600 0.095100 0.312000 5.53e-01 5.16e-02
DAP12 signaling 20 1.43e-01 2.26e-01 0.25000 0.249000 -0.021800 5.44e-02 8.66e-01
DDX58/IFIH1-mediated induction of interferon-alpha/beta 55 1.43e-01 2.27e-01 0.15800 0.044000 0.152000 5.73e-01 5.13e-02
Post NMDA receptor activation events 45 1.44e-01 2.28e-01 0.17800 0.078000 0.160000 3.66e-01 6.34e-02
EPHA-mediated growth cone collapse 14 1.45e-01 2.29e-01 0.29400 0.289000 -0.051700 6.12e-02 7.38e-01
NRIF signals cell death from the nucleus 12 1.47e-01 2.32e-01 0.31900 -0.028800 0.318000 8.63e-01 5.64e-02
Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase 16 1.49e-01 2.35e-01 0.26700 -0.092400 0.251000 5.22e-01 8.23e-02
Sphingolipid de novo biosynthesis 31 1.51e-01 2.38e-01 0.21500 0.159000 0.144000 1.24e-01 1.65e-01
Ion transport by P-type ATPases 36 1.53e-01 2.40e-01 0.19900 0.148000 0.134000 1.25e-01 1.65e-01
ABC transporters in lipid homeostasis 11 1.54e-01 2.41e-01 0.35700 -0.304000 -0.187000 8.13e-02 2.83e-01
SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion 12 1.54e-01 2.42e-01 0.30700 0.291000 -0.098100 8.12e-02 5.57e-01
Role of LAT2/NTAL/LAB on calcium mobilization 12 1.54e-01 2.42e-01 0.33700 0.307000 0.140000 6.56e-02 4.01e-01
Interleukin receptor SHC signaling 15 1.56e-01 2.45e-01 0.29900 0.277000 0.113000 6.32e-02 4.48e-01
TNFR1-induced proapoptotic signaling 12 1.57e-01 2.45e-01 0.32500 0.052000 0.321000 7.55e-01 5.42e-02
Alpha-protein kinase 1 signaling pathway 11 1.57e-01 2.45e-01 0.31500 -0.140000 0.282000 4.21e-01 1.05e-01
Translesion Synthesis by POLH 18 1.58e-01 2.45e-01 0.24400 -0.205000 0.133000 1.32e-01 3.30e-01
Interleukin-20 family signaling 14 1.58e-01 2.45e-01 0.28500 0.278000 -0.064700 7.22e-02 6.75e-01
Cleavage of the damaged pyrimidine 16 1.58e-01 2.45e-01 0.25800 -0.196000 0.168000 1.75e-01 2.46e-01
Depyrimidination 16 1.58e-01 2.45e-01 0.25800 -0.196000 0.168000 1.75e-01 2.46e-01
Recognition and association of DNA glycosylase with site containing an affected pyrimidine 16 1.58e-01 2.45e-01 0.25800 -0.196000 0.168000 1.75e-01 2.46e-01
Interferon alpha/beta signaling 44 1.60e-01 2.48e-01 0.16500 0.165000 -0.000205 5.81e-02 9.98e-01
Synthesis of PIPs at the late endosome membrane 11 1.61e-01 2.49e-01 0.35000 0.309000 0.164000 7.56e-02 3.48e-01
Basigin interactions 17 1.62e-01 2.51e-01 0.26100 -0.030200 0.259000 8.29e-01 6.48e-02
Metabolism of steroid hormones 16 1.63e-01 2.52e-01 0.25700 -0.220000 0.134000 1.28e-01 3.55e-01
GRB2 events in ERBB2 signaling 12 1.64e-01 2.53e-01 0.32800 0.105000 0.311000 5.27e-01 6.25e-02
SHC-mediated cascade:FGFR1 11 1.65e-01 2.54e-01 0.34400 0.319000 0.129000 6.69e-02 4.58e-01
SHC-mediated cascade:FGFR4 10 1.68e-01 2.58e-01 0.34600 0.344000 0.027000 5.93e-02 8.82e-01
Interaction between L1 and Ankyrins 16 1.70e-01 2.60e-01 0.28900 0.237000 0.165000 1.01e-01 2.52e-01
Base-Excision Repair, AP Site Formation 18 1.70e-01 2.60e-01 0.24200 -0.222000 0.097200 1.04e-01 4.75e-01
Spry regulation of FGF signaling 16 1.70e-01 2.60e-01 0.28400 0.109000 0.262000 4.50e-01 7.00e-02
ROS and RNS production in phagocytes 23 1.70e-01 2.60e-01 0.22000 0.033800 -0.217000 7.79e-01 7.12e-02
RHO GTPases activate CIT 18 1.71e-01 2.61e-01 0.26700 0.245000 0.107000 7.20e-02 4.31e-01
Keratinization 13 1.72e-01 2.61e-01 0.29500 0.021400 -0.294000 8.94e-01 6.62e-02
KSRP (KHSRP) binds and destabilizes mRNA 14 1.74e-01 2.64e-01 0.29800 0.085000 0.285000 5.82e-01 6.48e-02
Kinesins 23 1.74e-01 2.64e-01 0.21100 0.106000 -0.182000 3.78e-01 1.30e-01
Glutamate binding, activation of AMPA receptors and synaptic plasticity 22 1.74e-01 2.64e-01 0.21500 -0.119000 0.179000 3.34e-01 1.46e-01
Trafficking of AMPA receptors 22 1.74e-01 2.64e-01 0.21500 -0.119000 0.179000 3.34e-01 1.46e-01
Cytochrome P450 - arranged by substrate type 25 1.74e-01 2.64e-01 0.20400 0.080800 -0.187000 4.84e-01 1.05e-01
FGFR2 alternative splicing 20 1.76e-01 2.66e-01 0.23900 0.000908 0.239000 9.94e-01 6.47e-02
Initiation of Nuclear Envelope Reformation 12 1.76e-01 2.66e-01 0.32900 0.182000 0.275000 2.76e-01 9.96e-02
Nuclear Envelope Reassembly 12 1.76e-01 2.66e-01 0.32900 0.182000 0.275000 2.76e-01 9.96e-02
Uptake and function of anthrax toxins 11 1.77e-01 2.66e-01 0.34200 0.297000 0.171000 8.85e-02 3.27e-01
ERBB2 Regulates Cell Motility 11 1.77e-01 2.67e-01 0.30500 -0.136000 0.273000 4.36e-01 1.17e-01
Ion channel transport 102 1.78e-01 2.68e-01 0.10400 -0.008270 0.104000 8.85e-01 6.97e-02
MHC class II antigen presentation 75 1.79e-01 2.69e-01 0.13200 0.095600 0.091300 1.53e-01 1.72e-01
Calnexin/calreticulin cycle 23 1.80e-01 2.69e-01 0.22800 0.046500 0.223000 6.99e-01 6.46e-02
Netrin-1 signaling 38 1.83e-01 2.74e-01 0.18200 0.159000 0.089200 9.03e-02 3.42e-01
Heparan sulfate/heparin (HS-GAG) metabolism 31 1.85e-01 2.77e-01 0.18900 0.000266 -0.189000 9.98e-01 6.88e-02
Regulation of pyruvate dehydrogenase (PDH) complex 15 1.85e-01 2.77e-01 0.29200 0.192000 0.220000 1.99e-01 1.40e-01
RAB geranylgeranylation 41 1.85e-01 2.77e-01 0.17000 0.040400 0.165000 6.55e-01 6.80e-02
Interleukin-37 signaling 17 1.86e-01 2.77e-01 0.24600 0.238000 -0.062000 8.89e-02 6.58e-01
WNT5A-dependent internalization of FZD4 12 1.86e-01 2.77e-01 0.30900 0.046600 0.306000 7.80e-01 6.68e-02
Synthesis of bile acids and bile salts via 24-hydroxycholesterol 10 1.87e-01 2.78e-01 0.35700 -0.250000 -0.254000 1.71e-01 1.64e-01
Phosphorylation of the APC/C 16 1.88e-01 2.78e-01 0.24600 -0.151000 0.194000 2.96e-01 1.79e-01
Intrinsic Pathway of Fibrin Clot Formation 11 1.88e-01 2.78e-01 0.31900 -0.026200 -0.318000 8.81e-01 6.79e-02
Formation of the cornified envelope 12 1.88e-01 2.78e-01 0.29100 0.087900 -0.277000 5.98e-01 9.65e-02
Negative regulation of MET activity 18 1.89e-01 2.80e-01 0.25600 0.071600 0.246000 5.99e-01 7.13e-02
Peroxisomal lipid metabolism 22 1.90e-01 2.81e-01 0.22400 -0.224000 -0.013100 6.94e-02 9.16e-01
Antigen Presentation: Folding, assembly and peptide loading of class I MHC 21 1.93e-01 2.84e-01 0.23700 0.225000 0.074100 7.48e-02 5.57e-01
Processing and activation of SUMO 10 1.93e-01 2.84e-01 0.34500 0.129000 0.320000 4.79e-01 7.98e-02
DNA Damage Bypass 42 1.94e-01 2.85e-01 0.15100 -0.089600 0.121000 3.15e-01 1.75e-01
Downregulation of ERBB2:ERBB3 signaling 12 1.94e-01 2.85e-01 0.28400 -0.256000 0.124000 1.25e-01 4.57e-01
Lagging Strand Synthesis 20 1.94e-01 2.85e-01 0.23200 -0.232000 -0.003100 7.25e-02 9.81e-01
Collagen degradation 18 1.94e-01 2.85e-01 0.23300 0.089000 -0.215000 5.14e-01 1.14e-01
Regulation of TP53 Activity through Phosphorylation 72 1.95e-01 2.85e-01 0.13200 0.090700 0.095400 1.84e-01 1.62e-01
RHO GTPases Activate ROCKs 19 1.96e-01 2.87e-01 0.25400 0.208000 0.146000 1.17e-01 2.71e-01
Mitochondrial tRNA aminoacylation 20 1.97e-01 2.87e-01 0.22600 -0.223000 0.036300 8.44e-02 7.79e-01
Neutrophil degranulation 318 1.97e-01 2.88e-01 0.06110 0.019600 0.057900 5.50e-01 7.73e-02
PCNA-Dependent Long Patch Base Excision Repair 18 1.98e-01 2.89e-01 0.24900 -0.245000 -0.046200 7.24e-02 7.34e-01
Meiotic recombination 20 1.99e-01 2.90e-01 0.24200 0.090700 0.224000 4.83e-01 8.29e-02
Diseases of metabolism 64 2.02e-01 2.94e-01 0.12000 -0.096200 0.072500 1.84e-01 3.16e-01
Activation of RAC1 10 2.03e-01 2.95e-01 0.33500 0.092400 0.322000 6.13e-01 7.76e-02
The role of Nef in HIV-1 replication and disease pathogenesis 20 2.06e-01 2.99e-01 0.22100 -0.048600 0.215000 7.07e-01 9.53e-02
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) 71 2.10e-01 3.05e-01 0.11300 0.071000 -0.087700 3.02e-01 2.02e-01
Gap-filling DNA repair synthesis and ligation in GG-NER 23 2.11e-01 3.05e-01 0.21400 -0.213000 -0.026700 7.78e-02 8.25e-01
Pyruvate metabolism 26 2.14e-01 3.09e-01 0.19600 -0.008980 0.196000 9.37e-01 8.44e-02
IRAK1 recruits IKK complex 10 2.15e-01 3.09e-01 0.32900 0.318000 0.084100 8.18e-02 6.45e-01
IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation 10 2.15e-01 3.09e-01 0.32900 0.318000 0.084100 8.18e-02 6.45e-01
WNT5A-dependent internalization of FZD2, FZD5 and ROR2 11 2.16e-01 3.12e-01 0.29400 -0.057100 0.289000 7.43e-01 9.75e-02
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein 63 2.21e-01 3.17e-01 0.13400 -0.116000 -0.067600 1.13e-01 3.54e-01
Endosomal/Vacuolar pathway 10 2.22e-01 3.19e-01 0.30300 0.293000 -0.079200 1.09e-01 6.65e-01
PKA activation 15 2.24e-01 3.22e-01 0.24200 0.214000 -0.113000 1.52e-01 4.48e-01
Recognition of DNA damage by PCNA-containing replication complex 27 2.26e-01 3.24e-01 0.17800 -0.134000 0.117000 2.28e-01 2.91e-01
Voltage gated Potassium channels 10 2.27e-01 3.24e-01 0.29500 0.254000 -0.149000 1.65e-01 4.14e-01
Post-translational protein phosphorylation 65 2.27e-01 3.24e-01 0.11500 0.084600 -0.077700 2.39e-01 2.79e-01
Transport of vitamins, nucleosides, and related molecules 25 2.27e-01 3.25e-01 0.20300 -0.198000 -0.046800 8.67e-02 6.86e-01
Cellular hexose transport 10 2.28e-01 3.25e-01 0.33400 -0.270000 -0.196000 1.39e-01 2.83e-01
SHC1 events in ERBB4 signaling 10 2.28e-01 3.25e-01 0.33500 0.233000 0.240000 2.01e-01 1.88e-01
Signaling by Leptin 10 2.29e-01 3.26e-01 0.32500 0.307000 0.105000 9.28e-02 5.65e-01
Regulation of innate immune responses to cytosolic DNA 11 2.29e-01 3.26e-01 0.30800 -0.295000 -0.085500 8.99e-02 6.23e-01
Sema4D in semaphorin signaling 23 2.31e-01 3.27e-01 0.22000 0.174000 0.133000 1.48e-01 2.68e-01
Termination of translesion DNA synthesis 27 2.31e-01 3.28e-01 0.18700 -0.187000 0.010800 9.32e-02 9.23e-01
Caspase-mediated cleavage of cytoskeletal proteins 11 2.32e-01 3.29e-01 0.31700 0.200000 0.246000 2.51e-01 1.58e-01
Diseases associated with N-glycosylation of proteins 14 2.35e-01 3.32e-01 0.27000 -0.260000 -0.073100 9.23e-02 6.36e-01
SUMOylation of chromatin organization proteins 55 2.35e-01 3.32e-01 0.14100 0.109000 0.090400 1.64e-01 2.47e-01
rRNA modification in the nucleus and cytosol 47 2.37e-01 3.34e-01 0.13300 -0.097800 0.090200 2.46e-01 2.85e-01
Arachidonic acid metabolism 23 2.40e-01 3.38e-01 0.21700 -0.139000 -0.167000 2.49e-01 1.67e-01
Carboxyterminal post-translational modifications of tubulin 23 2.45e-01 3.45e-01 0.20600 -0.042600 -0.202000 7.24e-01 9.43e-02
Activation of kainate receptors upon glutamate binding 19 2.52e-01 3.54e-01 0.23400 -0.140000 -0.187000 2.91e-01 1.57e-01
O-linked glycosylation of mucins 29 2.52e-01 3.54e-01 0.16700 0.142000 -0.086300 1.84e-01 4.22e-01
Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template 34 2.55e-01 3.58e-01 0.15600 -0.147000 0.051700 1.38e-01 6.02e-01
Nucleobase biosynthesis 15 2.57e-01 3.60e-01 0.25700 -0.234000 -0.107000 1.16e-01 4.74e-01
Sema4D induced cell migration and growth-cone collapse 19 2.60e-01 3.64e-01 0.22400 0.215000 0.065000 1.05e-01 6.24e-01
Gap junction trafficking and regulation 15 2.61e-01 3.65e-01 0.24900 0.244000 0.051700 1.02e-01 7.29e-01
SLC-mediated transmembrane transport 131 2.61e-01 3.65e-01 0.08450 -0.083000 -0.016100 1.02e-01 7.51e-01
Surfactant metabolism 10 2.62e-01 3.65e-01 0.31100 -0.290000 -0.112000 1.12e-01 5.40e-01
RHO GTPases activate PAKs 20 2.64e-01 3.67e-01 0.22200 0.198000 0.099400 1.25e-01 4.42e-01
Prolactin receptor signaling 10 2.64e-01 3.68e-01 0.30000 0.035900 0.298000 8.44e-01 1.03e-01
Chemokine receptors bind chemokines 12 2.67e-01 3.70e-01 0.25200 0.175000 -0.181000 2.94e-01 2.78e-01
TP53 Regulates Transcription of Cell Cycle Genes 37 2.69e-01 3.73e-01 0.16300 0.083500 0.140000 3.80e-01 1.41e-01
Complement cascade 19 2.69e-01 3.74e-01 0.21200 0.006860 -0.212000 9.59e-01 1.10e-01
Signal regulatory protein family interactions 11 2.72e-01 3.77e-01 0.26400 0.122000 -0.234000 4.83e-01 1.79e-01
Trafficking of GluR2-containing AMPA receptors 12 2.72e-01 3.77e-01 0.25200 -0.119000 0.222000 4.75e-01 1.82e-01
FCERI mediated Ca+2 mobilization 21 2.73e-01 3.77e-01 0.21600 0.133000 0.171000 2.92e-01 1.76e-01
Activation of ATR in response to replication stress 26 2.73e-01 3.77e-01 0.17500 -0.169000 0.044300 1.35e-01 6.96e-01
Listeria monocytogenes entry into host cells 16 2.76e-01 3.81e-01 0.24400 0.120000 0.213000 4.06e-01 1.41e-01
VLDLR internalisation and degradation 11 2.78e-01 3.84e-01 0.27800 0.013400 0.277000 9.39e-01 1.11e-01
Inhibition of replication initiation of damaged DNA by RB1/E2F1 12 2.80e-01 3.85e-01 0.27200 0.064200 0.265000 7.00e-01 1.12e-01
Metabolism of cofactors 16 2.81e-01 3.86e-01 0.22700 -0.010400 0.226000 9.43e-01 1.17e-01
Regulation of TP53 Activity through Acetylation 29 2.81e-01 3.86e-01 0.18000 0.158000 0.086300 1.41e-01 4.22e-01
Nuclear signaling by ERBB4 21 2.83e-01 3.87e-01 0.20500 0.047900 0.199000 7.04e-01 1.14e-01
Sema3A PAK dependent Axon repulsion 14 2.85e-01 3.90e-01 0.25400 0.239000 0.084800 1.22e-01 5.83e-01
TRAF6 mediated NF-kB activation 18 2.87e-01 3.92e-01 0.22900 0.177000 0.146000 1.94e-01 2.84e-01
SUMOylation of transcription factors 15 2.89e-01 3.95e-01 0.25000 0.195000 0.157000 1.91e-01 2.94e-01
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain 19 2.94e-01 4.01e-01 0.22100 0.157000 0.155000 2.35e-01 2.41e-01
Processive synthesis on the lagging strand 15 2.94e-01 4.01e-01 0.23400 -0.233000 -0.021100 1.18e-01 8.87e-01
Class I peroxisomal membrane protein import 15 2.95e-01 4.01e-01 0.22400 -0.056800 0.216000 7.04e-01 1.47e-01
Resolution of AP sites via the multiple-nucleotide patch replacement pathway 22 2.95e-01 4.01e-01 0.19600 -0.192000 -0.036400 1.18e-01 7.68e-01
Potassium Channels 34 2.95e-01 4.01e-01 0.14500 0.068000 -0.128000 4.93e-01 1.95e-01
PKA activation in glucagon signalling 15 2.96e-01 4.01e-01 0.21800 0.187000 -0.111000 2.10e-01 4.55e-01
Opioid Signalling 68 2.98e-01 4.03e-01 0.11700 0.085400 0.079400 2.24e-01 2.58e-01
Transcriptional regulation by small RNAs 45 2.98e-01 4.03e-01 0.14300 0.089600 0.111000 2.99e-01 1.97e-01
Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters 16 2.98e-01 4.03e-01 0.21900 -0.029000 0.217000 8.41e-01 1.34e-01
RNA Polymerase III Transcription Initiation From Type 1 Promoter 22 3.03e-01 4.09e-01 0.18100 -0.057200 0.172000 6.43e-01 1.62e-01
Signalling to RAS 17 3.03e-01 4.09e-01 0.22200 0.215000 0.056100 1.25e-01 6.89e-01
Interferon gamma signaling 63 3.04e-01 4.10e-01 0.10600 0.098500 -0.040200 1.77e-01 5.81e-01
Depolymerisation of the Nuclear Lamina 12 3.05e-01 4.10e-01 0.27100 0.235000 0.135000 1.58e-01 4.18e-01
Long-term potentiation 13 3.06e-01 4.12e-01 0.23500 -0.072600 0.223000 6.50e-01 1.63e-01
ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression 20 3.11e-01 4.17e-01 0.21100 0.160000 0.137000 2.15e-01 2.90e-01
eNOS activation 11 3.14e-01 4.21e-01 0.28300 0.216000 0.182000 2.15e-01 2.95e-01
Signal transduction by L1 17 3.15e-01 4.23e-01 0.21500 0.033400 0.213000 8.12e-01 1.29e-01
CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling 22 3.17e-01 4.25e-01 0.18800 0.022800 0.187000 8.53e-01 1.30e-01
Mitotic Telophase/Cytokinesis 10 3.19e-01 4.27e-01 0.28400 0.079100 0.273000 6.65e-01 1.35e-01
Josephin domain DUBs 11 3.24e-01 4.33e-01 0.25800 -0.010400 0.257000 9.52e-01 1.40e-01
EPH-ephrin mediated repulsion of cells 31 3.28e-01 4.38e-01 0.16200 0.148000 0.066600 1.55e-01 5.21e-01
TP53 Regulates Transcription of DNA Repair Genes 48 3.31e-01 4.41e-01 0.12500 0.017100 0.124000 8.38e-01 1.37e-01
Cristae formation 10 3.31e-01 4.41e-01 0.25400 -0.221000 0.126000 2.26e-01 4.92e-01
EPHB-mediated forward signaling 29 3.32e-01 4.41e-01 0.16900 0.093900 0.141000 3.82e-01 1.90e-01
MET activates PTK2 signaling 14 3.32e-01 4.41e-01 0.23900 0.221000 0.088900 1.51e-01 5.65e-01
Regulation of IFNA signaling 11 3.32e-01 4.41e-01 0.27500 0.223000 0.160000 2.00e-01 3.58e-01
Interactions of Vpr with host cellular proteins 34 3.33e-01 4.41e-01 0.14200 -0.030800 0.138000 7.56e-01 1.63e-01
Processing of DNA double-strand break ends 53 3.34e-01 4.42e-01 0.11500 -0.008430 0.115000 9.15e-01 1.47e-01
Synthesis of substrates in N-glycan biosythesis 50 3.37e-01 4.46e-01 0.12800 -0.077500 -0.102000 3.44e-01 2.12e-01
VxPx cargo-targeting to cilium 16 3.39e-01 4.48e-01 0.21000 0.210000 -0.002670 1.46e-01 9.85e-01
Amino acids regulate mTORC1 40 3.43e-01 4.51e-01 0.12400 -0.079000 0.096000 3.88e-01 2.94e-01
HIV Transcription Initiation 36 3.44e-01 4.51e-01 0.14100 0.009980 0.141000 9.18e-01 1.45e-01
RNA Polymerase II HIV Promoter Escape 36 3.44e-01 4.51e-01 0.14100 0.009980 0.141000 9.18e-01 1.45e-01
RNA Polymerase II Promoter Escape 36 3.44e-01 4.51e-01 0.14100 0.009980 0.141000 9.18e-01 1.45e-01
RNA Polymerase II Transcription Initiation 36 3.44e-01 4.51e-01 0.14100 0.009980 0.141000 9.18e-01 1.45e-01
RNA Polymerase II Transcription Initiation And Promoter Clearance 36 3.44e-01 4.51e-01 0.14100 0.009980 0.141000 9.18e-01 1.45e-01
RNA Polymerase II Transcription Pre-Initiation And Promoter Opening 36 3.44e-01 4.51e-01 0.14100 0.009980 0.141000 9.18e-01 1.45e-01
Cleavage of the damaged purine 11 3.46e-01 4.52e-01 0.23800 -0.108000 0.212000 5.34e-01 2.23e-01
Depurination 11 3.46e-01 4.52e-01 0.23800 -0.108000 0.212000 5.34e-01 2.23e-01
Recognition and association of DNA glycosylase with site containing an affected purine 11 3.46e-01 4.52e-01 0.23800 -0.108000 0.212000 5.34e-01 2.23e-01
Platelet sensitization by LDL 15 3.49e-01 4.55e-01 0.23000 0.143000 0.181000 3.37e-01 2.26e-01
Formation of the Early Elongation Complex 25 3.49e-01 4.55e-01 0.16500 -0.165000 0.006190 1.53e-01 9.57e-01
Formation of the HIV-1 Early Elongation Complex 25 3.49e-01 4.55e-01 0.16500 -0.165000 0.006190 1.53e-01 9.57e-01
Phospholipid metabolism 155 3.51e-01 4.57e-01 0.07140 0.037600 0.060700 4.21e-01 1.93e-01
Plasma lipoprotein assembly, remodeling, and clearance 48 3.60e-01 4.68e-01 0.11900 0.119000 0.006100 1.54e-01 9.42e-01
NF-kB is activated and signals survival 11 3.62e-01 4.69e-01 0.23800 -0.058300 0.231000 7.38e-01 1.84e-01
Homology Directed Repair 81 3.62e-01 4.69e-01 0.08550 -0.049900 0.069400 4.38e-01 2.81e-01
G beta:gamma signalling through PLC beta 12 3.63e-01 4.69e-01 0.24600 -0.084900 -0.231000 6.11e-01 1.65e-01
Presynaptic function of Kainate receptors 12 3.63e-01 4.69e-01 0.24600 -0.084900 -0.231000 6.11e-01 1.65e-01
SIRT1 negatively regulates rRNA expression 11 3.68e-01 4.75e-01 0.26100 0.218000 0.144000 2.11e-01 4.10e-01
Transcription of the HIV genome 54 3.68e-01 4.75e-01 0.11700 0.058500 0.102000 4.57e-01 1.96e-01
Processive synthesis on the C-strand of the telomere 11 3.69e-01 4.76e-01 0.25700 -0.234000 -0.107000 1.79e-01 5.37e-01
Repression of WNT target genes 12 3.70e-01 4.77e-01 0.24600 0.223000 0.103000 1.80e-01 5.36e-01
Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon 14 3.73e-01 4.80e-01 0.22600 0.208000 0.088700 1.77e-01 5.65e-01
tRNA Aminoacylation 39 3.74e-01 4.80e-01 0.12500 -0.122000 0.028900 1.89e-01 7.55e-01
Gap junction trafficking 13 3.75e-01 4.82e-01 0.23900 0.181000 0.157000 2.60e-01 3.27e-01
Removal of the Flap Intermediate 14 3.83e-01 4.91e-01 0.20700 -0.204000 0.035600 1.86e-01 8.18e-01
E2F mediated regulation of DNA replication 17 3.84e-01 4.93e-01 0.20400 0.098600 0.179000 4.82e-01 2.02e-01
Nuclear Envelope Breakdown 47 3.85e-01 4.93e-01 0.12300 0.106000 0.062800 2.09e-01 4.57e-01
CS/DS degradation 10 3.94e-01 5.03e-01 0.24000 0.054100 -0.234000 7.67e-01 2.01e-01
Regulation of Complement cascade 16 3.96e-01 5.06e-01 0.18300 0.103000 -0.152000 4.76e-01 2.94e-01
STING mediated induction of host immune responses 12 3.98e-01 5.08e-01 0.23300 -0.062000 -0.224000 7.10e-01 1.79e-01
TBC/RABGAPs 38 3.99e-01 5.08e-01 0.13500 0.070800 0.114000 4.50e-01 2.23e-01
Purine ribonucleoside monophosphate biosynthesis 12 3.99e-01 5.09e-01 0.22500 -0.224000 -0.005280 1.78e-01 9.75e-01
RNA Polymerase III Transcription Initiation 29 4.03e-01 5.13e-01 0.14200 -0.006040 0.142000 9.55e-01 1.85e-01
Metabolism of nitric oxide: eNOS activation and regulation 14 4.04e-01 5.13e-01 0.21800 0.196000 0.096000 2.04e-01 5.34e-01
Transport of inorganic cations/anions and amino acids/oligopeptides 65 4.06e-01 5.15e-01 0.08970 -0.054700 0.071100 4.46e-01 3.22e-01
Chondroitin sulfate/dermatan sulfate metabolism 35 4.06e-01 5.16e-01 0.12200 0.067500 -0.102000 4.90e-01 2.96e-01
Growth hormone receptor signaling 16 4.09e-01 5.19e-01 0.20400 0.104000 0.175000 4.72e-01 2.24e-01
RNA Polymerase III Transcription Initiation From Type 3 Promoter 22 4.12e-01 5.21e-01 0.17400 0.102000 0.141000 4.07e-01 2.52e-01
Zinc transporters 10 4.13e-01 5.21e-01 0.23000 0.087700 -0.212000 6.31e-01 2.45e-01
G-protein mediated events 44 4.15e-01 5.23e-01 0.10900 0.097200 -0.048800 2.65e-01 5.76e-01
Regulation of insulin secretion 49 4.15e-01 5.23e-01 0.11300 0.108000 0.032800 1.91e-01 6.91e-01
Nicotinate metabolism 23 4.15e-01 5.23e-01 0.16700 -0.153000 -0.066600 2.04e-01 5.80e-01
Branched-chain amino acid catabolism 18 4.23e-01 5.32e-01 0.17100 0.164000 -0.048500 2.29e-01 7.22e-01
Phase 2 - plateau phase 13 4.27e-01 5.37e-01 0.20400 -0.203000 0.019800 2.04e-01 9.02e-01
Early Phase of HIV Life Cycle 13 4.29e-01 5.39e-01 0.19800 -0.188000 0.063600 2.41e-01 6.91e-01
TICAM1-dependent activation of IRF3/IRF7 11 4.30e-01 5.40e-01 0.23100 0.051200 0.225000 7.69e-01 1.96e-01
SUMOylation of RNA binding proteins 45 4.32e-01 5.42e-01 0.11800 0.056900 0.103000 5.09e-01 2.32e-01
SLC transporter disorders 59 4.33e-01 5.42e-01 0.09410 -0.018900 0.092200 8.02e-01 2.21e-01
Glucagon signaling in metabolic regulation 23 4.37e-01 5.46e-01 0.14500 0.077700 -0.122000 5.19e-01 3.11e-01
Pink/Parkin Mediated Mitophagy 17 4.37e-01 5.46e-01 0.16900 -0.087400 0.144000 5.33e-01 3.04e-01
Glucagon-type ligand receptors 14 4.39e-01 5.48e-01 0.21100 -0.147000 -0.151000 3.40e-01 3.27e-01
Activated NTRK2 signals through FRS2 and FRS3 10 4.41e-01 5.50e-01 0.23800 0.233000 0.048800 2.02e-01 7.89e-01
Neuronal System 197 4.42e-01 5.50e-01 0.04960 0.042800 -0.025100 3.02e-01 5.44e-01
Metabolism of non-coding RNA 46 4.45e-01 5.53e-01 0.10300 -0.040700 0.094100 6.33e-01 2.70e-01
snRNP Assembly 46 4.45e-01 5.53e-01 0.10300 -0.040700 0.094100 6.33e-01 2.70e-01
InlB-mediated entry of Listeria monocytogenes into host cell 13 4.47e-01 5.55e-01 0.19900 -0.020200 0.198000 9.00e-01 2.17e-01
Insertion of tail-anchored proteins into the endoplasmic reticulum membrane 19 4.50e-01 5.58e-01 0.16600 0.003290 0.166000 9.80e-01 2.09e-01
DNA Double-Strand Break Repair 107 4.51e-01 5.58e-01 0.07030 0.002050 0.070300 9.71e-01 2.10e-01
Regulation of TP53 Activity through Association with Co-factors 11 4.51e-01 5.58e-01 0.21500 0.214000 -0.018400 2.19e-01 9.16e-01
Formation of RNA Pol II elongation complex 43 4.52e-01 5.58e-01 0.11000 0.001610 0.110000 9.85e-01 2.11e-01
RNA Polymerase II Transcription Elongation 43 4.52e-01 5.58e-01 0.11000 0.001610 0.110000 9.85e-01 2.11e-01
Metabolism of folate and pterines 13 4.53e-01 5.59e-01 0.19200 0.063700 -0.181000 6.91e-01 2.59e-01
Gamma carboxylation, hypusine formation and arylsulfatase activation 28 4.56e-01 5.62e-01 0.14500 -0.082700 -0.119000 4.49e-01 2.74e-01
Mismatch Repair 13 4.58e-01 5.64e-01 0.19600 0.013000 -0.196000 9.35e-01 2.21e-01
SUMOylation of DNA damage response and repair proteins 71 4.59e-01 5.64e-01 0.08980 0.037600 0.081500 5.84e-01 2.35e-01
Condensation of Prophase Chromosomes 15 4.62e-01 5.68e-01 0.17300 0.143000 -0.096800 3.37e-01 5.16e-01
Triglyceride metabolism 24 4.65e-01 5.70e-01 0.13800 -0.053400 0.127000 6.51e-01 2.80e-01
RNA Pol II CTD phosphorylation and interaction with CE 20 4.65e-01 5.70e-01 0.15100 -0.136000 0.065200 2.94e-01 6.14e-01
RNA Pol II CTD phosphorylation and interaction with CE during HIV infection 20 4.65e-01 5.70e-01 0.15100 -0.136000 0.065200 2.94e-01 6.14e-01
Gap junction degradation 10 4.67e-01 5.72e-01 0.23700 0.110000 0.210000 5.46e-01 2.50e-01
Role of phospholipids in phagocytosis 16 4.69e-01 5.73e-01 0.18900 0.156000 0.107000 2.82e-01 4.60e-01
Metabolism of porphyrins 13 4.69e-01 5.73e-01 0.19000 -0.185000 0.042500 2.49e-01 7.91e-01
CASP8 activity is inhibited 10 4.70e-01 5.73e-01 0.23500 -0.103000 -0.212000 5.72e-01 2.47e-01
Dimerization of procaspase-8 10 4.70e-01 5.73e-01 0.23500 -0.103000 -0.212000 5.72e-01 2.47e-01
Regulation by c-FLIP 10 4.70e-01 5.73e-01 0.23500 -0.103000 -0.212000 5.72e-01 2.47e-01
Glyoxylate metabolism and glycine degradation 21 4.71e-01 5.74e-01 0.15300 -0.004350 0.153000 9.72e-01 2.26e-01
Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) 17 4.72e-01 5.74e-01 0.16500 0.038900 -0.160000 7.81e-01 2.52e-01
Peptide hormone metabolism 41 4.73e-01 5.74e-01 0.10300 0.061500 -0.082500 4.96e-01 3.61e-01
Deposition of new CENPA-containing nucleosomes at the centromere 20 4.77e-01 5.78e-01 0.15200 -0.149000 0.028000 2.48e-01 8.28e-01
Nucleosome assembly 20 4.77e-01 5.78e-01 0.15200 -0.149000 0.028000 2.48e-01 8.28e-01
Regulation of TP53 Activity through Methylation 16 4.78e-01 5.78e-01 0.18700 -0.135000 -0.130000 3.49e-01 3.70e-01
RNA Polymerase III Chain Elongation 13 4.79e-01 5.79e-01 0.19800 0.036900 0.194000 8.18e-01 2.26e-01
Fatty acid metabolism 105 4.80e-01 5.80e-01 0.06670 -0.066100 0.008880 2.43e-01 8.75e-01
RNA Polymerase III Transcription Initiation From Type 2 Promoter 21 4.81e-01 5.81e-01 0.14900 -0.014400 0.148000 9.09e-01 2.39e-01
Activation of NMDA receptors and postsynaptic events 52 4.82e-01 5.81e-01 0.10200 0.050700 0.088800 5.27e-01 2.69e-01
Pentose phosphate pathway 11 4.84e-01 5.83e-01 0.20700 -0.007550 0.207000 9.65e-01 2.35e-01
Inactivation, recovery and regulation of the phototransduction cascade 15 4.85e-01 5.84e-01 0.17000 -0.061200 0.159000 6.82e-01 2.88e-01
LDL clearance 17 4.86e-01 5.84e-01 0.17800 0.089000 0.154000 5.25e-01 2.72e-01
Metal ion SLC transporters 14 4.89e-01 5.88e-01 0.17200 0.131000 -0.111000 3.97e-01 4.72e-01
IRF3-mediated induction of type I IFN 10 4.90e-01 5.88e-01 0.22500 -0.066000 -0.215000 7.18e-01 2.39e-01
Negative regulators of DDX58/IFIH1 signaling 33 4.94e-01 5.92e-01 0.11400 -0.036400 0.108000 7.17e-01 2.84e-01
Reduction of cytosolic Ca++ levels 10 4.94e-01 5.92e-01 0.20200 0.157000 -0.127000 3.91e-01 4.87e-01
HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) 76 4.96e-01 5.93e-01 0.07390 -0.034200 0.065500 6.07e-01 3.24e-01
Bile acid and bile salt metabolism 24 5.03e-01 6.00e-01 0.13700 -0.000496 0.137000 9.97e-01 2.46e-01
Synthesis of bile acids and bile salts 24 5.03e-01 6.00e-01 0.13700 -0.000496 0.137000 9.97e-01 2.46e-01
Glutamate and glutamine metabolism 11 5.04e-01 6.01e-01 0.20600 0.204000 0.031500 2.42e-01 8.56e-01
Formation of HIV-1 elongation complex containing HIV-1 Tat 31 5.09e-01 6.05e-01 0.11300 -0.101000 0.051000 3.29e-01 6.23e-01
HIV Transcription Elongation 31 5.09e-01 6.05e-01 0.11300 -0.101000 0.051000 3.29e-01 6.23e-01
Tat-mediated elongation of the HIV-1 transcript 31 5.09e-01 6.05e-01 0.11300 -0.101000 0.051000 3.29e-01 6.23e-01
PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases 13 5.13e-01 6.10e-01 0.19400 0.175000 0.084200 2.75e-01 5.99e-01
Iron uptake and transport 43 5.20e-01 6.16e-01 0.09990 -0.000064 0.099900 9.99e-01 2.57e-01
Loss of Nlp from mitotic centrosomes 60 5.20e-01 6.16e-01 0.09100 0.057000 0.070900 4.45e-01 3.43e-01
Loss of proteins required for interphase microtubule organization from the centrosome 60 5.20e-01 6.16e-01 0.09100 0.057000 0.070900 4.45e-01 3.43e-01
PLC beta mediated events 43 5.38e-01 6.37e-01 0.09320 0.087500 -0.032100 3.21e-01 7.16e-01
Resolution of D-Loop Structures 21 5.40e-01 6.38e-01 0.14200 -0.022600 -0.140000 8.58e-01 2.67e-01
Resolution of D-loop Structures through Holliday Junction Intermediates 21 5.40e-01 6.38e-01 0.14200 -0.022600 -0.140000 8.58e-01 2.67e-01
SUMOylation of ubiquitinylation proteins 37 5.41e-01 6.38e-01 0.11200 0.066600 0.090000 4.84e-01 3.44e-01
G-protein activation 15 5.41e-01 6.38e-01 0.15400 0.081100 -0.131000 5.87e-01 3.78e-01
Platelet homeostasis 61 5.48e-01 6.45e-01 0.07550 0.054300 -0.052500 4.64e-01 4.78e-01
Ras activation upon Ca2+ influx through NMDA receptor 15 5.52e-01 6.49e-01 0.15800 -0.023600 0.156000 8.74e-01 2.95e-01
Processing of Capped Intronless Pre-mRNA 25 5.53e-01 6.50e-01 0.11700 -0.098800 0.063500 3.93e-01 5.83e-01
p38MAPK events 13 5.54e-01 6.50e-01 0.18500 0.154000 0.102000 3.36e-01 5.26e-01
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest 13 5.58e-01 6.54e-01 0.16700 -0.163000 0.034300 3.08e-01 8.31e-01
TRAF3-dependent IRF activation pathway 11 5.59e-01 6.56e-01 0.19300 0.186000 0.052800 2.86e-01 7.62e-01
Dopamine Neurotransmitter Release Cycle 12 5.64e-01 6.59e-01 0.16900 0.063600 -0.157000 7.03e-01 3.48e-01
Interactions of Rev with host cellular proteins 35 5.64e-01 6.59e-01 0.10200 -0.008220 0.102000 9.33e-01 2.96e-01
Synthesis of IP3 and IP4 in the cytosol 22 5.65e-01 6.60e-01 0.12600 0.034400 -0.121000 7.80e-01 3.26e-01
Cell-cell junction organization 24 5.68e-01 6.62e-01 0.12600 0.125000 0.012600 2.87e-01 9.15e-01
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers 22 5.68e-01 6.62e-01 0.13300 -0.131000 -0.024000 2.88e-01 8.46e-01
Removal of the Flap Intermediate from the C-strand 10 5.70e-01 6.64e-01 0.19700 -0.193000 -0.036800 2.90e-01 8.41e-01
Association of TriC/CCT with target proteins during biosynthesis 32 5.72e-01 6.66e-01 0.11400 0.096100 0.062200 3.47e-01 5.43e-01
AURKA Activation by TPX2 62 5.75e-01 6.69e-01 0.08160 0.041500 0.070300 5.72e-01 3.39e-01
ADP signalling through P2Y purinoceptor 1 14 5.76e-01 6.69e-01 0.15100 0.107000 -0.106000 4.87e-01 4.94e-01
Glucagon-like Peptide-1 (GLP1) regulates insulin secretion 27 5.78e-01 6.71e-01 0.12100 0.114000 0.040300 3.06e-01 7.17e-01
Retrograde neurotrophin signalling 10 5.79e-01 6.71e-01 0.19800 0.063700 0.187000 7.27e-01 3.06e-01
Transport of Ribonucleoproteins into the Host Nucleus 30 5.84e-01 6.76e-01 0.11600 0.063700 0.097000 5.46e-01 3.58e-01
Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding 26 5.85e-01 6.77e-01 0.11800 -0.010200 -0.117000 9.28e-01 3.01e-01
TRAF6 mediated IRF7 activation 13 5.91e-01 6.83e-01 0.17400 0.148000 0.090200 3.54e-01 5.73e-01
Export of Viral Ribonucleoproteins from Nucleus 31 5.96e-01 6.88e-01 0.11200 0.057400 0.095700 5.80e-01 3.57e-01
Host Interactions with Influenza Factors 40 5.96e-01 6.88e-01 0.09810 0.085400 0.048300 3.50e-01 5.97e-01
Thromboxane signalling through TP receptor 13 6.03e-01 6.96e-01 0.15000 0.081100 -0.127000 6.13e-01 4.29e-01
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) 12 6.05e-01 6.97e-01 0.16900 -0.021900 -0.167000 8.95e-01 3.16e-01
Lysosome Vesicle Biogenesis 26 6.14e-01 7.07e-01 0.11600 0.041200 0.109000 7.16e-01 3.37e-01
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) 12 6.19e-01 7.12e-01 0.17200 0.081600 0.151000 6.25e-01 3.65e-01
DCC mediated attractive signaling 12 6.23e-01 7.15e-01 0.16700 0.161000 0.044300 3.35e-01 7.90e-01
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) 12 6.25e-01 7.16e-01 0.16500 -0.036600 -0.161000 8.26e-01 3.34e-01
Miscellaneous transport and binding events 19 6.25e-01 7.16e-01 0.13700 0.099500 0.094200 4.53e-01 4.77e-01
Visual phototransduction 47 6.26e-01 7.16e-01 0.08200 -0.007760 -0.081600 9.27e-01 3.33e-01
Regulation of FZD by ubiquitination 14 6.27e-01 7.18e-01 0.15600 0.064000 0.142000 6.79e-01 3.57e-01
Vpr-mediated nuclear import of PICs 32 6.29e-01 7.18e-01 0.09480 -0.020400 0.092600 8.42e-01 3.65e-01
G1/S-Specific Transcription 17 6.37e-01 7.27e-01 0.12700 0.123000 -0.034100 3.81e-01 8.07e-01
Formation of Senescence-Associated Heterochromatin Foci (SAHF) 10 6.39e-01 7.29e-01 0.18400 0.145000 0.113000 4.27e-01 5.36e-01
G0 and Early G1 17 6.42e-01 7.32e-01 0.13700 0.129000 0.044900 3.57e-01 7.49e-01
HDR through Single Strand Annealing (SSA) 30 6.47e-01 7.36e-01 0.09840 0.005740 0.098200 9.57e-01 3.52e-01
Rev-mediated nuclear export of HIV RNA 33 6.51e-01 7.40e-01 0.08880 -0.028300 0.084100 7.78e-01 4.03e-01
NS1 Mediated Effects on Host Pathways 38 6.51e-01 7.40e-01 0.09230 0.074500 0.054500 4.27e-01 5.61e-01
Nuclear Pore Complex (NPC) Disassembly 32 6.53e-01 7.41e-01 0.10100 0.073700 0.068500 4.71e-01 5.03e-01
Transport of bile salts and organic acids, metal ions and amine compounds 32 6.53e-01 7.41e-01 0.09580 -0.017400 -0.094200 8.65e-01 3.56e-01
WNT ligand biogenesis and trafficking 12 6.54e-01 7.41e-01 0.15000 -0.014200 0.150000 9.32e-01 3.70e-01
Transferrin endocytosis and recycling 20 6.56e-01 7.42e-01 0.11200 -0.103000 0.044200 4.25e-01 7.33e-01
SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs 10 6.60e-01 7.46e-01 0.15500 -0.129000 0.087200 4.81e-01 6.33e-01
Thrombin signalling through proteinase activated receptors (PARs) 18 6.63e-01 7.49e-01 0.11500 0.060600 -0.098100 6.56e-01 4.71e-01
Hyaluronan metabolism 12 6.64e-01 7.50e-01 0.15200 -0.151000 -0.020000 3.66e-01 9.04e-01
NEP/NS2 Interacts with the Cellular Export Machinery 30 6.74e-01 7.60e-01 0.09640 0.025900 0.092800 8.06e-01 3.79e-01
Cytosolic tRNA aminoacylation 22 6.78e-01 7.63e-01 0.10600 -0.105000 0.011700 3.93e-01 9.24e-01
Transcription of E2F targets under negative control by DREAM complex 15 6.78e-01 7.63e-01 0.13300 0.131000 0.018800 3.78e-01 9.00e-01
Glycosphingolipid metabolism 33 6.80e-01 7.64e-01 0.09430 -0.062100 -0.070900 5.37e-01 4.81e-01
RIPK1-mediated regulated necrosis 14 6.84e-01 7.68e-01 0.13000 0.127000 -0.025100 4.09e-01 8.71e-01
Regulated Necrosis 14 6.84e-01 7.68e-01 0.13000 0.127000 -0.025100 4.09e-01 8.71e-01
mRNA Capping 22 6.84e-01 7.68e-01 0.10500 -0.104000 0.011600 3.98e-01 9.25e-01
SUMOylation of DNA replication proteins 39 6.87e-01 7.69e-01 0.08170 0.015800 0.080100 8.64e-01 3.87e-01
Sulfur amino acid metabolism 21 6.95e-01 7.77e-01 0.11500 -0.086700 -0.075100 4.92e-01 5.51e-01
Synthesis of very long-chain fatty acyl-CoAs 13 6.96e-01 7.78e-01 0.14000 0.035200 0.135000 8.26e-01 3.98e-01
Mitophagy 23 6.97e-01 7.78e-01 0.09650 -0.040400 0.087600 7.37e-01 4.67e-01
Chaperonin-mediated protein folding 65 6.97e-01 7.78e-01 0.06450 0.054400 0.034700 4.48e-01 6.29e-01
HS-GAG biosynthesis 17 6.98e-01 7.78e-01 0.11200 0.101000 -0.048600 4.72e-01 7.29e-01
HDR through Homologous Recombination (HRR) 49 6.99e-01 7.78e-01 0.07200 -0.069200 -0.019900 4.02e-01 8.10e-01
Prostacyclin signalling through prostacyclin receptor 10 7.00e-01 7.79e-01 0.16000 -0.151000 -0.054700 4.10e-01 7.65e-01
Platelet calcium homeostasis 19 7.01e-01 7.79e-01 0.10800 0.024000 -0.105000 8.56e-01 4.29e-01
Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol 15 7.03e-01 7.81e-01 0.11900 -0.109000 0.045400 4.63e-01 7.61e-01
Signaling by NTRK3 (TRKC) 15 7.07e-01 7.84e-01 0.13000 0.119000 0.051200 4.24e-01 7.31e-01
Formation of HIV elongation complex in the absence of HIV Tat 33 7.07e-01 7.84e-01 0.07880 -0.071100 0.034000 4.80e-01 7.35e-01
Assembly and cell surface presentation of NMDA receptors 15 7.11e-01 7.87e-01 0.11800 -0.115000 0.028100 4.41e-01 8.51e-01
RHO GTPases Activate NADPH Oxidases 12 7.11e-01 7.87e-01 0.12800 -0.096200 0.084300 5.64e-01 6.13e-01
Plasma lipoprotein assembly 12 7.12e-01 7.87e-01 0.12800 -0.095700 0.084400 5.66e-01 6.13e-01
Cholesterol biosynthesis 20 7.12e-01 7.87e-01 0.10800 0.106000 0.021800 4.11e-01 8.66e-01
The phototransduction cascade 16 7.13e-01 7.87e-01 0.11100 -0.063500 0.090800 6.60e-01 5.30e-01
Adherens junctions interactions 14 7.14e-01 7.87e-01 0.12800 0.014000 0.127000 9.28e-01 4.12e-01
Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding 21 7.17e-01 7.90e-01 0.10200 -0.002440 0.102000 9.85e-01 4.20e-01
cGMP effects 11 7.19e-01 7.91e-01 0.14800 -0.135000 -0.061200 4.39e-01 7.25e-01
CREB1 phosphorylation through the activation of Adenylate Cyclase 10 7.22e-01 7.94e-01 0.15500 0.140000 0.066100 4.44e-01 7.17e-01
Nuclear import of Rev protein 32 7.24e-01 7.96e-01 0.08350 0.015900 0.081900 8.76e-01 4.23e-01
Degradation of cysteine and homocysteine 11 7.25e-01 7.96e-01 0.14200 -0.139000 -0.030400 4.24e-01 8.61e-01
Diseases associated with glycosylation precursor biosynthesis 15 7.26e-01 7.97e-01 0.12100 -0.119000 -0.022100 4.24e-01 8.82e-01
SUMOylation of DNA methylation proteins 15 7.30e-01 8.00e-01 0.11300 0.107000 -0.034200 4.72e-01 8.18e-01
Synthesis of IP2, IP, and Ins in the cytosol 13 7.36e-01 8.06e-01 0.11800 0.108000 -0.048900 5.02e-01 7.60e-01
RNA Polymerase I Transcription 48 7.39e-01 8.08e-01 0.06710 0.020100 0.064000 8.10e-01 4.43e-01
Sialic acid metabolism 26 7.40e-01 8.09e-01 0.09320 -0.050600 -0.078200 6.55e-01 4.90e-01
Receptor-type tyrosine-protein phosphatases 11 7.46e-01 8.14e-01 0.12400 0.085600 -0.089700 6.23e-01 6.07e-01
Negative epigenetic regulation of rRNA expression 44 7.53e-01 8.21e-01 0.06960 0.038300 0.058100 6.60e-01 5.05e-01
Caspase activation via extrinsic apoptotic signalling pathway 21 7.59e-01 8.26e-01 0.09930 0.083500 0.053700 5.08e-01 6.70e-01
Post-chaperonin tubulin folding pathway 15 7.59e-01 8.26e-01 0.11800 -0.079700 -0.087300 5.93e-01 5.58e-01
Sphingolipid metabolism 64 7.64e-01 8.31e-01 0.05640 0.045400 0.033400 5.31e-01 6.44e-01
SUMOylation of SUMOylation proteins 32 7.65e-01 8.31e-01 0.07400 -0.000793 0.074000 9.94e-01 4.69e-01
Pausing and recovery of Tat-mediated HIV elongation 22 7.66e-01 8.31e-01 0.08780 -0.010200 0.087200 9.34e-01 4.79e-01
Tat-mediated HIV elongation arrest and recovery 22 7.66e-01 8.31e-01 0.08780 -0.010200 0.087200 9.34e-01 4.79e-01
Formation of tubulin folding intermediates by CCT/TriC 16 7.68e-01 8.32e-01 0.09770 0.059500 -0.077500 6.80e-01 5.92e-01
Insulin receptor recycling 17 7.68e-01 8.32e-01 0.10400 -0.102000 -0.020600 4.69e-01 8.83e-01
TP53 Regulates Transcription of Genes Involved in Cytochrome C Release 15 7.72e-01 8.36e-01 0.11400 0.078600 0.083000 5.98e-01 5.78e-01
Caspase activation via Death Receptors in the presence of ligand 13 7.75e-01 8.36e-01 0.10700 0.052400 -0.093600 7.44e-01 5.59e-01
CaM pathway 29 7.75e-01 8.36e-01 0.07120 0.054200 -0.046300 6.14e-01 6.66e-01
Calmodulin induced events 29 7.75e-01 8.36e-01 0.07120 0.054200 -0.046300 6.14e-01 6.66e-01
Biotin transport and metabolism 10 7.77e-01 8.36e-01 0.13800 0.111000 0.081200 5.42e-01 6.57e-01
p75NTR signals via NF-kB 14 7.77e-01 8.36e-01 0.11700 0.071400 0.092200 6.44e-01 5.50e-01
Leading Strand Synthesis 14 7.78e-01 8.36e-01 0.11000 -0.109000 -0.007860 4.79e-01 9.59e-01
Polymerase switching 14 7.78e-01 8.36e-01 0.11000 -0.109000 -0.007860 4.79e-01 9.59e-01
Polymerase switching on the C-strand of the telomere 14 7.78e-01 8.36e-01 0.11000 -0.109000 -0.007860 4.79e-01 9.59e-01
N-glycan antennae elongation in the medial/trans-Golgi 17 7.79e-01 8.36e-01 0.10600 0.071100 0.078200 6.12e-01 5.77e-01
RNA Polymerase I Transcription Termination 24 7.82e-01 8.38e-01 0.07740 -0.066700 0.039300 5.72e-01 7.39e-01
Plasma lipoprotein clearance 26 7.83e-01 8.38e-01 0.08060 0.014400 0.079300 8.99e-01 4.84e-01
Glycerophospholipid biosynthesis 85 7.84e-01 8.39e-01 0.04070 -0.030000 0.027600 6.33e-01 6.61e-01
Inwardly rectifying K+ channels 16 7.87e-01 8.41e-01 0.09800 0.008400 -0.097600 9.54e-01 4.99e-01
Metabolic disorders of biological oxidation enzymes 17 7.87e-01 8.41e-01 0.09590 -0.001360 0.095900 9.92e-01 4.94e-01
Neurotransmitter release cycle 26 7.96e-01 8.50e-01 0.07160 0.036000 -0.061900 7.51e-01 5.85e-01
Recruitment of NuMA to mitotic centrosomes 68 8.02e-01 8.54e-01 0.04690 0.004910 0.046700 9.44e-01 5.06e-01
Acyl chain remodelling of PC 13 8.02e-01 8.54e-01 0.10600 -0.106000 -0.003320 5.09e-01 9.83e-01
Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 11 8.02e-01 8.54e-01 0.10900 0.102000 -0.040500 5.59e-01 8.16e-01
RNA Polymerase I Promoter Clearance 47 8.04e-01 8.54e-01 0.05610 0.006240 0.055700 9.41e-01 5.09e-01
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain 11 8.05e-01 8.54e-01 0.11900 0.038100 0.113000 8.27e-01 5.18e-01
alpha-linolenic (omega3) and linoleic (omega6) acid metabolism 11 8.06e-01 8.54e-01 0.11100 0.109000 -0.018200 5.30e-01 9.17e-01
alpha-linolenic acid (ALA) metabolism 11 8.06e-01 8.54e-01 0.11100 0.109000 -0.018200 5.30e-01 9.17e-01
Synthesis of PE 10 8.06e-01 8.54e-01 0.11200 -0.086300 0.070700 6.36e-01 6.99e-01
Defects in vitamin and cofactor metabolism 18 8.07e-01 8.54e-01 0.09200 0.088100 0.026600 5.18e-01 8.45e-01
DAG and IP3 signaling 35 8.15e-01 8.63e-01 0.06610 0.056200 0.034800 5.66e-01 7.22e-01
Lysine catabolism 10 8.18e-01 8.65e-01 0.11100 -0.028900 0.107000 8.74e-01 5.58e-01
Defects in cobalamin (B12) metabolism 10 8.25e-01 8.71e-01 0.10600 0.093200 -0.051200 6.10e-01 7.79e-01
Regulation of necroptotic cell death 13 8.26e-01 8.72e-01 0.09930 0.098900 0.009130 5.37e-01 9.55e-01
TP53 Regulates Transcription of Cell Death Genes 36 8.27e-01 8.72e-01 0.05730 0.056200 -0.011000 5.60e-01 9.09e-01
Metabolism of vitamins and cofactors 128 8.28e-01 8.72e-01 0.02960 0.013100 -0.026600 7.99e-01 6.04e-01
COPI-dependent Golgi-to-ER retrograde traffic 59 8.29e-01 8.73e-01 0.04470 -0.044000 0.007730 5.59e-01 9.18e-01
Synthesis of PC 21 8.33e-01 8.77e-01 0.07650 0.007810 0.076100 9.51e-01 5.46e-01
Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) 28 8.35e-01 8.77e-01 0.06800 0.023600 0.063800 8.29e-01 5.59e-01
Regulation of Glucokinase by Glucokinase Regulatory Protein 28 8.35e-01 8.77e-01 0.06800 0.023600 0.063800 8.29e-01 5.59e-01
ADP signalling through P2Y purinoceptor 12 12 8.44e-01 8.85e-01 0.09230 0.087300 -0.030000 6.01e-01 8.57e-01
mRNA decay by 3’ to 5’ exoribonuclease 13 8.46e-01 8.86e-01 0.09580 -0.091400 -0.028800 5.69e-01 8.57e-01
Purine catabolism 14 8.47e-01 8.87e-01 0.08280 -0.064700 0.051700 6.75e-01 7.38e-01
MicroRNA (miRNA) biogenesis 20 8.50e-01 8.89e-01 0.07810 0.065800 0.042000 6.10e-01 7.45e-01
G beta:gamma signalling through CDC42 12 8.51e-01 8.89e-01 0.08990 -0.084200 0.031400 6.14e-01 8.50e-01
RNA Polymerase I Promoter Escape 28 8.52e-01 8.89e-01 0.05890 -0.017500 0.056300 8.73e-01 6.06e-01
Prefoldin mediated transfer of substrate to CCT/TriC 20 8.52e-01 8.89e-01 0.07180 -0.004090 0.071700 9.75e-01 5.79e-01
Vitamin B5 (pantothenate) metabolism 13 8.59e-01 8.95e-01 0.08670 0.086400 -0.007110 5.90e-01 9.65e-01
Ca-dependent events 30 8.60e-01 8.96e-01 0.05450 0.048700 -0.024300 6.44e-01 8.18e-01
Transport of Mature mRNA Derived from an Intronless Transcript 40 8.63e-01 8.98e-01 0.05290 -0.037100 -0.037700 6.85e-01 6.80e-01
HIV elongation arrest and recovery 24 8.68e-01 9.02e-01 0.06530 0.023800 0.060800 8.40e-01 6.06e-01
Pausing and recovery of HIV elongation 24 8.68e-01 9.02e-01 0.06530 0.023800 0.060800 8.40e-01 6.06e-01
IL-6-type cytokine receptor ligand interactions 12 8.77e-01 9.09e-01 0.08240 -0.017700 0.080500 9.15e-01 6.29e-01
Synthesis of PA 22 8.77e-01 9.09e-01 0.06460 0.014900 0.062800 9.04e-01 6.10e-01
Transport of Mature mRNAs Derived from Intronless Transcripts 41 8.77e-01 9.09e-01 0.04860 -0.023400 -0.042700 7.96e-01 6.37e-01
Hyaluronan uptake and degradation 10 8.79e-01 9.10e-01 0.09800 -0.050500 -0.084000 7.82e-01 6.46e-01
Viral Messenger RNA Synthesis 38 8.79e-01 9.10e-01 0.04780 0.005050 0.047600 9.57e-01 6.12e-01
Nicotinamide salvaging 12 8.83e-01 9.13e-01 0.07730 0.047000 -0.061400 7.78e-01 7.13e-01
Acyl chain remodelling of PE 11 8.89e-01 9.18e-01 0.08680 -0.083500 -0.023600 6.32e-01 8.92e-01
Phase I - Functionalization of compounds 55 8.94e-01 9.23e-01 0.03750 0.036800 0.007250 6.37e-01 9.26e-01
Anchoring of the basal body to the plasma membrane 85 9.00e-01 9.28e-01 0.03070 0.018900 0.024200 7.64e-01 7.00e-01
Intraflagellar transport 33 9.01e-01 9.28e-01 0.04800 -0.044000 -0.019000 6.62e-01 8.51e-01
Cilium Assembly 156 9.03e-01 9.29e-01 0.01950 -0.014700 0.012900 7.53e-01 7.82e-01
Signaling by FGFR2 IIIa TM 13 9.14e-01 9.40e-01 0.06960 -0.017200 -0.067500 9.14e-01 6.74e-01
IRE1alpha activates chaperones 42 9.16e-01 9.41e-01 0.04000 0.029200 0.027400 7.44e-01 7.59e-01
Metabolism of water-soluble vitamins and cofactors 86 9.17e-01 9.41e-01 0.02690 -0.008590 -0.025500 8.91e-01 6.83e-01
RNA Polymerase I Transcription Initiation 40 9.18e-01 9.41e-01 0.03890 0.010300 0.037500 9.10e-01 6.82e-01
NoRC negatively regulates rRNA expression 41 9.27e-01 9.50e-01 0.03720 0.020900 0.030800 8.17e-01 7.33e-01
FGFR2 mutant receptor activation 16 9.34e-01 9.55e-01 0.05250 0.052300 -0.004000 7.17e-01 9.78e-01
G beta:gamma signalling through PI3Kgamma 14 9.34e-01 9.55e-01 0.05570 0.006780 -0.055300 9.65e-01 7.20e-01
Abortive elongation of HIV-1 transcript in the absence of Tat 18 9.34e-01 9.55e-01 0.05350 -0.043700 -0.030900 7.48e-01 8.21e-01
Protein folding 71 9.36e-01 9.56e-01 0.02650 0.014000 0.022500 8.38e-01 7.43e-01
NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 12 9.36e-01 9.56e-01 0.05840 -0.057400 0.010800 7.31e-01 9.48e-01
XBP1(S) activates chaperone genes 41 9.39e-01 9.58e-01 0.03360 0.015200 0.029900 8.66e-01 7.40e-01
PIWI-interacting RNA (piRNA) biogenesis 15 9.42e-01 9.60e-01 0.05140 0.051300 0.003370 7.31e-01 9.82e-01
Inositol phosphate metabolism 41 9.44e-01 9.61e-01 0.03180 0.029900 0.010800 7.40e-01 9.05e-01
Processing of Intronless Pre-mRNAs 17 9.46e-01 9.61e-01 0.04860 -0.044500 -0.019600 7.51e-01 8.89e-01
RA biosynthesis pathway 14 9.47e-01 9.61e-01 0.05040 -0.050400 0.002040 7.44e-01 9.89e-01
Neurotransmitter receptors and postsynaptic signal transmission 104 9.47e-01 9.61e-01 0.01770 0.016100 -0.007380 7.77e-01 8.97e-01
Cargo trafficking to the periciliary membrane 39 9.56e-01 9.69e-01 0.02640 -0.024500 0.009880 7.91e-01 9.15e-01
Cytosolic sulfonation of small molecules 11 9.59e-01 9.69e-01 0.04940 -0.006060 0.049000 9.72e-01 7.79e-01
Transmission across Chemical Synapses 140 9.59e-01 9.69e-01 0.01420 0.014200 0.000535 7.72e-01 9.91e-01
Glutamate Neurotransmitter Release Cycle 14 9.59e-01 9.69e-01 0.04760 0.026700 0.039400 8.63e-01 7.99e-01
Cobalamin (Cbl, vitamin B12) transport and metabolism 11 9.60e-01 9.69e-01 0.05250 0.045700 0.025700 7.93e-01 8.83e-01
Centrosome maturation 68 9.60e-01 9.69e-01 0.01950 -0.002300 0.019400 9.74e-01 7.82e-01
Recruitment of mitotic centrosome proteins and complexes 68 9.60e-01 9.69e-01 0.01950 -0.002300 0.019400 9.74e-01 7.82e-01
Fatty acyl-CoA biosynthesis 20 9.74e-01 9.82e-01 0.02890 0.028800 -0.002760 8.24e-01 9.83e-01
Presynaptic phase of homologous DNA pairing and strand exchange 30 9.80e-01 9.87e-01 0.01970 -0.014900 0.012900 8.88e-01 9.02e-01
Golgi Cisternae Pericentriolar Stack Reorganization 10 9.80e-01 9.87e-01 0.03750 0.035900 0.010800 8.44e-01 9.53e-01
TP53 Regulates Transcription of Caspase Activators and Caspases 11 9.81e-01 9.87e-01 0.03440 -0.033900 -0.005550 8.46e-01 9.75e-01
Nucleobase catabolism 26 9.83e-01 9.88e-01 0.02130 -0.020800 -0.004780 8.55e-01 9.66e-01
G-protein beta:gamma signalling 20 9.86e-01 9.90e-01 0.02270 -0.021600 -0.006990 8.67e-01 9.57e-01
N-Glycan antennae elongation 11 9.87e-01 9.90e-01 0.02980 -0.018900 -0.023100 9.14e-01 8.95e-01
Homologous DNA Pairing and Strand Exchange 32 9.88e-01 9.90e-01 0.01710 -0.009680 -0.014100 9.25e-01 8.90e-01
Transport of the SLBP independent Mature mRNA 33 9.91e-01 9.92e-01 0.01290 -0.010300 0.007850 9.19e-01 9.38e-01
p75NTR recruits signalling complexes 11 9.92e-01 9.93e-01 0.02040 0.009860 -0.017800 9.55e-01 9.18e-01
Transport of the SLBP Dependant Mature mRNA 34 9.98e-01 9.98e-01 0.00552 0.005490 0.000548 9.56e-01 9.96e-01


Detailed Gene set reports


Signal Transduction
Signal Transduction
metric value
setSize 1466
pMANOVA 1.77e-37
p.adjustMANOVA 2.13e-34
s.dist 0.22
s.RNA.expression 0.182
s.H3K9.Acetylati 0.124
p.RNA.expression 4.3e-30
p.H3K9.Acetylati 9.09e-15



Top 20 genes
Gene RNA expression H3K9 Acetylati
NR4A1 6720 10517
PPP1R15A 6673 10507
NRIP1 6704 10436
JUN 6715 10304
DUSP1 6580 10477
FOXO3 6621 10395
VEGFA 6599 10414
USP2 6526 10511
FKBP5 6643 10299
PDE4B 6713 10179
PPP1R12B 6477 10532
FOS 6524 10376
SKIL 6639 10113
HSP90AB1 6389 10467
AKAP13 6288 10571
DUSP16 6435 10251
NEDD4 6246 10550
HES1 6494 10127
ARHGEF12 6210 10458
NR3C1 6033 10592

Click HERE to show all gene set members

All member genes
RNA expression H3K9 Acetylati
DNAJB1 6744 6071
CXCL2 6741 2974
SOX17 6738 -902
RHOB 6737 7851
LDLR 6725 2821
SERPINE1 6723 -1234
NR4A1 6720 10517
HSP90AA1 6716 9085
JUN 6715 10304
PDE4B 6713 10179
CX3CL1 6706 370
NRIP1 6704 10436
PIK3R3 6702 6598
CCL2 6698 5797
JUND 6697 7702
ACTG1 6691 1358
SOCS3 6690 3124
CDKN1A 6688 9517
FLT1 6681 -1938
USP34 6676 5613
DUSP2 6675 -622
PPP1R15A 6673 10507
GPR4 6672 4218
KAT2A -6367 4839
RGS2 6663 7290
SDC4 6662 3290
RGS5 6656 2397
DUSP5 6654 8767
PHC3 6646 7555
FKBP5 6643 10299
SKIL 6639 10113
EGR1 6636 7766
MYC 6633 8932
RIT1 6630 7848
FOXO3 6621 10395
SPOPL 6617 5756
NF1 6612 5338
DUSP6 -6357 3857
VEGFA 6599 10414
IQGAP1 6597 9274
TAOK1 6591 1213
FOXO1 6587 7502
MAPRE1 6586 6361
DUSP1 6580 10477
COL4A1 6575 2064
KMT2D 6569 5572
FKBP4 6567 2549
DLL1 6561 3548
YES1 6560 4371
SNAI1 6551 8168
LATS2 6545 8529
CBL 6543 6420
ALDH8A1 -6344 358
CHD1 6533 8056
USP2 6526 10511
FOS 6524 10376
POLR2A 6523 -225
LATS1 6517 6183
HSPG2 6510 -121
OBSCN 6504 8019
HES1 6494 10127
RANBP2 6490 7392
DLL4 6482 4111
CRK 6480 8284
KIDINS220 6479 8004
PPP1R12B 6477 10532
LAMC1 6467 8178
VWF 6464 -2151
PSMB7 -6318 8601
ULK3 -6316 1267
PIK3CB 6462 7189
A2M 6461 6564
PLCB1 6460 3172
ADRA2B 6459 1426
IRS2 6457 3297
PDE11A -6312 5542
DLC1 6447 1622
THBS1 6443 214
ARHGAP1 -6305 3332
DUSP16 6435 10251
IL6ST 6430 6933
LRRK2 6426 1749
KRAS 6424 6983
BMI1 6422 9711
RGS16 6419 3531
PDK4 6416 9681
FES 6410 1019
MYH14 6400 1723
APP 6390 1413
AKR1C1 -6286 513
PIN1 -6285 -304
HSP90AB1 6389 10467
RIPK2 6370 -375
LPL 6369 7329
FGD3 -6269 -2100
PTPRS -6265 -1770
PSMB5 -6257 1512
SRF 6354 7736
SOCS6 6352 6931
FOSB 6344 8435
AMER1 6343 7412
MYH9 6339 6683
ARPC2 -6240 9832
SCAI 6337 6072
DUSP8 6331 1554
ANXA1 6329 4452
DYNC1H1 6328 4072
ITCH 6325 6696
SMO -6226 670
DHRS3 -6223 8921
RBFOX2 -6221 10466
ARHGAP5 6313 5218
ARHGAP27 6306 -744
GLI3 -6210 7128
CXCR4 6303 4636
IL6 6297 5694
PIK3CA 6296 5808
SYDE2 6295 6601
AKAP13 6288 10571
PPP1R14A 6284 2472
HNRNPH1 6281 10097
SMAD7 6279 9726
RAPGEF2 6276 10175
TNFSF10 -6191 -359
POGLUT1 6272 -1317
ACTR3 6262 1616
RICTOR 6253 9823
ADCY9 6251 7609
NEDD4 6246 10550
HSPB1 6243 10148
CHUK 6239 5923
NFKBIA 6238 9475
RHOC 6233 7144
TNFRSF10D 6228 1879
FGD4 6227 9853
TNFRSF10B 6214 -97
PYGO1 6213 9531
ARHGEF12 6210 10458
EPAS1 6192 7036
PSMA4 -6145 8472
ATP1B4 -6143 9427
NCOA3 6183 9441
NDEL1 6176 9046
SPTBN1 6171 9714
USP9X 6163 8505
BMP2 6159 5213
HIST1H2BD 6155 8981
PAK2 6152 7895
PTPN11 6148 2816
ARHGAP29 6117 7126
CHD4 6116 4996
UHMK1 6114 9255
RPS6 -6080 4813
TEK 6102 7140
ERBB3 -6076 -91
POLR2C -6075 3645
FSTL1 6101 902
KITLG 6099 721
YWHAQ 6094 8892
REEP1 -6061 8511
SMAD5 6086 8239
RBPJ 6081 10125
APOE -6058 672
PPP2R1B 6069 10009
USF1 -6042 8492
SOX6 6056 10354
CREBBP 6050 9664
POLR2G -6031 5463
NUP85 -6024 5556
PTPRA -6023 5955
ZFYVE9 6040 8925
ACTB 6034 8383
NR3C1 6033 10592
ADRB2 6032 10288
FZD7 6028 9962
UBA52 -6013 8521
PDE7B -6009 10259
PDE7A 6005 10353
GRM2 -5995 -2461
GDNF 5998 4855
RAMP1 -5990 7687
MCF2L 5996 -2231
HBEGF 5991 9668
TLN1 5986 462
FMNL3 5982 3774
CKAP5 5980 8593
MYO7A -5971 -2416
SPPL2A 5976 9729
KDR 5975 204
COL6A3 5974 1138
PDE4D 5968 10501
LAMA2 5967 10203
NOTUM -5962 3262
IGF2 5961 3778
CDC14A 5943 6027
MAP3K11 5936 3863
RBBP5 5935 10065
INHBB 5934 3357
GPSM3 5932 4603
STMN1 -5927 4463
DYNC1LI2 5920 3404
AGO2 5917 3758
PRKAB2 5911 3668
GPS2 -5920 9773
YWHAH 5900 5267
WIPF2 5891 6322
JAG1 5886 5893
MKS1 -5902 -873
APC 5866 9763
SCRIB 5856 -2352
THBS2 -5883 -1755
TIA1 -5881 3219
NCBP1 5849 2136
PTEN 5843 9266
IKBKB -5874 1647
PSME1 -5870 3786
MAPK3 -5868 3840
CTNND1 5836 10437
YAP1 5828 6223
POU2F1 5826 2667
KIF5B 5805 3935
H3F3A 5799 9513
MTA2 5797 6087
HNRNPF 5795 9530
ITGAV 5791 8087
PLEKHG2 5790 1523
FMNL2 -5832 9725
P2RY1 5788 5221
TRRAP 5786 1692
LRP1 5782 -2426
PLCB4 5777 2702
ARHGEF1 -5821 425
RBBP4 -5817 3158
INCENP 5770 2919
SPRY1 5768 10074
TRIO 5765 7214
RAPGEF1 5764 6812
F11R 5763 2333
FRK 5754 10307
NCOA1 5747 9868
GNG11 -5793 8111
ATF2 5743 5098
UCHL5 5731 3952
RDH14 -5774 7334
PDE1A -5773 2539
NUP160 5712 8660
OTUD7B 5707 9224
NOTCH1 5704 -1096
BCL2L11 5703 5091
RPS27A -5761 2197
MYD88 5698 -777
SMURF1 5697 7402
RGS14 -5754 6127
MET 5695 10072
MDM2 5694 7741
PSMA3 -5745 9750
NOS3 5676 -1653
ARF6 5673 9307
KAT2B 5671 7685
PIP4K2B 5665 6188
CAMKMT -5711 2698
ABCA1 5653 1936
MEF2A 5651 10356
STRN 5648 7479
FURIN 5647 3714
XK 5646 4420
MDK 5641 1274
CLTC 5630 6978
FOXO4 5622 6623
UCN -5688 826
RPS6KB1 5620 3489
ARHGAP35 5616 3247
CXCL9 -5682 -1194
ATP6V1E1 -5676 1008
CCND1 5606 1152
POLR2D 5605 2543
GATA3 5600 -1881
CASP3 5597 4885
ESR1 5593 9631
PTPN18 -5643 2944
LAMB3 -5639 6400
HDAC5 5581 8312
NLN 5580 1878
TCF7 5579 1386
OR51E1 -5635 2063
APOB -5628 -357
DSN1 -5627 7474
MIB1 5567 9735
LGR5 5566 622
TNS3 5560 4919
STK4 5557 3649
RXRA 5553 8149
TLE1 5552 9614
RET 5549 279
AREG 5548 2374
ROCK2 5544 10339
GTF2F2 -5610 10107
PPP2CA 5543 8072
PRKCE 5536 8368
REST 5533 5597
RPS6KA3 5531 10051
AGO4 5529 5886
LGR4 5528 3754
SP1 5525 9130
PPP2R1A -5594 8945
FN1 5519 -1202
EEPD1 -5583 9091
SKI 5517 5325
COL4A2 5514 1727
PSME4 5513 4336
TLE3 5508 6043
PPP1CA -5578 4369
RBX1 -5573 8048
SPTB 5503 8838
NCOA2 5491 8814
NEURL1 5488 5482
VANGL2 5485 -84
SPRED1 5483 8185
SOS1 5482 9820
PRMT1 -5552 8832
PDGFB 5481 5367
SMAD6 5477 4575
HEYL 5471 5867
TBXA2R 5470 -762
USP13 5469 9059
MOB1A 5466 6907
YWHAZ 5465 10363
PPM1A 5464 9677
SPTAN1 5452 1147
EGFR 5444 7145
CENPP 5434 2143
PTENP1 5425 7078
CYBA -5505 -2134
VPS35 5402 5519
NRG2 -5499 4359
PKN1 5401 1011
MAPK13 -5493 -86
MTOR 5388 4256
RAP1B 5373 10101
SOS2 5364 9210
RASGEF1A -5452 -2431
RDH11 -5448 5883
FGF6 5360 6220
VEGFB -5440 416
BMPR2 5351 6675
LAMB2 -5437 4958
CDK8 5346 9984
EDNRB 5344 4921
H2AFJ -5427 5086
ATN1 5340 6133
SMURF2 5331 6120
XIAP 5326 9442
FABP7 -5406 476
STAT3 5316 10080
GNG5 -5396 8183
PEA15 5311 2553
ARHGEF2 5308 6836
GNA13 5306 7982
NSMAF 5304 8535
RHOG 5300 2199
IRS1 -5382 10476
CBX4 5296 3644
RAC1 -5376 9119
HGS -5374 51
ARHGAP31 5289 7172
PSMB2 -5360 8118
SRC 5280 -1493
ARHGEF10 5279 -686
CTTN -5344 -1280
PSMC2 -5342 8507
ABHD12 -5341 1438
BIRC2 5258 9930
ARHGAP25 -5328 205
CDH5 5251 1621
WWP1 5233 6566
GNB1 5231 1155
LFNG -5287 -147
CLIP1 5225 10488
CENPT -5267 8470
MOB1B 5215 6500
CAMKK1 -5259 1814
TP53 -5245 -1235
PPARG 5192 3380
KDM4C -5241 8293
AMOT 5189 9983
SPDL1 -5230 6770
ARHGAP23 5187 2715
PCSK6 5180 -815
PXN -5219 9541
BIRC3 5165 7464
CHD3 5145 6866
FSTL3 5143 760
IRAK4 -5190 3767
GRB10 5140 8321
DAB2IP 5136 8584
PIP5K1C 5128 2048
LRP6 5125 10198
TGIF1 5109 10239
STK3 5106 9283
ARHGAP33 -5167 -1842
GNAO1 5098 -2185
BCL9L 5096 5432
BCAR1 5089 8439
SFPQ 5083 10043
GNAI2 5082 5507
CCNK 5068 2798
CAB39 5067 9341
CXXC5 -5128 9689
GPNMB -5125 3986
CLASP2 5061 9960
BMPR1B 5052 9892
AMOTL1 5051 8835
AVPR1A 5046 3853
REEP2 -5107 486
RAPGEF3 5043 -363
PRKAG2 5034 6163
EDN1 5033 2885
TAB3 5024 7296
PSMD12 5013 7847
KHDRBS3 5009 4540
NLK 5007 8736
LAMA5 5005 -1476
PSMF1 -5062 564
THEM4 -5061 7994
BRK1 -5051 8969
PRC1 -5047 5022
NF2 4989 8027
RNF111 4988 10098
LTB4R -5037 -1195
NCKAP1 4978 9851
ARHGEF37 4974 4773
CD97 -5033 4028
HDAC4 4970 8905
KIF2A 4964 6766
ARHGEF7 4963 10012
PRKG1 4947 10235
TRADD -5011 5046
ARL4C 4943 3663
PPP2CB 4941 9703
SMAD2 4940 9138
FNTA -5000 6137
NUP98 4938 5452
ABL1 4936 9200
NUP133 4933 1325
NAPEPLD 4923 7067
PDK1 4920 192
PTGES3 4919 10542
BRAF 4915 9824
DTX2 4911 -129
PDHX 4906 5029
TGFBR1 4903 8009
SEL1L 4901 7549
IL17RD 4896 3369
RXRG -4961 10260
ATP6V0D1 -4948 5618
NRG4 -4943 7492
NET1 4879 10289
EPS15 4878 2537
PSMB6 -4939 8266
PLCB2 -4937 -614
ARHGAP10 4870 9252
RAMP2 -4929 -889
STAM2 4860 6994
ALDH1A3 4858 -973
ITGB1 4857 9564
ACTN2 4852 10073
STAT1 4845 6906
IER3 4844 723
BTRC 4842 8621
ADCY5 4838 -1174
ATP6V1A 4836 5967
CENPC 4834 7155
GAB2 4827 7171
PSMD1 -4887 8440
TRAF6 4822 5972
DNM1 -4885 -904
CENPH -4884 -719
RGS11 -4878 1696
PTPRU 4817 -707
SLC38A9 4811 8783
RHOD -4870 4826
SMAD3 4808 10416
NUP37 -4864 29
NOTCH3 4801 -876
PPP3CC 4800 9966
IGF1R 4780 6047
ARHGEF25 -4842 5240
SUZ12 4773 6745
PSMB4 -4827 8184
HNRNPA1 4755 10508
ATF1 4754 9037
SKP1 -4825 9991
RYK 4747 4883
S1PR3 4742 -1021
PPP1CB 4741 10326
CRABP2 -4812 3872
USP21 -4805 5703
HDAC9 4724 8877
RDH5 4722 8912
ATP6V1B2 4719 7289
CSNK1E 4717 7666
STAG1 4716 4202
MBD3 4713 7756
KL -4777 3749
PGF 4700 2093
FLNA 4698 1145
TRIM33 4697 9431
IFT57 4696 8296
ERBB2 -4764 4589
SOX7 4686 763
CUL3 4684 10135
GNAS -4752 10419
EIF4G1 4675 10061
IGF1 -4740 5721
CPT1A 4671 4847
OPHN1 -4730 3038
JAK1 4663 7112
WASF2 4661 9672
PSMB1 -4724 6031
APH1B 4658 9007
ALDH1A2 4647 5402
SMAD9 -4709 3330
GDI2 4640 1940
RCOR1 4634 6064
ARRB2 4627 2112
YWHAG 4626 10201
GNG2 -4692 -1748
PSME3 4624 1812
PHB 4620 3250
RPGRIP1L 4617 -739
ROCK1 -4678 9561
SOX4 -4672 7942
PRKAR1A 4593 10355
TLE2 -4645 2890
ARRB1 4587 1264
MXD4 -4641 4266
KDM4A 4582 8512
GNG7 -4639 -2024
KDM3A 4572 9553
HDAC10 -4621 2493
ATP6V0B -4613 6458
HEY1 4558 9707
PKN2 4556 2769
DNM2 4554 1750
WWP2 -4603 5479
PRKAR1B -4598 -2242
CENPN 4549 -117
TGFBR2 4540 6287
ANGPT1 4518 8339
CYP4V2 -4563 -292
ATP2A1 4513 6117
DLAT 4507 9493
MAP3K7 -4552 8806
JAG2 4502 3113
HDAC8 4496 4179
AXL 4494 3630
TNFRSF10A 4493 -2439
PTCH1 4481 3666
ITSN1 4470 3420
PRKAG3 -4531 9289
BAMBI 4467 4690
GABBR1 -4529 -733
ALDH1A1 4445 9649
PSMA7 -4495 5331
PDHA1 -4488 8565
AMHR2 4424 922
OS9 4422 6431
TJP2 4417 5292
REEP5 -4472 4247
TGFB1 4410 -1814
RAB4A -4468 4457
RGS12 4394 3010
PIK3CD -4449 -1127
HMHA1 4387 -900
MAPK11 4386 1969
FAM13B 4385 2645
AR 4384 5036
PIP5K1A -4440 9434
BAX -4439 8986
THBS4 4379 -2102
LRP12 4375 3927
IL1RAP 4359 4810
RAMP3 4353 1057
NEDD8 -4413 4032
EZH2 4337 5656
ARPC5 4334 7967
CAMK2A -4409 7413
TAB2 4332 9314
MEN1 -4402 5160
PTK2B 4319 -1614
ZNF217 4318 7003
GAB1 4310 10373
GNAI1 4291 5121
TMED5 4275 6522
WWOX 4273 1460
ADAM10 4258 9159
HNRNPM -4334 8710
RPS6KA2 4252 1864
FST -4321 7600
ARHGAP17 4231 2408
CCR3 4226 -2372
ARHGAP4 -4303 5456
WIPF3 -4302 9876
PTCH2 -4293 460
FKBP1A -4291 8028
GREB1 4211 805
IKBKG -4285 8856
CDC14B 4200 2945
PTPN12 4199 8006
CSNK1A1 4194 4956
RETSAT 4193 2057
FGD2 4190 -1472
GNRH1 4187 2634
RASA3 -4253 6556
SMPD3 4182 -542
PAQR3 4179 5264
ACVR1C 4168 3196
CNOT6L 4159 9738
SPPL2B -4219 -531
PRKAR2A 4155 2202
PREX1 -4216 614
OPN1SW -4214 2331
GSK3B 4131 9213
CSK -4196 4408
PSMB3 -4193 -940
NRP1 4119 8954
FZD1 -4181 4604
MAPK6 4104 6134
VRK3 4101 -1954
GNG12 4099 4118
DUSP10 -4167 10277
GATAD2A 4090 6860
KDM4B 4080 638
PLAT 4075 2303
NUMB 4071 8721
MAD2L1 -4142 6413
GNAQ 4066 5448
TULP3 -4131 7834
CAMKK2 4060 2779
SMC3 -4120 9247
RHEB 4032 10090
DRD2 -4103 -2472
MECOM -4096 6647
PAK1 -4078 8391
PSMD13 -4071 1261
PEBP1 -4070 4874
CXCL12 -4055 4476
AGTR1 -4054 522
MAPK12 -4052 5741
FZD9 -4034 3875
E2F3 3980 7761
MYO9A 3977 3887
DOCK1 3970 -2110
CCNE1 3964 1099
GRK4 -4015 134
NCAM1 -4009 -2331
PDGFRA 3952 2993
ARHGAP24 -4005 9198
PIP4K2A -3979 3350
ATP6V0A2 3921 5344
SHC1 3916 4152
PRKX 3906 -771
HIF1A 3900 6776
RGS3 3898 9171
TAS1R3 3890 -772
RBP1 3885 618
BCL9 -3956 10157
RNF31 3868 2329
ADH1C -3941 1738
MEF2C 3852 10612
CRKL 3847 7805
IFT172 3841 903
RPTOR -3923 3516
WWTR1 3825 4574
SIRT6 -3916 -2157
CASP8 -3910 3014
WASF3 3818 2848
GPR68 3807 3187
MYL9 3801 2417
CTBP1 -3894 -573
ARHGEF15 3788 -764
RTKN -3882 4209
TNRC6C 3778 9380
CYBB 3772 -460
PPP3CA 3771 8770
SPTBN4 3769 1073
SEC13 -3863 4435
GPR161 3746 1817
DIAPH2 3744 5311
CUL5 3742 7715
ARHGEF3 3737 8870
CTNNB1 3734 8719
KIF3A 3727 3243
RNF2 3722 8107
CHD8 -3833 10344
PPP1CC 3707 9534
C5 -3817 860
NTRK2 -3814 896
RGS6 -3813 -2330
CDC42EP2 3694 6569
MYLK 3686 -1756
TJP1 3685 1329
KALRN 3684 3835
ACTR2 3682 8106
DLG3 -3799 1260
LEO1 -3797 7615
CDKN1B 3675 7576
DVL1 3674 6986
RRAGB -3792 7042
ARAP1 -3782 6820
USP7 3662 9084
ITPR2 3660 4529
NOTCH4 3659 -1237
DGKD 3647 9740
PSMD9 -3768 2589
CBY1 -3767 -101
AKR1B10 -3765 4486
PPP5C -3757 4733
YBX1 -3751 7941
ARHGAP26 -3743 7919
CNTN1 3603 -1867
CENPF -3712 1905
FGFR1 3594 6643
CD55 3592 9384
NTRK3 -3706 -1626
ATP6AP1 -3705 -229
GAS1 -3704 9839
KBTBD7 3588 5829
ATP6V1D -3702 2802
CLTB -3695 6785
ADRA2C -3693 -1348
ESR2 -3691 605
SREBF1 3580 8290
ITGB3BP -3680 1511
PRKAB1 -3670 3848
STAT5A 3570 1302
HPN -3668 6414
PSMC3 -3661 10264
SPRY2 3553 9197
FGF9 3552 4952
ARHGDIA 3546 6727
ARPC1A -3644 5731
NEDD4L -3642 5438
GNAL 3544 -954
ATP6V0E1 -3631 2059
CAMK2B -3629 4531
DZIP1 3520 1222
WNT9A -3610 6697
PPP2R5D -3593 7141
AHCYL1 -3588 10088
DYNC1LI1 3501 9338
TLE4 3495 10114
PREX2 -3579 4132
USP15 3490 2773
ARAP2 3484 -1873
POLR2B 3481 3120
VCL 3479 10258
RNF146 3478 9849
DHRS4 3475 2949
CCDC88C -3554 -2306
YY1 3473 7578
DUSP3 3467 10388
CNKSR1 -3543 4537
CENPL -3535 264
ECT2 3455 7765
TNFRSF1A 3442 9682
NRAS 3431 3729
CPT1B 3429 5129
ACTA2 -3511 6746
WDR19 3427 4664
ZFYVE16 3423 9557
DIAPH1 3421 6389
STRAP -3502 8478
COL6A6 3412 1181
ITPR3 -3497 7377
AKT3 3405 5990
GNB2 3401 4337
TNKS 3398 5340
RAB6A 3392 -489
LAMTOR5 -3473 3184
KLC4 -3472 1349
SCD 3380 -466
CHRDL1 3378 188
PTPN3 3370 7832
LIMK1 -3450 321
IQCE -3437 -1642
CNGA1 3365 -334
LAMTOR1 -3426 10005
STAG2 3363 9181
KIF7 3361 -205
ECE1 3358 2953
RHOU 3356 7279
ATP6V0A1 3354 9954
CDC73 3353 9913
AVPR2 3351 965
CARM1 -3403 8097
TRIM27 3341 4157
LRP10 3340 5412
EGF -3393 9221
MAPK8 3330 8854
MIB2 -3388 3590
PHC1 3326 5660
AHCTF1 3312 8137
RXRB -3371 1505
DAGLB -3370 8773
PDE1B -3365 1633
CX3CR1 -3362 4659
KSR1 -3360 8850
MOV10 -3359 7228
USP8 3303 7116
RALBP1 3289 4869
DERL2 -3337 5253
PDE8A -3335 7149
ERBB4 3287 7460
MAPK4 -3329 4850
ARHGEF26 3281 1322
RASGRF2 3279 -1074
DGKA -3322 -335
ARHGAP32 3273 3725
RAF1 3270 9737
CLIP3 -3298 -1778
RASAL2 3255 9552
PPARD 3249 6751
ARHGAP18 3237 9952
GGA3 -3276 5214
REEP3 3221 8482
C3 3212 -2490
PIP5K1B -3247 3433
FRS2 3187 9340
MAPKAPK3 -3234 8104
RALB 3158 2813
PTBP1 3152 7642
PRKAR2B 3149 3421
EIF4B 3136 9184
SNAI2 -3193 6186
BAG4 3125 1571
JUP -3178 5974
PRKAG1 -3177 9373
LIMK2 -3172 6259
KCTD6 3111 8628
PBX1 3104 10492
PPP2R5C -3165 6453
AKT2 3103 8086
PIK3R4 3090 8468
FLRT1 3084 2973
NUP43 -3145 4833
ATP6V1H -3137 9023
ARHGEF17 -3127 4453
VEGFC 3053 6219
INSR 3052 2321
RASA2 3048 3114
PMEPA1 3036 4837
NCSTN -3091 6627
METAP2 -3090 9562
AGO3 3014 856
DUSP7 3013 5210
PARP1 3007 7804
DYNC2H1 -3052 1312
HDAC2 2996 961
JAK2 -3046 8652
CHEK1 2985 7655
MAP2K1 -3041 400
GNAI3 2982 9141
REEP4 -3028 8061
GPC1 -3015 2514
DVL2 -3012 7399
ARHGAP44 -3010 -2379
PRKCQ 2971 10136
FLT4 2965 -2475
MAGED1 -2984 4322
CCNC -2972 6656
PTPRJ 2945 1432
RAB4B -2969 872
RALA 2941 8866
RGS10 -2953 2521
ST3GAL3 2936 4862
PDE4C -2943 4264
PAFAH1B1 2926 9748
KLC1 2924 7311
MC1R 2918 -271
P4HB -2922 6344
PSMC4 2912 9069
PRKCA 2906 6689
STARD13 2901 9993
LAMTOR2 -2887 -1787
POMC -2879 5196
GLI2 -2878 1037
NCOR2 2884 8558
CBX6 -2865 6497
MYH10 2881 -681
ROR1 -2857 3493
CDC42EP3 2855 8096
PPP3CB 2854 9964
SQSTM1 2845 7486
ARHGEF4 -2824 -1178
PRKAA1 -2821 7665
REEP6 -2819 -1660
MAPK14 2832 8653
TFDP2 2829 5874
PDK2 -2813 5873
BCL2 2821 9001
PDGFA 2814 5053
CBX8 -2788 410
ACVRL1 2801 7169
CCND3 2799 6195
PTPN6 -2780 199
PLB1 -2779 6918
THBS3 -2774 322
AGRN -2762 -1478
CYLD 2771 9800
SAV1 2762 8897
SRGAP2 2756 571
HDAC7 -2738 8251
PTPRK 2750 9577
SHC2 2745 -2063
PPP2R5E 2739 1845
PSAP -2726 5150
AGO1 2733 2782
FER 2721 8557
PLCB3 -2712 1379
DOCK7 2716 2358
RAD21 2707 9611
GDI1 -2702 2544
RNF43 -2701 1797
HEBP1 2698 2640
NCBP2 -2685 -875
ADCY2 2686 8920
CSNK1G2 -2681 1653
SH3KBP1 -2675 875
CYFIP1 2674 168
ARHGEF9 -2670 6017
RBCK1 -2660 4092
FLRT3 2656 8983
STARD8 2651 5392
EDN3 -2644 -1904
RUVBL1 -2641 4436
PSMC1 -2634 5249
EIF4E -2633 985
PSMD3 -2625 9052
NR1H2 -2623 3968
LPAR1 2628 -318
PSMA6 -2614 4091
MAP2K5 2618 4870
CDK9 -2608 5203
RHOT2 -2605 7
OPN3 2612 5207
GNB4 2609 2933
ABR 2606 -677
OFD1 -2599 4987
MARK3 2604 10046
CALCR -2597 1514
STRADA 2596 6979
FGD1 -2587 3163
IL6R 2585 6606
XPO1 2582 10256
STAT6 2568 2189
GREM2 -2567 975
POFUT1 -2561 546
E2F5 2561 3975
YWHAB -2556 8699
ST3GAL6 2549 5113
IFT88 -2530 943
TNFAIP3 2534 4509
MTA3 -2528 4151
FGFBP3 2522 3723
PSMD7 -2518 3414
PDE1C -2517 -2165
CASP9 -2516 8013
ZDHHC7 -2513 7861
AMOTL2 2507 7696
PRKCD 2491 4466
CLASP1 2469 9460
DRAP1 2465 3035
SPRED2 2464 1553
AXIN2 2457 6590
GOPC 2454 7744
TTC21B 2453 6459
PHLPP1 2443 5473
MAML3 2439 8443
EVL -2431 -1886
ARHGAP30 -2423 -2260
RASA1 2429 6956
ELMO1 -2419 -413
CMKLR1 2427 -1948
TRIP10 -2414 9910
DAGLA -2408 6891
CYFIP2 2413 -569
E2F4 2412 4155
RHOQ 2406 8418
ACVR1B 2403 7964
YWHAE -2381 10604
VAV2 -2380 -1340
DLD 2399 8885
NR1H3 -2376 2976
MYO9B -2375 -1813
LEPR 2394 1926
APLN -2344 2932
TACR2 2376 -234
SDC2 2369 6677
PSMD8 -2340 10199
MADD -2339 2791
RPS6KA5 2355 287
ITGA3 -2324 4715
CXCL16 -2320 3480
GPAM 2335 7324
ADCY7 2332 -2067
KTN1 -2312 10122
ARAP3 2331 -419
OCRL 2325 6529
PIP4K2C -2300 4601
NEURL1B 2318 6311
FBXW7 2314 10486
PLK1 -2294 -515
PHLPP2 2298 37
LPAR6 -2280 7943
RHOBTB2 2287 4255
GNA11 -2257 2737
IFT122 -2254 3658
UBE2D1 2279 10286
MAML2 2275 -1466
USP4 -2248 7788
SH2B3 2252 4797
PTGDR2 2251 -678
FOXO6 -2227 4857
CHN2 -2224 -893
VCP 2240 9673
FGFRL1 2237 3776
FZD3 2230 6460
ARHGAP36 -2213 -714
MED1 2217 6525
WNT4 -2201 3448
CENPO -2199 3948
CDK5R1 2199 3855
PTPN2 2196 6644
DOK1 -2184 -1732
IL3RA 2183 491
PLCG1 2181 7009
PDHA2 2174 -2182
ATP2A2 2169 8887
ARHGAP11B 2164 6290
ARHGEF11 2158 4265
DLG2 -2155 1914
NFATC1 2154 5089
HDAC6 -2150 3179
CILP 2149 5699
TIAM2 2147 237
ABI2 2144 353
SFRP1 -2138 -662
ACVR2A -2131 9812
CALM1 -2123 10248
PENK 2130 -2226
DGKH -2120 7572
EPN1 2104 -2027
ARHGAP42 2102 5654
ADORA1 2098 3156
INPP5B -2079 5872
GRK5 -2076 -2000
MAMLD1 -2071 6729
GPC4 2062 7557
GRK6 -2048 6470
NTF4 -2041 3732
STK11 2056 8146
TBL1XR1 2045 9919
H2AFV 2043 6316
PDHB -2024 7467
LAMA3 2034 -237
PSEN1 2027 6548
ZW10 2022 -1126
CHN1 2017 3973
RTN4 -1992 10586
DAAM1 -1991 7988
TRAF1 2010 2526
DGKE -1985 7819
CBX2 -1983 -1095
OTULIN 1985 6958
ARPC3 1984 6987
LIN7B -1966 5453
ACVR2B 1978 5602
CTNNA1 -1961 7278
PRICKLE1 1971 5244
PSMB9 -1954 1824
WIPF1 1968 3510
DLK1 -1947 -2338
PORCN 1963 1643
BAIAP2 1960 -1005
RRAGD 1956 10205
DLG4 -1933 356
PDGFD 1951 2603
GNB5 1946 1573
NELFB 1944 693
PPID -1918 6905
RIPK1 1926 6443
ABCG1 -1902 -438
CDC37 -1892 -1547
ARHGDIG 1905 -796
STAM -1884 8393
SYNGAP1 1903 1290
RPS6KB2 1892 6592
GPIHBP1 1873 -2432
PSMC6 1862 9551
NCKIPSD -1832 1120
TNRC6B -1822 9869
EPOR 1852 4041
LRP5 1851 4364
CDKN2B -1815 9949
FNTB 1844 8953
CRHR2 -1802 1150
TRAF2 -1801 1090
SUFU 1838 1537
FGFR4 -1794 -1228
KIT 1834 -414
AP2B1 1820 10334
LRIG1 1817 8684
PDE3A 1806 4513
DYNC1I2 1800 9279
P2RY6 1798 1995
SHARPIN -1749 1230
USF2 -1747 5503
RAPGEF4 1784 5461
SMC1A 1759 2029
SNX3 -1721 9882
NPHP4 -1710 -2478
GTF2A1 1717 5668
GFRA1 -1702 5307
ARHGAP21 -1698 9334
GPSM1 1713 -2428
GATAD2B -1697 10452
INTU -1696 3646
PFN2 -1694 9175
UBB 1683 4803
AGT 1673 5335
CDC42 1671 7354
RANBP9 1668 10262
TIAL1 -1641 10338
RNF41 -1636 3588
IFT52 1649 5843
FMNL1 -1616 636
SMAD4 1642 10533
PLTP 1640 2405
MAPKAPK2 1637 8884
NCKAP1L -1607 1109
AATF -1605 4378
PRDM4 1632 4187
RCC2 -1597 5768
BMPR1A 1621 9505
TEC 1612 5771
PSMD11 1605 2701
SPOP 1597 10156
MAML1 1591 8336
CALCB -1565 -1153
LAMTOR4 -1563 7353
PLXND1 -1556 -884
RANGAP1 -1550 7969
SPTBN2 1564 -1231
FASN -1544 -1121
CASP10 1559 3427
WDR35 1558 3892
FAS -1530 3040
PSMA1 -1528 4522
SCMH1 -1526 2132
TNRC6A 1534 8046
PRKCH 1532 9003
RARG 1519 6112
GAS8 1518 -1556
CUL1 -1502 5052
RASGRP3 1511 10335
NCK2 -1496 3710
CBFB 1501 8431
HDAC3 -1485 5746
MFNG -1483 -2127
PSMD14 -1472 8169
IL33 1479 -1795
KLHL12 1469 9152
GNA12 -1455 4989
GTF2A2 -1452 6807
EDNRA -1449 516
SPHK1 1438 -1056
SH2B1 -1434 1006
AP2A1 1419 4493
RALGDS -1409 6535
NCK1 1411 5647
RHOA -1406 2155
SMAD1 1406 9343
AXIN1 1404 1140
RBBP7 -1401 7908
FGF7 -1399 6350
VAPA 1384 9629
APOD -1375 8278
CAV1 1375 7125
ELMO2 -1366 3286
SYK 1370 584
ARHGAP39 -1354 -2483
ARHGEF40 -1352 -958
KPNA2 1359 6965
MGLL -1340 8208
ADCY4 1346 -1388
RARA 1345 9772
ST3GAL4 1338 -119
COL6A2 -1330 -2414
EPS15L1 1335 6113
RASA4 -1324 3107
CSNK2A2 1328 5032
HTR7 -1318 7524
RSPO3 1327 7536
CTBP2 -1311 8987
CTSD -1309 3153
PSMD5 1303 572
STAT5B 1288 4858
ARHGEF6 1274 8857
TMED2 -1288 3669
MYL12B -1287 2937
TCF7L1 1271 4554
PSMD4 -1277 8454
SCT -1269 5353
RDH13 1259 -217
SYVN1 -1264 6583
ASH2L 1254 5475
CCNT1 1237 9501
NFKB1 1226 6016
VIPR2 -1244 4693
LAMA4 1216 1789
FADD 1212 1200
PCSK5 1209 4934
HDAC11 1207 3765
PIK3C3 -1235 7021
PPP3R1 -1229 8094
AP2S1 -1227 2861
PDE2A -1224 -1961
DTX4 -1221 344
P2RY14 -1203 3793
TBP -1201 2956
IFT140 -1194 -1386
PDE4A -1185 4973
HSD17B1 1136 4822
CFL1 -1169 -1486
PDGFC 1133 6821
NMT2 -1150 6048
WNT11 -1144 3518
EEF2K 1115 7240
TAX1BP1 1078 7030
CREB1 1075 6511
GSK3A -1109 777
CNR1 -1103 241
DKK2 -1102 3978
PPP1R12A -1096 2138
PLCG2 1060 -2492
NOTCH2 1059 1746
CLTA -1090 8550
MYLIP 1049 9602
EVC 1045 -2322
RING1 -1076 -850
RELA -1063 6444
TSC2 -1057 -2360
COL6A1 1036 -908
AKR1C3 1023 -892
MYH11 1014 526
TCF7L2 -1032 -1851
AP2A2 -1026 5592
RDH10 1002 1979
PDPK1 997 8142
PKN3 -1010 1757
CCR1 989 -1201
METAP1 -998 4047
FGF1 -995 5049
WLS -985 9850
PELP1 972 1677
ARHGAP6 -971 9253
UBE2D3 959 10332
CSNK2A1 958 8167
ARHGEF10L 955 5285
ECE2 949 -1998
NPY1R -957 9371
ARHGAP28 938 1679
PLIN1 -949 2988
BCR -948 -1958
GTF2F1 -943 -2113
NUDC -941 8961
SMARCA4 925 2803
OTUD3 -937 7677
RHOBTB1 -934 10319
FYN -930 5170
KDM1A 909 6633
DNM3 906 5400
DGKZ -922 8623
SRGAP1 901 4605
DACT1 897 3708
SH2B2 -911 3919
ATP6V1E2 885 1744
RPS27 -901 8716
GUCA1B 875 -212
ARHGAP22 845 -1069
PTPN1 836 8566
PARD3 -865 4188
S1PR1 824 -1263
SEH1L 814 6825
PPP2R5B 806 5462
PSEN2 -844 3706
EIF4EBP1 -836 6604
MAPKAP1 -829 5547
ADCY6 784 -753
COL4A3 781 2477
PLEKHG5 -816 -1393
ZWILCH 774 56
POLR2E 769 4519
PSMA2 765 7441
TSC1 -797 6538
PPP2R5A 751 9394
RASGRP2 743 7592
EFCAB7 -775 3979
LAMC2 -774 312
VPS26A -770 9948
ARHGEF16 731 -2009
PAG1 730 3125
KAT5 -760 6298
CTNNBIP1 726 5844
TYK2 -756 -193
PRKCI -753 5135
GPR176 -743 -1132
FRS3 -742 3789
DUSP4 -740 5110
EED -733 10397
ELK1 -726 5791
KDM1B 695 3782
CDK4 -723 8215
BOC 677 2738
BCO2 -713 7739
FZD8 -694 4908
LRRC7 -692 4191
RASAL3 650 234
PDGFRB 648 1280
P2RY2 -675 9661
STRADB -664 2972
CAB39L -660 6062
MMP2 626 702
KANK1 -655 6274
MAP2K2 -654 4871
SNW1 620 2719
SH3GL1 -643 8305
DEPDC7 -642 8255
BRAP 604 3155
NOG -625 5529
ATP6V0E2 590 -1301
NCOR1 581 5502
CAMK2D 580 10449
DGKG -611 -1217
PSMD6 -608 4978
PHC2 -606 8616
TCF4 576 10614
SDC3 573 -634
GRB2 -594 1946
FZD5 -590 5406
ITPR1 -584 3756
KNTC1 563 333
MUC20 -579 -592
ARAF -571 7956
TFDP1 -566 -183
POLR2K 546 9430
POLR2H 544 4284
CDON -561 1137
WNT5B 537 -196
DLG1 535 9068
GNAZ -548 -1374
PLXNB1 521 -1641
CIT 518 1732
PTH1R 516 -1655
CCNT2 512 2330
MAPK1 -520 8067
SYDE1 499 -1489
MAPKAPK5 492 -1707
GPER1 -517 1992
AKT1S1 489 5180
CASP2 483 5541
NDE1 481 3082
CAMK2G 464 6383
KHDRBS1 456 8651
CNKSR2 453 3544
ARHGAP12 -464 9588
PSMA5 -462 10219
NUP107 429 3020
SLC24A1 -450 -2015
ADCY3 -449 -544
ARHGDIB -436 1153
PRKACB 407 7008
MTMR4 -434 4711
RRAGC -426 4758
RARB 397 9942
AKT1 389 814
VIPR1 -415 -2106
DVL3 382 8130
MYL6 -401 8229
FAM13A -397 10128
WNT5A -389 3162
ABHD6 -386 2326
ARPC1B 353 272
RHOT1 -378 1623
TGIF2 -366 -426
SPARC 341 9929
KLC2 339 4056
DGKQ 338 -408
TCIRG1 -345 653
PDE8B 320 -1878
MAD1L1 319 1536
FRAT1 312 5481
CXXC4 -330 7483
CYP26B1 310 6040
LAMB1 307 3017
HRAS -322 787
PIK3R1 295 10491
BUB3 294 6934
PTK2 292 9048
EBAG9 282 10153
COL4A5 281 1297
RBL1 -294 506
TBL1X 266 6775
PRKACA 265 8672
ARHGAP19 -288 -724
CFLAR -285 9836
SCUBE2 249 528
RASGRP4 248 736
ATP2A3 -269 -612
DYNC1I1 -266 4547
CXCR6 -259 6327
APOC1 236 7285
IRAK1 -250 259
NMT1 -247 9718
PSMD2 230 6527
MEMO1 224 5979
WNT2B -220 541
IQGAP2 217 -2313
HDAC1 211 191
ADCY1 206 -429
NRP2 -201 -162
MKNK1 190 1045
MTA1 -188 -211
ATP6V1G1 177 7045
GPSM2 -180 7728
CAV2 -175 1000
ABI1 167 9585
PGR -170 2158
FUZ -169 8042
FLRT2 -163 265
RHOJ -161 5123
RUNX1 145 8592
LAMTOR3 -147 9429
FZD6 -134 167
SRGAP3 -118 2700
CALCRL -117 7650
ATP6V1C1 115 1039
MST1R -113 -2257
SOX13 110 3962
TACC3 -101 -1668
PML -90 796
TAB1 -70 4521
RACGAP1 58 3054
OPRD1 55 -840
ACKR3 46 6586
AP2M1 -45 7854
APLNR 36 644
RAP1A -34 8174
ZDHHC21 35 4447
PTGER4 34 6668
LYN 25 220
ADCYAP1R1 18 -1988
UBC 12 8551
INHBA 5 1917
MKRN1 0 6331



Metabolism of RNA
Metabolism of RNA
metric value
setSize 545
pMANOVA 1.74e-26
p.adjustMANOVA 1.04e-23
s.dist 0.256
s.RNA.expression -0.142
s.H3K9.Acetylati 0.213
p.RNA.expression 1.71e-08
p.H3K9.Acetylati 3.2e-17



Top 20 genes
Gene RNA expression H3K9 Acetylati
PCBP2 -6164 10547
APOBEC2 -5982 10234
SRSF5 -6332 9583
RPS15A -5825 10207
RPL37 -6258 9201
GTF2F2 -5610 10107
BCAS2 -6336 8876
PSMA3 -5745 9750
PSMB7 -6318 8601
RPS24 -6095 8816
RPL11 -5934 9054
RPL14 -5807 9137
PSMA4 -6145 8472
RPS27L -5650 9129
SRRT -5652 9066
UBA52 -6013 8521
TFIP11 -5495 9241
RPLP1 -5894 8534
PPP2R1A -5594 8945
U2AF2 -5419 9202

Click HERE to show all gene set members

All member genes
RNA expression H3K9 Acetylati
HSPA1A 6747 5250
ZFP36L1 6696 10196
ZFP36 6679 8304
MYC 6633 8932
SRSF3 6631 10393
POLR2A 6523 -225
BCAS2 -6336 8876
DCP1A 6521 10037
SRSF5 -6332 9583
HNRNPA0 6491 9265
RANBP2 6490 7392
TNPO1 6484 10383
TRA2B 6466 10611
PSMB7 -6318 8601
RPL35 -6304 1065
SRSF11 -6287 4832
HNRNPU 6375 10302
PAN2 -6278 3043
RPL35A -6277 -532
RPS13 -6275 -1
AAAS -6274 7401
LAS1L -6262 4894
SF3A3 -6260 3822
RPL37 -6258 9201
PSMB5 -6257 1512
RPS12 -6239 2398
RBM28 -6235 6150
GTF2H1 -6229 2365
RPL32 -6220 -286
EIF4A3 6319 1640
CPSF2 6308 297
RPL27A -6207 6609
RPL37A -6198 281
HNRNPH1 6281 10097
SNRNP35 -6195 7692
UTP20 6271 6702
SNRNP70 -6184 5857
DCP2 6244 9182
HSPB1 6243 10148
TNKS1BP1 6231 5474
PCBP2 -6164 10547
RPL7 6209 1570
PSMA4 -6145 8472
ZBTB8OS -6142 -411
SMG1 6186 9284
XRN1 6168 6192
CSNK1D 6164 8246
RPL34 -6118 4347
PAPOLA 6136 5056
RPS24 -6095 8816
OSGEP -6083 810
THG1L -6081 7305
RPS6 -6080 4813
POLR2C -6075 3645
DDX52 6092 2805
EXOSC10 -6044 815
RPS17 -6040 1412
POLR2G -6031 5463
NUP85 -6024 5556
SRSF9 -6022 2729
ACTB 6034 8383
UBA52 -6013 8521
TRMU -6011 1933
CPSF4 -6008 -633
KRR1 6013 8627
APOBEC2 -5982 10234
SNRPA1 -5968 6552
IGF2 5961 3778
NXF1 -5944 7148
HSPA8 5938 9720
RPS16 -5937 -113
RPL11 -5934 9054
EXOSC8 -5930 1262
DCAF13 -5922 4974
CNOT10 -5914 6237
RPL19 -5910 8377
DHX15 5887 9140
ELAC2 -5898 4201
RPLP1 -5894 8534
CNOT1 5863 8723
NCBP1 5849 2136
CNOT6 5848 2801
RPL13 -5873 3602
RPL36 -5872 5735
PSME1 -5870 3786
HNRNPF 5795 9530
RPL30 -5836 8232
NUP205 5781 8790
RPS15A -5825 10207
SF3A1 5758 5608
RPL14 -5807 9137
NUP153 5751 23
RPL29 -5796 6230
RPS5 -5794 8033
GSPT1 5738 3303
NUP160 5712 8660
RPS27A -5761 2197
TPR 5702 5177
PSMA3 -5745 9750
POM121 -5744 6799
ZCCHC6 5681 8724
EXOSC3 5675 7016
PRPF19 -5722 8603
RPL6 -5719 7953
CWC15 -5702 5370
NOL11 5613 2192
POLR2D 5605 2543
MTO1 5601 -1011
SRSF6 -5663 8148
GEMIN6 -5661 4277
SRRT -5652 9066
RPS27L -5650 9129
PNRC2 5571 10481
RNPS1 -5620 5355
GTF2F2 -5610 10107
PPP2CA 5543 8072
PPP2R1A -5594 8945
PSME4 5513 4336
RPL5 -5561 8424
RPL41 -5559 -522
NUP210 -5549 -1297
YWHAZ 5465 10363
NOC4L -5538 -2120
DDX6 5455 7233
UPF1 5436 4965
RPL27 -5518 8802
SNRPF -5513 3031
FYTTD1 5410 4416
TFIP11 -5495 9241
POP4 -5463 4895
RPL38 -5457 5792
RPS19 -5454 7065
SRRM1 -5442 9090
RPL10A -5436 172
U2AF2 -5419 9202
BYSL 5322 5000
CNOT8 5314 3566
SMG5 -5378 -98
GTPBP3 -5368 155
PSMB2 -5360 8118
SF3B5 -5356 9105
PSMC2 -5342 8507
RPL31 -5337 -1170
HNRNPC 5249 10367
TRMT1 -5324 1710
DIEXF -5251 5890
SNRPB -5247 9245
TPRKB -5243 8824
PCF11 5182 10524
HNRNPA3 5173 9959
WTAP 5149 2941
GEMIN2 -5185 8015
TRMT12 5129 7033
RPL23 -5170 -1247
CCAR1 -5164 8007
ENPP2 5101 1808
METTL3 -5146 6279
WDR61 5078 1159
SMG8 -5134 6680
WDR36 5065 5176
PRPF6 -5112 3483
ERCC2 -5109 -499
EPRS 5020 4959
PSMD12 5013 7847
NUP93 -5064 1340
PSMF1 -5062 564
RPS4X -5018 4764
NUP155 4956 7298
DHX9 4944 8572
NUP98 4938 5452
NUP133 4933 1325
RPL13A -4980 3333
RPS14 -4964 8580
CPSF3 -4963 1853
GLE1 -4949 4629
PSMB6 -4939 8266
NUDT21 4864 3129
RNGTT 4856 2509
EFTUD2 4828 1747
PUF60 -4888 5576
PSMD1 -4887 8440
UTP6 -4880 9645
DDX42 4819 5997
NUP37 -4864 29
NOL12 -4859 681
NOL6 -4855 6386
SMG7 4782 7387
QTRT1 -4840 2892
PSMB4 -4827 8184
HNRNPA1 4755 10508
TRMT11 4733 9045
CSNK1E 4717 7666
NOB1 -4780 8287
PRPF31 4685 -689
EIF4G1 4675 10061
RPS7 -4744 6754
CWC27 -4743 7877
DIMT1 4672 4766
DHX16 4669 2992
CTNNBL1 -4728 4632
PSMB1 -4724 6031
TEX10 4656 6737
CNOT4 4653 10109
POP5 -4706 8177
PSME3 4624 1812
ETF1 4584 10293
DDX21 4581 7740
CLNS1A -4632 5085
EXOSC4 -4624 2685
THOC2 -4616 5104
TYW3 -4614 2351
HNRNPR -4606 10096
DUS2 -4599 8562
RIOK3 4548 6381
RIOK1 -4588 4167
PRPF8 4539 3636
RPL15 -4562 -1725
UPF2 -4527 6304
PSMA7 -4495 5331
EXOSC9 -4494 9296
MPHOSPH10 4402 2567
TRMT10A -4457 6546
MAPK11 4386 1969
RPS10 -4441 4510
GTF2H3 -4438 -349
NUP35 4328 4615
RBM22 -4403 10083
FBL 4320 7619
NOP58 -4388 9671
LSM6 4281 6082
PPIL4 4266 10055
UPF3A -4338 7297
THOC1 -4336 1993
HNRNPM -4334 8710
SMG6 4244 9114
SNUPN 4239 390
NHP2 -4312 4985
RPP30 4225 9218
TSEN2 4222 8679
RNMT 4218 5904
TTC37 4196 7165
THOC7 -4233 6415
CNOT6L 4159 9738
PSMB3 -4193 -940
RPL4 -4191 816
CSTF3 -4190 3695
NUP50 4103 5054
LSM8 -4140 9462
RIOK2 4063 9658
RPL36A -4114 876
SRSF7 4039 8837
PDCD7 -4098 4333
SF3B4 -4092 8506
TSEN54 -4090 3213
PSMD13 -4071 1261
RPS3 -4049 1446
FAM98B 3986 6870
SNRPN -4008 -2344
NSUN2 -3976 4481
LSM4 -3954 8852
FIP1L1 -3929 8108
ADAR 3844 5882
DDX39A 3809 4451
SF3B3 3803 5665
RPS9 -3879 4281
KHSRP 3776 6714
SEC13 -3863 4435
PPIL3 -3860 3088
DDX23 3704 4844
RPS15 -3815 3075
WDR46 -3774 368
PSMD9 -3768 2589
MTERF4 -3764 7784
NUP54 -3753 8085
YBX1 -3751 7941
SLBP 3629 2491
ZC3H11A 3626 8642
RPL24 -3709 10306
RPS23 -3701 766
POP7 -3684 5671
TBL3 -3676 -1854
PSMC3 -3661 10264
PUS1 -3640 -1536
CNOT7 3536 7308
RPL39 -3632 8907
CDK7 -3624 8000
CNOT3 -3594 4966
SUGP1 -3587 -1561
DDX49 -3584 -1891
TXNL4A -3578 8501
POLR2B 3481 3120
TRMT61B 3464 8527
ELAVL1 -3529 4126
PPIL1 -3506 7177
CD44 3415 1179
RPL22 -3495 6498
LTV1 -3466 5834
PHAX 3373 7778
CHERP 3360 -1883
RPL10 -3399 -19
RNPC3 -3331 6573
PES1 3275 4818
GPKOW 3274 5206
LAGE3 -3293 3101
SNRNP40 -3290 2709
BMS1 3214 7107
FCF1 3205 1350
LSM10 -3253 6811
HNRNPUL1 3191 9957
TSEN15 -3224 9148
PTBP1 3152 7642
EIF4B 3136 9184
HNRNPL 3098 8608
NUP43 -3145 4833
ZCCHC11 3076 8010
ADAT1 -3132 8316
SART1 3069 4078
SMNDC1 3066 9593
NXT1 -3106 5960
EDC3 -3102 8938
DHX37 3026 -1432
CPSF7 -3085 3027
USP39 -3053 7776
DKC1 -3042 9713
PABPN1 -2982 7434
RRP9 -2949 1629
PSMC4 2912 9069
PDCD11 2908 3067
PRKCA 2906 6689
C1D 2870 9411
DDX47 -2853 8829
MAPK14 2832 8653
RPL3 2788 -1016
SF1 2732 9076
SKIV2L -2719 558
WDR75 -2709 10112
TRMT10C -2706 7645
NCBP2 -2685 -875
RBM5 -2664 9801
TYW1 -2646 1582
PATL1 2637 4628
PSMC1 -2634 5249
EIF4E -2633 985
PSMD3 -2625 9052
PSMA6 -2614 4091
WDR33 2603 8611
PPP2R2A 2598 10504
XPO1 2582 10256
YWHAB -2556 8699
PPIH -2533 6735
PSMD7 -2518 3414
PRPF40A 2500 3341
PRKCD 2491 4466
AQR -2476 8919
CDC40 -2395 3423
CLP1 -2394 6742
NOP14 2389 809
PSMD8 -2340 10199
SNRPA -2338 -507
PPIL6 2367 3446
POP1 -2332 1254
CSTF2T -2281 9147
EBNA1BP2 -2262 -1054
ERI1 2253 5517
MAGOH -2229 7672
UTP14A 2248 5707
IGF2BP2 2225 3771
NT5C3B -2204 -1085
SENP3 2180 4660
SRRM2 -2179 5357
SRSF4 2170 9905
MRM1 -2136 4922
SNRNP48 -2121 7092
RPL18A -2107 2506
DNAJC8 -2099 9317
CDC5L 2108 9019
SMG9 2081 1372
GSPT2 -2055 6326
UPF3B -2043 7365
NCL 2046 7875
GCFC2 -2016 9756
CHTOP -2011 9257
SNRNP200 2032 6341
RPL3L -1999 8687
PPWD1 -1993 4657
PAN3 2014 -12
HSD17B10 1980 3061
WDR12 1972 2888
TFB1M -1956 9544
PSMB9 -1954 1824
U2SURP -1925 8133
NDC1 -1920 5622
FTSJ1 -1901 3941
TSR1 -1896 3347
ISY1 -1888 -1130
LSM2 -1883 9225
ZRSR2 -1843 8610
RQCD1 -1841 3391
PSMC6 1862 9551
PRPF4 1859 679
GEMIN4 1823 -112
DDX1 -1730 7328
URM1 -1680 8632
ADARB1 -1678 9306
EDC4 -1675 7752
UBB 1683 4803
DCPS 1678 1606
RAE1 -1660 2378
RPS3A 1669 4802
ISG20L2 -1640 3739
PRCC -1638 2024
THADA -1635 8918
NUP62 1657 1543
MNAT1 -1626 10462
LSM7 -1624 -1501
MAPKAPK2 1637 8884
CNOT11 -1610 5009
RCL1 -1608 7714
PSMD11 1605 2701
TRNT1 -1581 1177
EIF4A2 1590 1215
GPRC5A 1574 91
CTU1 -1548 5286
PSMA1 -1528 4522
UTP15 1546 -1277
RPSA -1522 -1622
GEMIN8 1503 8057
WDR43 1490 6911
BUD31 1487 2166
UTP18 -1473 2843
PSMD14 -1472 8169
SNRNP27 -1461 6892
UTP3 1456 9939
IMP4 -1451 2619
METTL14 1448 10193
HBS1L 1441 2481
RAN -1441 4411
CDKAL1 1436 8504
EXOSC2 -1436 7914
RBM17 1434 9422
SNRPC -1391 9100
SUPT5H -1339 7528
NOL9 -1331 -1550
ALKBH8 -1329 6119
PAIP1 1307 9316
PSMD5 1303 572
TRDMT1 -1296 5712
PSMD4 -1277 8454
PRPF3 -1255 6971
NUP88 1239 2650
HNRNPA2B1 1238 9229
PRMT5 -1228 4583
ANP32A -1206 8649
SET 1172 7997
RRP1 1158 1010
POM121C 1157 4076
RTCB -1179 8395
SF3B1 1149 9982
CD2BP2 1142 1737
CASC3 -1140 8528
EXOSC6 -1112 2818
RRP36 -1097 8353
RPL22L1 1052 7225
FUS -1050 8864
POLDIP3 -1040 6930
PNO1 -1009 2895
SNRPD1 -1004 9111
ADAT2 -999 1503
PELP1 972 1677
CWC25 -956 -1059
RRP7A 929 857
GTF2F1 -943 -2113
MAGOHB 913 9115
TRIT1 -924 3702
RPS27 -901 8716
WDR18 -896 2677
NSUN6 862 9219
HNRNPD 861 9458
EXOSC7 -888 7501
CWC22 854 8735
LSM11 -881 4488
DHX38 838 -1549
THUMPD1 -871 8190
WBSCR22 830 -1017
SLU7 -863 6503
NUP214 -862 6024
SEH1L 814 6825
PPIE -854 -735
DCP1B 811 2601
SF3A2 -813 8433
POLR2E 769 4519
PSMA2 765 7441
THOC3 724 1953
NOP2 -746 4562
ZNF473 711 1752
CRNKL1 694 1560
CCNH 667 9945
UTP14C -690 2829
SNW1 620 2719
PLRG1 -646 8747
NAT10 -637 7265
SRSF10 -620 10336
LSM5 -609 7489
PSMD6 -608 4978
HNRNPK 567 5324
POLR2K 546 9430
POLR2H 544 4284
TSEN34 531 -1424
TGS1 529 -103
RPP14 487 6417
RPS4Y1 482 2536
SNRPE 474 8204
PUS7 -474 2382
PSMA5 -462 10219
NUP107 429 3020
FTSJ3 -448 3005
RPL9 418 2277
TRMT13 409 956
XPOT -425 8780
AKT1 389 814
TRMT44 -396 -799
THOC5 -393 3458
SNRPG 362 9073
PABPC1 355 9691
NUP188 321 2377
PUS3 -323 1184
RPP40 -317 9324
SYF2 -307 7531
XAB2 -293 -584
CNOT2 268 4606
RBMX 259 2977
SF3B2 -255 4468
PSMD2 230 6527
ERCC3 -204 3178
ALYREF -191 931
DDX20 -184 6140
SYMPK -150 -1658
PARN 147 6867
WBP11 -85 4465
HEATR1 84 8197
DDX46 -47 8224
CPSF1 -33 309
NSUN4 -26 7425
UBC 12 8551
GEMIN5 8 5726



Translation
Translation
metric value
setSize 228
pMANOVA 1.28e-25
p.adjustMANOVA 5.13e-23
s.dist 0.39
s.RNA.expression -0.362
s.H3K9.Acetylati 0.145
p.RNA.expression 5.01e-21
p.H3K9.Acetylati 0.000177



Top 20 genes
Gene RNA expression H3K9 Acetylati
RPS15A -5825 10207
MRPL15 -5875 10081
MRPL33 -5912 9986
RPL37 -6258 9201
MRPS28 -5706 10085
RPS24 -6095 8816
RPL11 -5934 9054
RPL14 -5807 9137
RPS27L -5650 9129
UBA52 -6013 8521
RPLP1 -5894 8534
RPL19 -5910 8377
MRPS25 -5835 8466
RPL27 -5518 8802
RPL30 -5836 8232
MRPS23 -4800 9997
RPL5 -5561 8424
RPS5 -5794 8033
RPL6 -5719 7953
SRP9 -4269 10325

Click HERE to show all gene set members

All member genes
RNA expression H3K9 Acetylati
WARS 6601 3742
MRPL32 -6348 3308
RPL35 -6304 1065
RPL35A -6277 -532
RPS13 -6275 -1
RPL37 -6258 9201
RPS12 -6239 2398
RPL32 -6220 -286
RPL27A -6207 6609
RPL37A -6198 281
MRPS11 -6188 2858
RPL7 6209 1570
EIF3A 6175 9670
RPL34 -6118 4347
RPS24 -6095 8816
MRPL27 -6085 587
RPS6 -6080 4813
MRPL17 -6043 5598
RPS17 -6040 1412
EIF1AX 6047 -184
UBA52 -6013 8521
RPS16 -5937 -113
RPL11 -5934 9054
MRPL39 5926 8213
EIF3K -5926 1783
MRPL33 -5912 9986
RPL19 -5910 8377
MRPS14 -5900 2450
RPLP1 -5894 8534
MRPL15 -5875 10081
RPL13 -5873 3602
RPL36 -5872 5735
RPL30 -5836 8232
MRPS25 -5835 8466
RPS15A -5825 10207
RPL14 -5807 9137
MRPL45 -5797 4242
RPL29 -5796 6230
VARS2 -5795 4049
RPS5 -5794 8033
GSPT1 5738 3303
MRPL1 -5776 1638
RPS27A -5761 2197
RPL6 -5719 7953
GADD45GIP1 -5715 6214
MRPS28 -5706 10085
EIF2B5 -5690 6848
EIF2B1 -5683 -665
MRPL37 -5672 -951
RPS27L -5650 9129
MRPL38 5584 6198
SSR2 -5623 5985
MRPL10 -5617 2581
TSFM 5511 6935
MRPL40 -5570 -1138
TRAM1 5494 5900
RPL5 -5561 8424
RPL41 -5559 -522
RPL27 -5518 8802
RPL38 -5457 5792
RPS19 -5454 7065
RPL10A -5436 172
RPN1 -5391 7593
EIF3B -5377 1544
RARS2 -5375 1531
RPL31 -5337 -1170
CARS -5293 4639
GFM1 5170 9364
IARS 5156 418
RPL23 -5170 -1247
MRPL54 -5147 -41
MRPL30 -5083 4362
EPRS 5020 4959
LARS 4993 3976
MRPS33 -5027 6227
RPS4X -5018 4764
MRPS21 -5016 5978
RPL13A -4980 3333
SARS -4977 8421
RPS14 -4964 8580
MRPL11 -4936 1499
QARS -4920 8358
MRPL41 -4853 2948
EIF3C 4774 3087
CARS2 -4837 3353
EIF2B4 -4813 1844
MRPS23 -4800 9997
NARS2 4690 8396
EIF4G1 4675 10061
RPS7 -4744 6754
EEF1E1 -4690 -1734
SEC11C -4682 2990
SEC11A -4677 9190
EIF2S2 -4642 9353
ETF1 4584 10293
EIF5B -4602 2153
RPL15 -4562 -1725
EIF3H -4514 8398
MRPS9 -4444 6405
RPS10 -4441 4510
MRPL22 -4344 9002
MRPL44 -4283 8485
DARS2 4203 2274
SRP9 -4269 10325
RPL4 -4191 816
MTIF3 -4176 8242
EIF2B2 -4168 7760
AARS 4054 -1147
TARS2 -4123 5718
MRPL55 -4115 7816
RPL36A -4114 876
MRPL19 4019 9446
RPS3 -4049 1446
MRPL13 -3991 5634
CHCHD1 -3985 9388
EIF3D -3972 6810
MARS -3969 862
GARS -3958 1470
KARS -3952 1429
MRPS18C -3942 7610
DDOST -3892 7153
RPS9 -3879 4281
HARS -3859 -1345
RPS15 -3815 3075
MRPL24 -3802 9300
MARS2 3610 9802
RPL24 -3709 10306
RPS23 -3701 766
RPL39 -3632 8907
MRPS15 -3539 9038
MRPL18 -3508 3524
RPL22 -3495 6498
SEC61A2 3379 -1548
MRPL48 3349 7244
RPL10 -3399 -19
MRPL34 -3382 1026
MRPL16 -3325 6709
MRPS30 3231 6094
EEF1A1P5 -3230 1176
EIF4B 3136 9184
MRPS27 -3167 9122
NARS 3081 8055
N6AMT1 2988 9071
AARS2 -3043 867
LARS2 2964 8630
MRPS18A 2957 10058
SSR3 -2954 8617
MRPL49 -2927 1453
EIF3M 2907 5780
PTCD3 2858 4515
EIF3L -2837 5012
RPL3 2788 -1016
MRPS26 -2771 2735
MRPL3 -2770 7737
MRPL36 -2760 1114
SARS2 -2713 -1650
PPA2 -2692 9798
MRPL28 -2661 2187
SRPRB 2654 6009
EIF4E -2633 985
SRP19 2514 2096
EEF1D -2377 2500
MRPL46 -2316 3375
EIF2S1 2270 1968
EIF3G -2238 4069
EIF3J 2246 6152
SEC61G -2168 2911
SSR4 -2153 729
MRPS36 -2130 7015
RPL18A -2107 2506
WARS2 2086 4328
GSPT2 -2055 6326
RPL3L -1999 8687
FARSA -1891 4579
DARS -1885 6116
MRPL23 -1834 3109
MRPL4 -1792 5823
TARS 1770 5681
PARS2 -1699 8180
APEH 1710 4805
RPS3A 1669 4802
EIF3E -1596 5745
EEF2 1616 8161
EIF4A2 1590 1215
MTFMT 1581 3691
RPSA -1522 -1622
AURKAIP1 -1521 5152
IARS2 1506 3279
EEF1A2 1484 9554
MRPS31 -1290 7257
EIF4H 1273 9032
MRPS6 1270 3218
PPA1 -1275 8840
SRP68 1245 969
RPN2 -1257 9290
MRPS10 -1192 10243
MRRF 1100 2292
MTIF2 -1129 3425
SRP72 1083 8855
RPL22L1 1052 7225
MRPL42 1021 6380
FARSB -1027 8063
YARS2 -1015 6260
DAP3 -987 503
EIF2B3 -967 5772
RPS27 -901 8716
MRPL35 -842 10004
EIF4EBP1 -836 6604
GFM2 -817 1954
SRP54 -761 2750
RPS4Y1 482 2536
EIF5 -511 756
SPCS3 -461 8573
RPL9 418 2277
EARS2 -395 -1858
YARS -391 1681
PABPC1 355 9691
SEC61A1 351 9402
MRPS22 -341 1391
MTRF1L 293 9368
VARS 273 7960
MRPS5 -153 5061
EIF3F -132 6861
SSR1 120 6834
RARS 98 6077
EIF2S3 -80 7664
EEF1A1 72 8555
FARS2 10 1815



Regulation of expression of SLITs and ROBOs
Regulation of expression of SLITs and ROBOs
metric value
setSize 125
pMANOVA 2.44e-22
p.adjustMANOVA 7.34e-20
s.dist 0.49
s.RNA.expression -0.458
s.H3K9.Acetylati 0.173
p.RNA.expression 8.97e-19
p.H3K9.Acetylati 0.000849



Top 20 genes
Gene RNA expression H3K9 Acetylati
RPS15A -5825 10207
RPL37 -6258 9201
PSMA3 -5745 9750
PSMB7 -6318 8601
RPS24 -6095 8816
RPL11 -5934 9054
RPL14 -5807 9137
PSMA4 -6145 8472
RPS27L -5650 9129
UBA52 -6013 8521
RPLP1 -5894 8534
RPL19 -5910 8377
RPL27 -5518 8802
RPL30 -5836 8232
RPL5 -5561 8424
RPS5 -5794 8033
RPL6 -5719 7953
PSMC2 -5342 8507
RBX1 -5573 8048
PSMB2 -5360 8118

Click HERE to show all gene set members

All member genes
RNA expression H3K9 Acetylati
PSMB7 -6318 8601
RPL35 -6304 1065
RPL35A -6277 -532
RPS13 -6275 -1
RPL37 -6258 9201
PSMB5 -6257 1512
RPS12 -6239 2398
RPL32 -6220 -286
EIF4A3 6319 1640
RPL27A -6207 6609
RPL37A -6198 281
RPL7 6209 1570
PSMA4 -6145 8472
RPL34 -6118 4347
RPS24 -6095 8816
RPS6 -6080 4813
RPS17 -6040 1412
UBA52 -6013 8521
RPS16 -5937 -113
RPL11 -5934 9054
RPL19 -5910 8377
RPLP1 -5894 8534
NCBP1 5849 2136
RPL13 -5873 3602
RPL36 -5872 5735
PSME1 -5870 3786
RPL30 -5836 8232
RPS15A -5825 10207
RPL14 -5807 9137
RPL29 -5796 6230
RPS5 -5794 8033
GSPT1 5738 3303
RPS27A -5761 2197
PSMA3 -5745 9750
RPL6 -5719 7953
RPS27L -5650 9129
RNPS1 -5620 5355
PSME4 5513 4336
RBX1 -5573 8048
RPL5 -5561 8424
RPL41 -5559 -522
ROBO3 -5537 -76
RPL27 -5518 8802
RPL38 -5457 5792
RPS19 -5454 7065
RPL10A -5436 172
PSMB2 -5360 8118
PSMC2 -5342 8507
RPL31 -5337 -1170
RPL23 -5170 -1247
PSMD12 5013 7847
PSMF1 -5062 564
RPS4X -5018 4764
RPL13A -4980 3333
RPS14 -4964 8580
PSMB6 -4939 8266
PSMD1 -4887 8440
PSMB4 -4827 8184
EIF4G1 4675 10061
RPS7 -4744 6754
PSMB1 -4724 6031
PSME3 4624 1812
ETF1 4584 10293
RPL15 -4562 -1725
UPF2 -4527 6304
PSMA7 -4495 5331
RPS10 -4441 4510
UPF3A -4338 7297
PSMB3 -4193 -940
RPL4 -4191 816
RPL36A -4114 876
PSMD13 -4071 1261
RPS3 -4049 1446
RPS9 -3879 4281
RPS15 -3815 3075
PSMD9 -3768 2589
ROBO1 3639 7062
RPL24 -3709 10306
RPS23 -3701 766
PSMC3 -3661 10264
RPL39 -3632 8907
LDB1 -3574 8159
RPL22 -3495 6498
RPL10 -3399 -19
USP33 3157 5730
DAG1 -2956 8774
PSMC4 2912 9069
RPL3 2788 -1016
NCBP2 -2685 -875
ZSWIM8 2671 7952
PSMC1 -2634 5249
PSMD3 -2625 9052
PSMA6 -2614 4091
PSMD7 -2518 3414
PSMD8 -2340 10199
MAGOH -2229 7672
RPL18A -2107 2506
GSPT2 -2055 6326
UPF3B -2043 7365
RPL3L -1999 8687
PSMB9 -1954 1824
PSMC6 1862 9551
SLIT2 1821 851
UBB 1683 4803
RPS3A 1669 4802
PSMD11 1605 2701
PSMA1 -1528 4522
RPSA -1522 -1622
PSMD14 -1472 8169
PSMD5 1303 572
PSMD4 -1277 8454
CASC3 -1140 8528
RPL22L1 1052 7225
MAGOHB 913 9115
RPS27 -901 8716
PSMA2 765 7441
PSMD6 -608 4978
RPS4Y1 482 2536
PSMA5 -462 10219
RPL9 418 2277
PABPC1 355 9691
CUL2 -320 5336
COL4A5 281 1297
PSMD2 230 6527
UBC 12 8551



Viral mRNA Translation
Viral mRNA Translation
metric value
setSize 62
pMANOVA 1.39e-20
p.adjustMANOVA 3.34e-18
s.dist 0.687
s.RNA.expression -0.684
s.H3K9.Acetylati 0.0611
p.RNA.expression 1.16e-20
p.H3K9.Acetylati 0.406



Top 20 genes
Gene RNA expression H3K9 Acetylati
RPS15A -5825 10207
RPL37 -6258 9201
RPS24 -6095 8816
RPL11 -5934 9054
RPL14 -5807 9137
RPS27L -5650 9129
UBA52 -6013 8521
RPLP1 -5894 8534
RPL19 -5910 8377
RPL27 -5518 8802
RPL30 -5836 8232
RPL5 -5561 8424
RPS5 -5794 8033
RPL6 -5719 7953
RPS14 -4964 8580
RPL27A -6207 6609
RPS19 -5454 7065
RPL24 -3709 10306
RPL29 -5796 6230
RPL36 -5872 5735

Click HERE to show all gene set members

All member genes
RNA expression H3K9 Acetylati
RPL35 -6304 1065
RPL35A -6277 -532
RPS13 -6275 -1
RPL37 -6258 9201
RPS12 -6239 2398
RPL32 -6220 -286
RPL27A -6207 6609
RPL37A -6198 281
RPL7 6209 1570
RPL34 -6118 4347
RPS24 -6095 8816
RPS6 -6080 4813
RPS17 -6040 1412
UBA52 -6013 8521
RPS16 -5937 -113
RPL11 -5934 9054
RPL19 -5910 8377
RPLP1 -5894 8534
RPL13 -5873 3602
RPL36 -5872 5735
RPL30 -5836 8232
RPS15A -5825 10207
RPL14 -5807 9137
RPL29 -5796 6230
RPS5 -5794 8033
RPS27A -5761 2197
RPL6 -5719 7953
RPS27L -5650 9129
RPL5 -5561 8424
RPL41 -5559 -522
RPL27 -5518 8802
RPL38 -5457 5792
RPS19 -5454 7065
RPL10A -5436 172
RPL31 -5337 -1170
RPL23 -5170 -1247
RPS4X -5018 4764
RPL13A -4980 3333
RPS14 -4964 8580
RPS7 -4744 6754
RPL15 -4562 -1725
RPS10 -4441 4510
RPL4 -4191 816
RPL36A -4114 876
RPS3 -4049 1446
RPS9 -3879 4281
RPS15 -3815 3075
RPL24 -3709 10306
RPS23 -3701 766
RPL39 -3632 8907
RPL22 -3495 6498
RPL10 -3399 -19
RPL3 2788 -1016
RPL18A -2107 2506
RPL3L -1999 8687
RPS3A 1669 4802
RPSA -1522 -1622
RPL22L1 1052 7225
RPS27 -901 8716
GRSF1 842 7597
RPS4Y1 482 2536
RPL9 418 2277



Here is the session info with all the versions of packages used.

sessionInfo()
## R version 4.3.3 (2024-02-29)
## Platform: x86_64-pc-linux-gnu (64-bit)
## Running under: Ubuntu 22.04.4 LTS
## 
## Matrix products: default
## BLAS:   /usr/lib/x86_64-linux-gnu/blas/libblas.so.3.10.0 
## LAPACK: /usr/lib/x86_64-linux-gnu/lapack/liblapack.so.3.10.0
## 
## locale:
##  [1] LC_CTYPE=en_US.UTF-8       LC_NUMERIC=C              
##  [3] LC_TIME=en_US.UTF-8        LC_COLLATE=en_US.UTF-8    
##  [5] LC_MONETARY=en_US.UTF-8    LC_MESSAGES=en_US.UTF-8   
##  [7] LC_PAPER=en_US.UTF-8       LC_NAME=C                 
##  [9] LC_ADDRESS=C               LC_TELEPHONE=C            
## [11] LC_MEASUREMENT=en_US.UTF-8 LC_IDENTIFICATION=C       
## 
## time zone: Australia/Melbourne
## tzcode source: system (glibc)
## 
## attached base packages:
## [1] stats     graphics  grDevices utils     datasets  methods   base     
## 
## other attached packages:
##  [1] mitch_1.15.3     kableExtra_1.4.0 pkgload_1.3.4    GGally_2.2.1    
##  [5] ggplot2_3.5.0    reshape2_1.4.4   beeswarm_0.4.0   gplots_3.1.3.1  
##  [9] gtools_3.9.5     tibble_3.2.1     dplyr_1.1.4      echarts4r_0.4.5 
## 
## loaded via a namespace (and not attached):
##  [1] gtable_0.3.4       xfun_0.43          bslib_0.7.0        htmlwidgets_1.6.4 
##  [5] caTools_1.18.2     vctrs_0.6.5        tools_4.3.3        bitops_1.0-7      
##  [9] generics_0.1.3     parallel_4.3.3     fansi_1.0.6        highr_0.10        
## [13] pkgconfig_2.0.3    KernSmooth_2.23-22 RColorBrewer_1.1-3 lifecycle_1.0.4   
## [17] compiler_4.3.3     farver_2.1.1       stringr_1.5.1      munsell_0.5.1     
## [21] httpuv_1.6.15      htmltools_0.5.8.1  sass_0.4.9         yaml_2.3.8        
## [25] later_1.3.2        pillar_1.9.0       jquerylib_0.1.4    tidyr_1.3.1       
## [29] MASS_7.3-60.0.1    cachem_1.0.8       mime_0.12          ggstats_0.6.0     
## [33] tidyselect_1.2.1   digest_0.6.35      stringi_1.8.3      purrr_1.0.2       
## [37] labeling_0.4.3     fastmap_1.1.1      grid_4.3.3         colorspace_2.1-0  
## [41] cli_3.6.2          magrittr_2.0.3     utf8_1.2.4         withr_3.0.0       
## [45] scales_1.3.0       promises_1.3.0     rmarkdown_2.26     gridExtra_2.3     
## [49] shiny_1.8.1.1      evaluate_0.23      knitr_1.46         viridisLite_0.4.2 
## [53] rlang_1.1.3        Rcpp_1.0.12        xtable_1.8-4       glue_1.7.0        
## [57] xml2_1.3.6         jsonlite_1.8.8     svglite_2.1.3      rstudioapi_0.16.0 
## [61] R6_2.5.1           plyr_1.8.9         systemfonts_1.0.6

END of report